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General introduction and outline of the thesis
General Introduction
The prostate is an exocrine gland of the male reproductive system. It surrounds the 
urethra just below the urinary bladder. The prostate gland is surrounded by a 
fibromuscular layer, the prostatic capsule. The prostatic urethra divides the prostate into
4 distinct zones; the anterior zone, the transition zone, the central zone and the 
peripheral zone (Fig. 1) [1]. A healthy prostate is not larger than a walnut and weighs 
approximately 20 grams. The prostate gland produces prostatic fluid which is a mixture 
of citric acid, polyamines (spermine and spermidine), prostaglandins, zinc and enzymes 
like alkaline phosphatase, prostate-specific antigen (PSA) and various proteins. PSA is 
produced by the secretory epithelial cells of the prostate and is excreted together with 
the other constituents of prostatic fluid into the ducts that are located within the gland. 
Upon ejaculation, the prostatic fluid is excreted into the urethra together with the fluid 
from the seminal vesicles (sperm). The prime function of PSA is to liquefy the clotted 
semen in order to release the spermatozoa and thereby it influences fertility [2].
The prevalence of prostatic diseases, like prostatitis, benign prostatic hyperplasia 
(BPH), and prostate cancer, is very high in the aging male population. Prostatitis is an 
inflammation in the peripheral zone of the gland, which in only 5-10% of the cases is 
caused by a bacterial infection [3]. As a result, swelling of the prostate tissue may occur, 
which in turn may lead to the obstruction of the prostate urethra. Prostatitis-like 
symptoms occur in 11.5% of men younger than 50 years and in 8.5% of men older than 
50 years [4]. Prostatitis can be very painful and can have a major effect on quality of life.
During puberty, the prostate doubles in size. After the age of 25, it is common for the 
gland to enlarge again. The gland will continue to grow during most of man's life. This 
condition is known as BPH. BPH originates from the transition zone of the prostate 
gland. The prevalence of BPH increases with age. Histological evidence of BPH can be 
found in 42% of 51-60 year old males, in 70% of 61-70 year old males and in 90% of 80­
90 year old males. BPH becomes clinically significant in 40-50% of these men [5]. This 
adenomatous prostate growth may lead in some of the males to obstruction of the 
prostatic urethra that necessitates surgery. Both prostatitis and BPH are common, 
problematic, sometimes serious, but not life-threatening diseases.
The incidence of prostate cancer increases more with age than any other type of 
cancer. Therefore, the number of newly diagnosed cases continues to rise as the life 
expectancy of the general population increases. Adenocarcinoma of the prostate 
develops from epithelial cells in the glandular tissue. Most of the prostate cancers (68%) 
originate from the peripheral zone, 24% originate from the transition zone and 8% of 
prostate cancers originate from the central zone of the gland. The anterior zone is
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located at the site of the abdomen and consists of non-glandular muscular tissue. Since 
it lacks epithelial cells, it does not give rise to carcinoma [1]. Autopsy reports indicate that 
early stages in the development of prostate cancer can already be identified within the 
gland of 30 year-old males [6]. These data show that prostate cancer is a slow growing 
tumor with an initiation at approximately the age of 30 and in 10% of the western male 
population a detectable tumor (> 0.5 cc) at the age of 50. From autopsy reports it is 
estimated that 50% of all men in their fifties will have histological evidence of prostate 
cancer, increasing to 80% in 80 year old males [6]. Epidemiology studies indicate that 
prostate cancer is an indolent disease and that more men die with prostate cancer than 
from it. About 1 in 26 men (4%) will die from this disease [7].
In the western male population, prostate cancer has become a major public health 
problem. In the Netherlands, prostate cancer is the most commonly diagnosed 
malignancy. In 2006, 9,516 Dutch men were diagnosed with this disease. Furthermore, 
prostate cancer is the second leading cause of cancer-related deaths; in 2006, 2,394 
Dutch men died of this disease (www.ikcnet.nl). Between 1989 and 1994 the number of 
Dutch men newly diagnosed with prostate cancer increased with approximately 40%. 
This was followed by a period in which the incidence rate of prostate cancer stabilized. 
However, between 2000 and 2006 the incidence rate of prostate cancer increased again 
from 88.1 per 100,000 men to 104.3 per 100,000 men (www.npknet.nl).
The natural aging of the population and the widespread implementation of the serum 
PSA test have resulted in the increase of men diagnosed with organ-confined prostate 
cancer (clinical stage T1-T2; Fig. 2). In a healthy male, most of the PSA is excreted in 
the prostate ductal system and little PSA leaks into the blood vessels. Due to a 
disruption of the anatomical prostate structure that is caused for example by a growing 
tumor, PSA can leak into the bloodstream. The threshold value above which biopsies are 
indicated has decreased now to a serum PSA value of 3 ng/ml. Since its first clinical 
application in the early 1990s, serum PSA has shown to be the most valuable tool in the 
detection, staging and monitoring of prostate cancer.
However, there are also limitations associated with the widespread use of serum 
PSA. The first limitation is the low specificity of serum PSA. Although widely accepted as 
a prostate tumor marker, PSA has turned out to be organ-specific but not prostate 
cancer-specific. PSA levels have been reported to be increased in men with BPH and 
prostatitis. This substantial overlap in serum PSA values between men with non- 
malignant prostatic diseases and prostate cancer is the limitation of PSA as a prostate 
tumor marker. Upon detection of serum PSA values greater than 3 ng/ml, the 
conventional diagnostic approach are transrectal ultrasound (TRUS)- guided prostate
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Fig.1. View of the prostate gland that specifically illustrates the four zones of the organ.
Fig.2. The most widely used system for staging prostate cancer is called the TNM System. It 
describes the extent of the primary tumor (T stage), the absence or presence of spread to nearby 
lymph nodes (N stage) and the absence or presence of distant spread, or metastasis (M stage). At 
the T1 stage, the tumor is too small to be detected by digital rectal examination (DRE) or transrectal 
ultrasound. A clinical T1(c) cancer is often identified by a biopsy specimen performed because of an 
elevated serum PSA. At stage T2, the tumor can be felt during a DRE and the cancer is confined 
within the prostate gland. At stage T3, the tumor has extended through the prostatic capsule and/or 
growths into the seminal vesicles. No other organs are affected. At stage T4, the tumor has spread 
to tissues next to the prostate (other than the seminal vesicles).
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biopsies. In patients with serum PSA values between 3-10 ng/ml, the negative biopsy 
rate is approximately 60-75% [8]. Although prostate biopsy is considered the gold 
standard for prostate cancer diagnosis, this method has its limitations and associated 
morbidities [9]. Biopsies are considered to be uncomfortable by 38% of the men [10]. 
Pain and discomfort may be the result of the frequent complications associated with 
TRUS-guided prostate biopsies such as macroscopic hematurea (observed in 90% of 
the cases), hematochezia (in 36% of the cases) and hematospermia (in 13% of the 
cases) [11]. Furthermore, uncertainty about the future and waiting for biopsy results is 
the most stressful event in 65% of men [12]. If there is continued suspicion of prostate 
cancer after the initial negative biopsy because of persistently elevated serum PSA 
levels, a repeat prostate biopsy is considered with a detection rate of approximately 10% 
to 35%. Since the detection rate of prostate cancer increases when more biopsies are 
taken, some investigators advocate for more aggressive biopsy-schemes, with more 
than 12 cores up to a saturation biopsy of more than 20 cores [13]. Thus, the ability of 
the serum PSA test to predict the chance of men actually having prostate cancer is 
limited. This results in a high number of negative biopsies and thereby it produces 
significant anxiety among men.
The second limitation of the widespread use of serum PSA is the risk of over­
treatment due to the increased diagnosis of prostate cancer. Nowadays, prostate cancer 
is detected in younger men with no signs or symptoms of disease. The detected prostate 
cancers are smaller and are diagnosed at an early, organ-confined stage. Since these 
men have a life expectancy of more than ten years, they are offered radical therapy. 
There is a slight decrease in prostate cancer mortality rates since 1995 (www.rivm.nl). 
The results from the European Randomized Study of Screening showed that PSA-based 
screening reduced the rate of death from prostate cancer by 20% [14]. However, many 
of the detected prostate cancers are clinically insignificant, do not pose a serious life 
threat, and without screening these tumors would not have been identified (clinical stage 
T1c). The increased incidence/mortality ratio in the western male population indicates 
that a large proportion of the identified cancers are currently being over-treated [14]. 
Furthermore, incontinence and impotence, side-effects of radical surgery and 
radiotherapy, negatively affect the patient's quality of life.
As a positive consequence of the widespread clinical application of serum PSA, the 
number of patients presenting with classic metastatic disease has dramatically declined. 
Nowadays, approximately 15-20% of newly diagnosed prostate cancer cases present 
with locally advanced disease or metastatic prostate cancer [15]. Locally advanced 
prostate cancer is defined as a tumor that has extended clinically beyond the prostatic 
capsule, with invasion of the capsule, apex, bladder neck or seminal vesicle, but without
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lymph node involvement or distant metastasis (clinical stage T3-T4; Fig. 2). In these 
patients surgical management is inadequate to control this disease. However, 
understaging of locally advanced prostate cancer is common and as a result, the risk of 
extra-prostatic disease in patients with apparently clinically localized disease is high. As 
many as one third of patients undergoing radical prostatectomy will be found to have 
locally advanced prostate cancer and will eventually experience a detectable rise in 
serum PSA after treatment [16]. As many of two-thirds of these patients are by definition 
at higher risk of metastatic disease and worse outcomes [17]. The 10-year metastatic 
free survival rates in these patients treated with radical prostatectomy only is 32% [18].
These data show the third limitation of serum PSA: it cannot predict at an early stage 
which prostate cancers are locally advanced and for which radical treatment is less likely 
to be effective. Despite the fact that locally advanced disease is not usually curable, 
current forms of therapy such as the combination of external beam radiation therapy with 
androgen deprivation therapy can offer long-term remissions to a very high proportion of 
patients if they receive suitable and early intervention [19]. For patients with advanced 
stage prostate cancer there are no therapeutic options available. These patients initially 
respond to androgen deprivation therapy at a rate of >90%. However, they eventually 
relapse into the castration-resistant state and finally die, usually within 3 years after 
relapse.
In conclusion, new tools are urgently needed for the diagnosis, staging and prediction 
of outcome of prostate cancer. Although prostate tumors are slow growing compared to 
other human cancers, they vary widely in their aggressiveness. Prostate cancer is a 
heterogeneous disease. Several prostate tumors may occur in the prostate of a single 
patient due to the multifocal nature of the disease. Each of these tumors can show 
remarkable differences in gene expression and behavior that are associated with varying 
prognosis. Therefore, the optimal management in men with localized prostate cancer or 
locally advanced prostate cancer remains uncertain.
In the last years, more insight has been gained in the molecular basis of prostate 
cancer through the identification of genes that are believed to be relevant in the initiation 
and development of this disease. This increasing body of knowledge can aid in the 
development of therapies, particularly for castration resistant prostate cancer. 
Furthermore, application of prostate cancer-specific biomarkers for the diagnosis and 
prognosis of prostate cancer can eventually lead to the more accurate identification of 
men with aggressive prostate cancer and who would gain prolonged survival and 
improved quality of life from early radical intervention.
In this thesis, the focus will be on improving the specificity in prostate cancer 
diagnosis by using prostate cancer-specific genes in adjunct to serum PSA testing.
Chapter 1
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Methods to enhance the specificity of serum PSA have assisted clinicians in deciding 
which patients should undergo biopsy, but have not necessarily improved diagnostic 
accuracy or facilitated optimal therapeutic decision-making. More-accurate tests are 
needed that are based on prostate cancer-specific markers. These tests may aid the 
clinician to stratify patients according to their risk of developing prostate cancer, and 
identify those who require repeat prostate biopsy. In this thesis, the potential of the new 
prostate cancer biomarkers PCA3 and TMPRSS2-ERG  gene fusions to improve the 
specificity in the early diagnosis of prostate cancer is evaluated and discussed.
Outline of the thesis
The identification of prostate cancer-specific genes would represent a considerable 
advance in the improvement of diagnostic tests for prostate cancer. In chap te r 2, a list of 
biomarkers is presented and the applicability of these biomarkers in the diagnosis of 
prostate cancer is discussed. Prostate cancer gene 3 (PCA3) was identified as the prime 
candidate biomarker for the detection of prostate cancer.
In 1999, PCA3 was identified using differential display analysis, a technique used to 
compare mRNA expression patterns of tumor and adjacent non-neoplastic tissue in 
radical prostatectomy specimens. The strong association between PCA3 over­
expression and malignant transformation of prostate epithelium has prompted its 
potential use as a biomarker for the diagnosis of prostate cancer; however, since PCA3 
is a non-coding RNA, an RNA-based molecular assay for PCA3 needed to be 
developed. RNA is prone to degradation, especially in biological fluids, which can lead to 
a decreased sensitivity of any RNA-based test. Thus, a good clinical RNA-based test will 
rely on the robustness of sample collection and having a high degree of sensitivity for its 
target. In chap te r 3, the sensitive quantitative RT-PCR technique that uses dual time- 
resolved fluorescence (TRF), an exogenous internal control and an external calibration 
curve, was compared with the transcription-mediated amplification-based test (Gen­
Probe Inc.), which became available at the end of 2006, for the detection of PCA3 
expressing prostate cancer cells in urinary sediments.
In chap te r 4, the RT-PCR-based PCA3 test was used to evaluate the utility of PCA3 
to detect prostate cancer cells in urinary sediments after digital rectal examination 
(DRE). This single institution study was the first to demonstrate the potential of a 
quantitative PCA3-based urine test to aid in the prediction of biopsy outcome.
In chap te r 5, the diagnostic performance of the RT-PCR-based PCA3 test was 
validated in a Dutch multicenter study on 583 men with elevated serum PSA values who 
were to undergo prostate biopsies. The PCA3 score determined in urinary sediments
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was correlated with the results of the prostate biopsies.
In chap te r 6, the PCA3 score in urinary sediments after DRE was correlated to the 
clinical stage, biopsy Gleason score, radical prostatectomy Gleason score, tumor 
volume, and pathological stage to assess its potential as predictor of prostate cancer 
aggressiveness.
Because prostate cancer is a heterogeneous disease, the use of a panel of 
biomarkers can further improve diagnostic accuracy. Fusions of the 5'-untranslated 
region of the TMPRSS2 gene with the ETS transcription factors ERG, ETV1, ETV4, and 
ETV5 have been reported in prostate cancer [20-22]. In chapter 7, the feasibility of the 
non-invasive detection of TMPRSS2-ERG  gene fusion transcripts in urinary sediments 
obtained after DRE using an RT-PCR-based research assay is studied. Furthermore, the 
diagnostic utility of the combination of PCA3 with TMPRSS2-ERG gene fusion 
transcripts in predicting biopsy outcome is evaluated.
Chapter 8 is an overview on PCA3, from its identification and its systematic and 
critical evaluation to a fully translated molecular assay in body fluids that is a valuable 
tool in predicting biopsy outcome.
In chap te r 9 a summary is provided of this thesis followed by the perspectives in 
chap te r 10.
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Chapter 2 
Abstract
Early diagnosis of prostate cancer can increase the curative success rate for this 
disease. Although serum prostate-specific antigen measurement is regarded as the best 
conventional tumor marker available, there is little doubt that it has great limitations. The 
threshold above which biopsies are indicated has now decreased to a serum prostate- 
specific antigen value of 3 ng/ml, which results in a high negative biopsy rate. This can 
readily be explained by the fact that prostate-specific antigen is not specific for prostate 
cancer. Clinicians need more sensitive tools to help diagnose prostate cancer and 
monitor progression of the disease. Molecular oncology is playing an increasing role in 
the field of diagnosis and therapy for prostate cancer and has already been instrumental 
in elucidating many of the basic mechanisms underlying the development and 
progression of this disease. The identification of new prostate cancer-specific genes, 
such as PCA3, would represent a considerable advance in the improvement of 
diagnostic tests for prostate cancer. This could subsequently lead to a reduction of the 
number of unnecessary biopsies.
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Introduction
Since there are no effective therapeutic options for advanced prostate cancer, early 
detection of this tumor is pivotal and can increase the curative success rate. Although 
the routine use of serum prostate-specific antigen (PSA) testing has undoubtedly 
increased prostate cancer detection, one of its main drawbacks has been the lack of 
specificity. Serum PSA is an excellent marker for prostatic diseases and even modest 
elevations almost always reflect a disease or perturbation of the prostate gland including 
benign prostatic hyperplasia (BPH) and prostatitis. Since the advent of frequent PSA 
testing over 20 years ago, the specificity of PSA for cancer has declined due to the 
selection of a large number of men who have elevated PSA due to non-cancer 
mechanisms. This results in a high negative biopsy rate. Therefore, new tests are 
needed for the diagnosis and screening of prostate cancer. These tests have to meet 
four basic requirements to be an effective and practical approach for early detection [1]:
•  Accurately discriminate between healthy males or males with non-malignant 
prostatic diseases and males with prostate cancer, with both high sensitivity and 
high specificity.
•  Detection of prostate cancer should occur when the cancer is still confined to the 
prostate and radical treatment is potentially curative.
•  Distinguish the indolent from the aggressive tumors to avoid the problem of over­
treatment.
•  Be well accepted by the population targeted for screening and be inexpensive.
An approach to improve diagnostic accuracy of tests for prostate cancer is through 
the identification of prostate cancer-specific genes. For the identification of new 
candidate markers for prostate cancer, it is necessary to study expression patterns in 
malignant as well as nonmalignant prostate tissues. Recent developments in the field of 
molecular techniques have provided new tools that enable the comprehensive and rapid 
assessment of both genomic and proteomic alterations in samples. For instance, the 
identification of different chromosomal abnormalities such as changes in chromosome 
number, translocations, deletions, rearrangements and duplications in cells can be 
studied using fluorescence in situ hybridization (FISH) analysis. Comparative genomic 
hybridization (CGH) is able to screen the entire genome for large changes in DNA 
sequence copy number or deletions larger than 10 Mbp. Differential display analysis, 
serial analysis of gene expression (SAGE), oligonucleotide arrays and complementary 
DNA (cDNA) arrays characterize gene expression profiles. These techniques are often 
used in combination with tissue microarrays (TMAs) for the identification of genes that
Biomarkers in the early diagnosis of prostate cancer
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play an important role in specific biological processes [2].
Since genetic alterations often lead to mutated or altered proteins, the signaling 
pathways of a cell may become affected. Eventually, this may lead to a growth- 
advantage or survival of a cancer cell. Proteomics is the term that refers to the 
identification of altered proteins in terms of structure, quantity, and post-translational 
modifications. Disease-related proteins can be directly sequenced and identified in intact 
whole tissue sections using the matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry (MS). Additionally, surface-enhanced laser 
desorption/ionization time-of-flight (SELDI-TOF) MS can provide a rapid protein 
expression profile from tissue cells and body fluids like serum or urine [3].
In the last years, these molecular tools have led to the identification of many genes 
that are believed to be relevant in the development of prostate cancer. Not only have 
these findings led to more insight in the initiation and progression of prostate cancer, 
they have also shown that prostate cancer is a heterogeneous disease. Several prostate 
tumors may occur in the prostate of a single patient due to the multifocal nature of the 
disease. Each of these tumors can show remarkable differences in gene expression and 
behavior that are associated with varying prognoses. Therefore, in predicting the 
outcome of the disease, it is more likely that a set of different markers will become 
clinically important.
This chapter focuses on the available data concerning the applicability of both old 
and new biomarkers in the early detection of prostate cancer in body fluids, such as 
urine and serum. It is based on the review 'Applicability of biomarkers in the early 
diagnosis of prostate cancer' that was published in 2004, and is updated with the latest 
available data on the biomarkers discussed [4]. The biomarkers are classified into four 
different prostate cancer-specific events: genomic alterations, prostate cancer-specific 
biological processes, epigenetic modifications and genes uniquely expressed in prostate 
cancer. This chapter will focus on whether current tests developed for several markers 
have the potential to reduce the number of unnecessary biopsies in men with total serum 
PSA values > 3 ng/ml.
Genomic alterations in prostate cancer 
Prostate cancer-associated gene mutations
One of the strongest epidemiological risk factors for prostate cancer is a positive 
family history. A study of 44,788 pairs of twins in Denmark, Sweden and Finland has 
shown that 42% of the prostate cancer cases were attributable to inheritance [5]. It has 
been observed that brothers of affected patients are consistently at higher risk for the
Chapter 2
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disease compared with the sons of the same patients. This has led to the hypothesis that 
there is an X-linked or recessive genetic component involved in the risk for prostate 
cancer [6]. Genome-wide scans in affected families implicated at least seven prostate 
cancer susceptibility loci, HPC1 (1q24), CAPB (1p36), PCAP (1q42), ELAC2 (17p11), 
HPC20 (20q13), 8p22-23 and HPCX  (Xq27-28). Recently, three candidate hereditary 
prostate cancer genes have been mapped to these loci, HPC1/2'-5'-oligoadenylate 
dependent ribonuclease L (RNASEL) on chromosome 1q24-25, macrophage scavenger 
1 gene (MSR1) located on chromosome 8p22-23, and HPC2/ELAC2 on chromosome 
17p11 [7].
It has been estimated that prostate cancer susceptibility genes account for only 10% 
of prostate cancer cases. Familial prostate cancers are most likely associated with 
shared environmental factors or more common genetic variants or polymorphisms. Since 
such variants may occur at high frequencies in the affected population, their impact on 
prostate cancer risk can be substantial. Recently, polymorphisms in the genes coding for 
the androgen-receptor (AR), 5a-reductase type II (SRD5A2), CYP17, CYP3A, vitamin D 
receptor (VDR), PSA, GST-T1, GST-M1, GST-P1, insulin-like growth factor (/GF)-I, and 
IGF binding protein-3 (/GFBP3) have been studied. These studies were performed to 
establish whether these genes can predict the presence of prostate cancer in patients 
indicated for prostate biopsies due to PSA levels >3 ng/ml. No associations were found 
between the AR, SRD5A2, CYP17, CYP3A4, VDR, GST-M1, GST-P1, and /GFBP3 
genotypes and prostate cancer risk. Only GST-T1 and /GF-/ polymorphisms were found 
to be modestly associated with prostate cancer risk [8].
Unlike the adenomatous polyposis coli (APC) gene in familial colon cancer, none of 
the mentioned prostate cancer susceptibility genes and loci were by themselves 
responsible for the largest portion of prostate cancers. Epidemiology studies support the 
idea that most prostate cancers can be attributed to factors as race, lifestyle and diet. 
The role of gene mutations in known oncogenes and tumor suppressor genes is 
probably very small in primary prostate cancer. For instance, the frequency of p53 gene 
mutations in primary prostate cancer is reported to be low but have been observed in 
almost 50% of advanced prostate cancers [9, 10].
Screening men for the presence of cancer-specific gene mutations or polymorphisms 
is time-consuming and costly. Moreover, it is ineffective in the detection of primary 
prostate cancers in the general male population. Therefore, it cannot be applied as a 
prostate cancer screening test.
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Mitochondrial DNA alterations
Mitochondrial DNA is present in approximately 1,000 to 10,000 copies per cell [11]. 
Due to these quantities, mitochondrial DNA mutations have been used as a target for the 
analysis of plasma and serum DNA from prostate cancer patients. Recently, 
mitochondrial DNA mutations were detected in all three prostate cancer patients who 
had the same mitochondrial DNA mutations in their primary tumor [12]. Different 
urological tumor specimens must be studied and larger patient groups are needed to 
define the overall diagnostic sensitivity of this method.
Microsatellite alterations
Critical alterations in gene expression can lead to the progression of prostate cancer. 
Microsatellite alterations, which are polymorphic repetitive DNA sequences, often appear 
as loss of heterozygosity (LOH) or as microsatellite instability. Defined microsatellite 
alterations are known in prostate cancer. However, for the detection of microsatellite 
instability, the ratio of tumor to normal must be greater than 0.5%. For the detection of 
LOH, at least 20% of the analyzed genomic DNA must be obtained from tumor cells [13]. 
This might become a problem in blood or urine samples, in which a single prostate 
cancer cell must be detected in a huge background of normal cells. Furthermore, 
microsatellite analysis using small amounts of DNA is prone to artifacts. Because of the 
low amounts of genomic DNA, microsatellite analysis and LOH may fail in the detection 
of tumor DNA in body fluids.
Prostate cancer-specific biological processes
Since many proteins are shed into the circulation as a consequence of disease 
progression, screening the blood for overexpressed proteins appears to be an excellent 
way to search for new prostate cancer biomarkers. From recent studies, there is growing 
evidence that kallikreins and kallikrein-like genes are related to many types of 
malignancies. Recently, it has been suggested that there may be crosstalk between the 
kallikreins and that they participate in pathways that affect normal physiological or 
pathological processes [14]. PSA is a member of the kallikrein family and since it has 
been successful in the diagnosis of prostate cancer, it is assumed that other kallikreins 
may also have diagnostic potential in prostate cancer.
Recently, 15 members of this gene family have been identified on chromosome 
19q13.3-13.4. These 15 genes have a highly conserved structural organization and 
encode for putative secreted proteases. Their enzymatic activity may initiate or terminate 
biological events such as angiogenesis and growth-factor release [15]. The release of
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these proteases into the blood circulation may reflect growth patterns of prostate cancer. 
In Table 1, an overview of the current biomarker-based tests and their sensitivity and 
specificity in the diagnosis of prostate cancer is given. In Table 2, the potential 
application of these biomarkers in the detection of prostate cancer is shown.
PSA and serum subforms of PSA
PSA, encoded by the KLK3 gene, is the most studied biomarker. Although widely 
accepted as a prostate tumor marker, PSA has turned out to be organ-specific but not 
prostate cancer-specific. Serum PSA levels have been reported to be increased in men 
with BPH and prostatitis. This substantial overlap in serum PSA values between men 
with non-malignant prostatic diseases and prostate cancer is the limitation of PSA as a 
prostate tumor marker. The threshold above which biopsies are indicated has now 
decreased to a serum PSA value of 3 ng/ml, which results in a high negative biopsy rate. 
Moreover, PSA cannot be used to differentiate the aggressive from the indolent tumors.
PSA is not overexpressed in prostate cancer cells. In fact, the PSA messenger RNA 
(mRNA) expression is approximately 1.5-fold lower in prostate tumor tissue compared 
with normal prostate tissue [16]. Therefore, it is assumed that the increase in serum PSA 
is a result of cancer progression. In the normal prostate, most of the produced PSA will 
be excreted into the semen where it acts as an androgen-regulated serine protease. 
Only a small amount of PSA will leak into the blood circulation. It is speculated that due 
to tumor development, the tissue architecture is altered by the disruption of the basal cell 
layer and basement membrane. It has been demonstrated that prostate cancer tissue 
releases 30-times more PSA into the circulation than normal prostate tissue [17]. 
Circulating PSA can occur in the serum either in an unbound free form or it can be bound 
to either a1-antichymotrypsin (a1-ACT) or a2-macroglobulin.
There have been several attempts to improve the specificity of serum PSA for the 
detection of prostate cancer in the range of 3 to 10 ng/ml, the so-called diagnostic PSA 
gray zone. These improvements include assessment of prostate size or PSA density, the 
rate of PSA increase with time (PSA velocity), age-specific or age-adjusted PSA cut-offs 
and free PSA (fPSA) [18-21]. All of these methods, separately or in combination, have 
aided decisions for biopsy. In particular, a very recent study of PSA velocity has revealed 
that men whose PSA increases by more than 2.0 ng/ml a year before diagnosis have a 
relatively high risk of death from prostate cancer even after radical prostatectomy [22].
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Percent free PSA
Although total PSA increases with probability of cancer, fPSA shows an inverse 
relationship. Studies on percent fPSA (%fPSA), which is the ratio of fPSA to total PSA, 
appeared promising to increase the specificity in the diagnostic gray zone. Significantly 
higher %fPSA values have been observed in the serum of patients with BPH compared 
with those found in the serum of patients with prostate carcinomas. As a consequence, 
the probability of prostate cancer increased with a decrease of %fPSA values [23]. In 
patients with serum PSA values of 4-10 ng/ml, %fPSA values at or below 25% resulted 
in the detection of 95% of prostate cancers upon biopsy and a reduction of 20% of 
unnecessary biopsies. Using a %fPSA cut-off value of 22% in the same group of 
patients, the sensitivity dropped to 90% but led to a 29% reduction of unnecessary 
biopsies [24].
On the other hand, patients with chronic prostatitis were demonstrated to have 
%fPSA values that are comparable with those of patients with prostate cancer [25]. This 
might lead to false-positive indications and thus to unnecessary biopsies. To date, 
controversy exists over using %fPSA values in addition to total PSA in screening for 
prostate cancer [26-28]. However, it has been reported that %fPSA appears to be more 
effective in the decision making of a repeat biopsy following an initial negative biopsy. In 
this way, a %fPSA cut-off value of 30% is optimal, leading to 90% sensitivity and a 
reduction of 50% of unnecessary biopsies [29].
ProPSA
Free PSA in serum is composed of three distinct forms of inactive PSA, as reviewed 
by Micolajczyk and coworkers [30, 31]. Two forms, benign PSA (BPSA) and intact 
nonnative PSA (inPSA) represent the correlation of fPSA with benign disease. Recent 
studies have shown that BPSA is more closely correlated with prostate size and BPH 
than fPSA, suggesting that this biomarker may be useful for monitoring therapy of BPH 
[32-35].
ProPSA is the third molecular form of fPSA and is the name for native proPSA ([- 
7]proPSA) as well as truncated proPSA forms ([-2]proPSA, [-4]proPSA and [-5]proPSA) 
[36, 37]. Serum proPSA is correlated directly with cancer. It has been demonstrated that 
in the diagnostic gray zone, total PSA had a specificity of 23%, %fPSA had a specificity 
of 33% and proPSA had a specificity of 13% at 90% sensitivity. A combination of these 
three variables resulted in a specificity of 44% in the diagnostic gray-zone, which 
remarkably improved the specificity for early prostate cancer detection [38].
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In a recent study, the development of highly sensitive and specific immunoassays for 
all intact and truncated forms of proPSA was described [39]. This study showed that the 
percentage of all proPSA forms (sum-proPSA/fPSA; area under the curve [AUC] of 0.69) 
is able to improve the detection of prostate cancer compared to %fPSA (AUC of 0.63) 
and total PSA (AUC of 0.53) in the PSA gray-zone used here of 4 to 10 ng/ml. Overall, 
%[-2]proPSA ([-2]proPSA/fPSA) showed the same diagnostic potential as %sum- 
proPSA. However, in men with high (>25%) %fPSA values, %[-2]proPSA showed better 
diagnostic potential than %sum-proPSA. In these samples, %[-2]proPSA would have 
spared 36% of men from unnecessary biopsies, whereas %sum-proPSA would only 
have spared 29% of men. Recently, at 90% sensitivity the combination of an articificial 
neural network (ANN) and logistic regression (LR) model each using %[-2]proPSA, 
%fPSA, total PSA and age reached the highest AUC (0.85) and specificity (ANN: 62.1%; 
LR:53.1%) compared with total PSA (22.7%) and %fPSA (45.5%). Furthermore, %[-2]- 
proPSA could better discriminate between pT2 and pT3 disease, and better distinguish 
Gleason score <7 prostate cancers from Gleason score >7 prostate cancers than total 
PSA and %fPSA [40]. In the 2-10 ng/ml PSA range, %[-2]proPSA was shown to have a 
high correlation with aggressive prostate cancers [41].
The use of [-5/-7] proPSA could not improve the diagnostic accuracy for prostate 
cancer [42]. However, the ratio [-5/-7]proPSA/%fPSA could discriminate Gleason score 
<7 prostate cancers from Gleason score >7 prostate cancers (p=0.001) and organ - 
confined from non-organ confined prostate cancer (p<0.0001) [43]. These studies 
suggest that the inclusion of proPSA can increase specificity of prostate cancer and 
provide information regarding the prognostic course of a patient.
hK2
There have been many studies on hK2, encoded by the KLK2 gene, which is another 
member of the kallikrein family. Like PSA, hK2 expression is regulated by androgens and 
has been detected in several other biological fluids such as amniotic fluid, breast milk, 
breast cyst fluid and in malignant and non-malignant breast tissues. In vitro studies have 
shown that active hK2, KLK4 and KLK15, which are also expressed at high levels in the 
prostate, convert latent proPSA into active PSA. The genes KLK2 and KLK3 show 80% 
homology and hK2 and PSA show 78% amino acid sequence identity. hK2 is found at 
much lower concentrations (1-2% of PSA concentrations) in prostate tissue. The 
presence of hK2 in seminal plasma, albeit at only 0.1-1% of PSA concentrations, 
suggests that hK2 is also involved the cleavage of gel forming proteins. The 
concentration of hK2 in serum is less than 3% of the PSA concentrations, and unlike 
PSA it exists mainly in the free, unbound form. The development of specific hK2
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immunoassays has been hampered by the high homology with PSA and the low hK2 
concentrations. This has resulted in highly sensitive assays for hK2 with low detection 
limits (<10 ng/l) [44].
Like PSA, hK2 is expressed less in malignant prostate tissue compared with non- 
malignant prostate tissue, albeit that the downregulation is less for hK2 than for PSA
[45]. In a study where gene expression of KLK2 and KLK3 in Gleason grade 4 or 5 
tumors was compared with the gene expression of both genes in BPH specimens, both 
genes were found to be more than tenfold overexpressed compared with other genes
[46]. However, there was no difference in gene expression between Gleason grade 4 or 
5 tumors and the BPH samples. The clinical use of hK2 as a replacement for total PSA 
based on relative gene expression levels did not appear to be promising. Recently it was 
shown that serum hK2 values alone were no more discriminatory than total PSA [47].
It has been determined that serum hK2 levels are remarkably higher in patients with 
advanced disease (median 116 ng/l) compared to patients with low Gleason scores 
(median 72 ng/l) or healthy men (median 26 ng/l) [48]. Moreover, serum hK2 is predictive 
of locally advanced and recurrent cancer in patients with PSA < 10 ng/ml. Independent of 
PSA and fPSA, hK2 can predict an unfavorable prognosis [49, 50].
It has been demonstrated that the ratio of serum hK2 to fPSA (%hK2) could better 
distinguish prostate cancer from BPH than total PSA. In the diagnostic gray zone at 
100% sensitivity, %hK2 had a specificity of 48.2% [51]. This would have spared 
unnecessary biopsies in half of the men with elevated PSA levels. The improved 
diagnostic value of %hK2 was confirmed by others [47, 52-54].
Recently it was shown that total PSA, fPSA or PSA-a1-ACT were not able to 
distinguish the poorly differentiated G3 tumors from the moderately differentiated G1 and 
G2 prostate tumors [55]. However, hK2 significantly improved the identification of G3 
prostate tumors compared with %fPSA. Furthermore, multivariate regression analysis 
revealed that combinations of %hK2 and fPSA/(total PSA x hK2) were significant 
predictors of G3 tumors in the PSA range of 3 to 15 ng/ml. The free PSA/(total PSA x 
hK2) ratios were also helpful in prediction of organ-confined disease. Higher ratios 
showed a better chance for curative treatment and lower ratios showed a lower chance 
for successful surgery.
These studies show that the %hK2 has diagnostic applicability in the diagnostic gray 
zone to distinguish prostate cancer patients from men with BPH (Table 1 and 2). As 
such, it can lead to a reduction of the number of unnecessary biopsies. Additionally, 
serum hK2 alone or in combination with total PSA and fPSA may improve the detection 
of extraprostatic or advanced disease. Multivariate regression analysis including hK2 
may become more important for prostate cancer diagnosis since it allows the more
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accurate prediction of tumor grade, stage or organ-confined disease.
KLK4
KLK4, which encodes the KLK4 protein, is one of the more recently discovered 
members of the kallikrein gene family. Initial studies using northern blot analysis, 
indicated that KLK4 expression was restricted to the prostate [56]. However, reverse 
transcription (RT)-PCR analysis demonstrated high KLK4 mRNA expression in prostate, 
testis, adrenals, uterus and thyroid. KLK4 expression was shown to be regulated either 
by androgens in the prostate cancer cell-line LNCaP, or by androgens and progestins in 
the breast cancer cell line BT-474 [57]. Using RT-PCR and immunohistochemistry (IHC) 
experiments, it has been shown that KLK4 is expressed both at the mRNA and protein 
level in normal human prostate tissues, primary prostate cancer tissues and metastatic 
prostate cancer tissues [58]. KLK4 mRNA expression was found to be higher in the 
majority of prostate cancer tissues compared with matched normal prostate tissues [59, 
60]. RNA in situ hybridization studies on normal and hyperplastic prostate tissue 
specimens in TMAs indicated that KLK4 is predominantly expressed in basal cells of the 
normal prostate [60].
There are two major endogenous isoforms of KLK4 protein expressed in the prostate, 
full-length KLK4-254 and the truncated KLK4-205 [61]. Full-length KLK4-254 is secreted 
in seminal fluid and is predominantly localized in cytoplasm of glandular epithelial cells 
[59, 61, 62]. The KLK4-254 transcript and its protein KLK4-254 were found to be 
overexpressed in prostate cancer [59, 61, 62]. The truncated KLK4-205 form is localized 
in the nucleus and could less discriminate between benign and malignant prostate tissue 
than KLK4-254 [60, 61].
Recently, KLK4 and PSA were implicated in the epithelial-mesenchymal transition 
(EMT) process, a critical event in the progression of most cancers [62]. Furthermore, a 
role for KLK4 in prostate cancer bone metastases has been suggested, since an 
interaction of KLK4 with both tumor cells and osteoblasts has been observed [63]. KLK4 
was found to be a proliferative factor with effects on gene expression [64]. Therefore, 
KLK4 may be a potential target for prostate cancer treatment because of its proteolytic 
ability to activate many tumorigenic and metastatic pathways including the protease 
activated receptors (PARs)[65, 66].
KLK4-specific antibodies have been detected in the sera of prostate cancer patients. 
These antibodies could have been generated by the immune system of prostate cancer 
patients after recognition of the KLK4 protein. It is not known whether the protein enters 
the blood circulation in individuals with or without prostatic disease [58].
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All these data suggest that KLK4 has a unique structure and function compared with 
the other members of the kallikrein family. In ovarian cancer, KLK4 expression appears 
to be associated with advanced ovarian carcinomas that have an unfavourable 
prognostic outcome of disease. Further studies are needed to assess the value of KLK4 
mRNA or protein as biomarker for prostate cancer.
KLK11
The KLK11 gene encodes for hippostasin, also known as hK11, trypsin-like serine 
protease (TLSP) or PRSS20. The protein KLK11 was found to be highly expressed in the 
prostate. A highly sensitive KLK11 immunofluorometric assay has been developed and 
high serum KLK11 values were determined in 60% of prostate cancer patients [67]. 
Recently, it has been demonstrated that the serum KLK11 values were significantly 
lower in prostate cancer patients compared with men with BPH. In this group of men with 
BPH, 45% would have avoided prostate biopsies based on %fPSA values of over 20%. 
When the ratio KLK11 to total PSA (%KLK11; >0.05) was applied, 51.5% of these men 
with BPH would not have to undergo unnecessary biopsies. At 90% sensitivity, %KLK11 
(0.05) had a specificity of 51.5% [68]. This indicates that in addition to PSA, %fPSA 
values combined with %KLK11 can lead to a higher reduction of unnecessary biopsies 
(Table 2). Future studies involving more patients are needed to confirm these preliminary 
data.
KLK14
KLK14 is another member of the kallikrein gene family. KLK14 expression has been 
found in the central nervous system and endocrine-related tissues, such as prostate, 
thyroid and testis [69]. Recently, KLK14 was shown to play a major role in semen 
liquefaction [70]. In situ hybridization studies have shown KLK14 mRNA expression in 
secretory epithelial cells of the normal prostate, prostatic intraepithelial neoplasia (PIN) 
and malignant prostate cells [71]. This expression pattern is similar to that observed for 
PSA and hK2. In a recent study a median 2.15-fold overexpression of KLK14 mRNA has 
been found in prostate cancer tissues compared with normal prostate tissues. Higher 
expression levels of KLK14 mRNA seem to correlate with advanced and more 
aggressive tumors [72].
Increased KLK14 protein expression in prostate cancer tissue samples correlated 
with shorter progression-free survival after radical prostatectomy and non-organ confined 
disease [73]. Serum KLK14 protein levels were significantly elevated in prostate cancer 
patients compared with healthy males [74]. The potential of KLK14 as new marker for 
prostate cancer diagnosis is worth studying.
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KLK15
The KLK15 gene has recently been identified. KLK15 is primarily expressed in the 
thyroid gland but expression has also been found in the prostate, salivary gland, adrenal 
glands, colon, testis and kidney, albeit at much lower levels. Studies in the LNCaP 
prostate cancer cell line have shown that KLK15 expression was upregulated by steroid 
hormones. In prostate cancer tissues, KLK15 mRNA was found to be overexpressed 
compared with normal prostate tissues [75]. A recent study using quantitative real-time 
PCR has shown an association between the upregulation of KLK15 and advanced and 
more aggressive prostate tumors [76]. Recently, a sensitive immunoassay specific for 
KLK15 protein has been developed, and KLK15 protein was detected in tissues of the 
prostate, colon and thyroid, as well as in breast milk and seminal plasma [77]. Studies on 
KLK15 protein levels in the serum of men with and without prostate cancer have not 
been published yet.
50.8-kDa protein
Using peptide mass fingerprinting, a 50.8-kDa protein (previously known as NMP48) 
was shown to be related to a vitamin D-binding protein. The protein has been detected in 
the sera of 96% of prostate cancer-affected men and in 53% of men with high-grade PIN. 
No expression has been found in the sera of men with benign prostates (75%), BPH 
(70%), status after radical prostatectomy (80%) or healthy controls (96%). This small 
preliminary study indicates a role for this protein as a biomarker for the early detection of 
prostate cancer [78] (Table 2).
The many studies showing enhanced specificity and sensitivity as well as prognostic 
utility for PSA, PSA forms and hK2 strongly suggests that a biomarker panel will provide 
significantly more diagnostic information than any one biomarker [39]. In particular, the 
combination of serum hK2 or KLK11 with different forms of serum PSA has the potential 
to reduce the number of unnecessary biopsies in the diagnostic gray zone. Moreover, 
serum hK2 may improve the detection of extraprostatic disease and %[2]pro-PSA may 
be used to discriminate between the more aggressive and indolent tumors.
Support for using a panel of proteins came from a recent study in which a novel 
technique, similar to SELDI-TOF MS, was combined with bioinformatics. It showed that 
complex serum protein profiles have the potential to identify prostate cancer and that the 
combination of two array types with different surface chemistries increased the number 
of more clinically significant discriminators. This new tool had an 85% sensitivity and 
specificity for the detection of prostate cancer [79]. In addition, such a serum-based 
proteomic pattern analysis has already proven to be successful in the early detection of
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ovarian cancer [80]. Using this method, the diagnosis of ovarian cancer was based on a 
panel of individual proteins, each of which was not independently discriminatory for the 
disease.
Epigenetic modifications
Alterations in DNA, without changing the order of bases in the sequence, often leads 
to changes in gene expression. These epigenetic modifications include changes such as 
DNA methylation and histone acetylation/deacetylation. Many gene promoters contain 
GC-rich regions also known as CpG islands. Abnormal methylation of CpG islands 
results in decreased transcription of the gene into mRNA. Recently, it has been 
suggested that the DNA methylation status may be influenced in early life by 
environmental exposures, such as nutritional factors or stress, and that this leads to an 
increased risk for cancer in adults [81]. Changes in DNA methylation patterns have been 
observed in many human tumors [82]. A technique known as methylation-specific PCR 
(MSP) is used for the detection of promoter hypermethylation. In contrast to 
microsatellite or LOH analysis, this technique requires a tumor-to-normal ratio of only
0.1-0.001%. This means that using this technique, hypermethylated alleles from tumor 
DNA can be detected in the presence of 104 -1 0 5 excess amounts of normal alleles [83]. 
Therefore, DNA methylation can serve as a useful marker in cancer detection. Recently, 
there have been many reports on hypermethylated genes in human prostate cancer. 
Two of these genes are Ras-association domain family protein isoform A (RASSF1A) 
and gluthathione S-transferase P1 (GSTP1).
RASSF1A
Hypermethylation of RASSF1A is a common phenomenon in breast, kidney, liver, 
lung and prostate cancer. The growth of human cancer cells can be reduced when 
RASSF1A is re-expressed. This supports a role for RASSF1A as a tumor suppressor 
gene [84]. Initially no RASSF1A hypermethylation was detected in normal prostate tissue 
[85, 86]. Recently, methylation of the RASSF1A gene was observed in both pre- 
malignant prostatic intra-epithelial neoplasms and benign prostatic epithelia [87]. 
RASSF1A hypermethylation has been observed in 60-74% of prostate tumors and in 
18.5% of BPH samples. Furthermore, the methylation frequency is clearly associated 
with high Gleason score and stage [85, 86, 88]. These findings suggest that RASSF1A 
hypermethylation may distinguish the more aggressive tumors from the indolent ones 
(Table 2).
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GSTP1
The most described epigenetic alteration in prostate cancer is the hypermethylation 
of the GSTP1 promoter. GSTP1 belongs to the cellular protection system against toxic 
effects and as such, is involved in the detoxification of many xenobiotics. GSTP1 
hypermethylation has been reported in approximately 6% of the proliferative 
inflammatory atrophy (PIA) lesions and in 70% of the prostate intra-epithelial neoplasia 
(PIN) lesions [89]. It has been shown that some PIA lesions merge directly with PIN and 
early carcinoma lesions, although additional studies are necessary to confirm these 
findings. Hypermethylation of GSTP1 has been detected in more than 90% of prostate 
tumors, whereas no hypermethylation has been observed in BPH and normal prostate 
tissues [90].
Hypermethylation of the GSTP1 gene has been detected in 50% of ejaculates from 
prostate cancer patients but not in men with BPH. Due to the fact that ejaculates are not 
always easily obtained from prostate cancer patients, hypermethylation of GSTP1 was 
determined in urinary sediments obtained from prostate cancer patients after prostate 
massage. Cancer could be detected in 77% of these sediments [91]. Moreover, 
hypermethylation of GSTP1 has been found in urinary sediments after prostate massage 
in 68% of patients with early confined disease, 78% of patients with locally advanced 
disease, 29% of patients with PIN and 2% of patients with BPH. These findings resulted 
in a specificity of 98% and a sensitivity of 73%. The negative predictive value of this test 
was 80%, which shows that this assay bears great potential to reduce the number of 
unnecessary biopsies. Recently, these results were confirmed and a higher frequency of 
GSTP1 methylation was observed in the urine of men with stage 3 versus stage 2 
disease [92]. Because hypermethylation of GSTP1 has a high specificity for prostate 
cancer, the presence of GSTP1 hypermethylation in urinary sediments of patients with 
negative biopsies (33%) and patients with atypia or high-grade PIN (67%) suggests that 
these patients may have occult prostate cancer [93].
Circulating cell-free DNA with GSTP1 CpG island hypermethylation could not be 
detected in the serum of healthy controls, men with a negative prostate biopsy and men 
with recurrence-free survival after radical prostatectomy. GSTP1 hypermethylation was 
detected in 12% of men with clinically localized disease, 15% of men who developed 
PSA recurrence and 28% of men with metastatic cancer. The presence of serum DNA 
with GTSP1 CpG island hypermethylation was the most significant predictor of PSA 
recurrence and correlates significantly with Gleason score and stage of disease [94, 95]. 
GSTP1 hypermethylation in the serum of castration resistant prostate cancer (CRPC) 
patients correlated significantly with differentiation of cancer and metastatic disease [95].
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The extent of GSTP1, RASSF1A, retinoic acid receptor p2 (RARB), and APC 
hypermethylation in blood samples increases during disease progression and can be 
used to identify the extent and duration of treatment response in prostate cancer [96]. 
Abberant methylation of these four genes in urinary cells obtained after prostate 
massage discriminated malignant from nonmalignant cases with 86% sensitivity and 
89% specificity [97].
Recently, a multiplexed assay consisting of 3 methylation markers, GSTP1, RARB, 
APC and an endogenous control was tested on urine samples from patients with serum 
PSA concentrations >2.5 pg/l. A  good correlation of GSTP1 with the number of prostate 
cancer-positive cores on biopsy was observed. Furthermore, samples that contained 
methylation for either GSTP1 or RARB correlated with higher tumor volumes [98].
Methylated genes have the potential to provide a new generation of cancer 
biomarkers, although prior to clinical utilisation, these findings require validation in 
prospective clinical studies. Furthermore, assays for measuring gene methylation need 
to be standardized, simplified and evaluated in external quality assurance programmes.
Genes uniquely expressed in prostate cancer
Microarray studies have been very useful and informative in identifying genes that 
are consistently up- or downregulated in prostate cancer compared with benign prostate 
tissue [99]. These genes can provide prostate cancer-specific biomarkers and provide a 
greater insight into the etiology of the disease. For the molecular diagnosis of prostate 
cancer, genes that are highly upregulated in prostate cancer compared with low or 
normal expression in normal prostate tissue are of special interest. Such genes could 
enable the detection of one tumor cell in a huge background of normal cells and thus be 
applied as a diagnostic marker in prostate cancer detection.
Gene fusions of TMPRSS2 with ETS family members
Differential gene expression analysis has been successfully used to identify prostate 
cancer-specific biomarkers by comparing malignant with non-malignant prostate tissues. 
Recently, a new biostatistical method called cancer outlier profile analysis (COPA) was 
used to identify genes that are differentially expressed in a subset of prostate cancers 
[100]. COPA identified strong outlier profiles for v-ets erythroblastosis virus E26 
oncogene (ERG) and ets variant gene 1 (ETV1) in 57% of prostate cancer cases [101]. 
This was in concordance with the results of a study where prostate cancer-associated 
ERG overexpression was found in 72% of prostate cancer cases [102]. In >90% of the 
cases that overexpressed either ERG or ETV1 a fusion of the 5' untranslated region of
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the prostate-specific and androgen-regulated transmembrane-serine protease gene 
(TMPRSS2) with these ETS family members was found. Recently, another fusion 
between TMPRSS2 and an ETS family member has been described, the TMPRSS2- 
ETV4 fusion, although this fusion is sporadically found in prostate cancers [103]. 
Furthermore, a fusion of TMPRSS2 with ETV5 was found. Overexpression of ETV5 in 
vitro was shown to induce an invasive transcriptional program [104]. These fusions can 
explain the aberrant androgen-dependent overexpression of ETS family members in 
subsets of prostate cancer because TMPRSS2 is androgen-regulated [101]. The 
discovery of the TMPRSS2-ERG gene fusion and the fact that ERG is the most- 
frequently overexpressed proto-oncogene described in malignant prostate epithelial cells 
suggests its role in prostate tumorigenesis. Fusions of the 5' untranslated region of the 
TMPRSS2 gene with the ETS transcription factors ERG, ETV1 and ETV4 have been 
reported in prostate cancer.
Recently, it was shown that non-invasive detection of TMPRSS2-ERG fusion 
transcripts is feasible in urinary sediments obtained after DRE using an RT-PCR-based 
research assay. Due to the high specificity of the test (93%), the combination of 
TMPRSS2-ERG fusion transcripts with prostate cancer gene 3 (PCA3) improved the 
sensitivity from 62% (PCA3 alone) to 73% (combined) without compromising the 
specificity for detecting prostate cancer [105].
Furthermore, it has been demonstrated that serine peptidase inhibitor Kazal type 1 
(SPINK1), golgi phosphoprotein 2 (GOLPH2) and TMPRSS2-ERG were, like PCA3, 
independent predictors of prostate cancer upon repeat biopsy [106]. By combining PCA3 
with these markers in a quantitative multiplexed RT-PCR analysis, the ROC AUC value 
improved from 0.66 (PCA3 alone) to 0.76. This multiplexed urine-based assay had 66% 
sensitivity and 76% specificity for detecting prostate cancer in repeat biopsies.
Using real-time PCR a positive correlation was found between TMPRSS2-ERG 
fusion transcripts in urine collected after prostate massage and a high serum PSA, 
pathological stage and Gleason score [107]. TMPRSS2-ERG gene fusions were highly 
associated with aggressive Gleason score >7 tumors and prostate cancer-related death 
[108].
AMACR
The gene coding for a-methylacyl-CoA racemase (AMACR) on chromosome 5p13 
has been found to be consistently up-regulated in prostate cancer. This enzyme plays a 
critical role in peroxisomal p-oxidation of branched chain fatty acid molecules obtained
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from dairy and beef [109]. Interestingly, the consumption of dairy and beef has been 
associated with an increased risk for prostate cancer [110].
In clinical prostate cancer tissue a ninefold over-expression of AMACR mRNA has 
been found compared with normal prostate tissue. Immunohistochemical (IHC) studies 
and western blot analyses have confirmed the upregulation of AMACR at the protein 
level. Furthermore, it has been shown that 88% of prostate cancer cases and both 
untreated metastases and castration resistant prostate cancers were strongly positive for 
AMACR [111]. AMACR expression has not been detected in atrophic glands, basal cell 
hyperplasia and urothelial epithelium or metaplasia. IHC studies also showed that 
AMACR expression in needle biopsies had a 97% sensitivity and a 100% specificity for 
prostate cancer detection [112]. Combined with a staining for p63, a basal cell marker 
absent in prostate cancer, AMACR greatly facilitated the identification of malignant 
prostate cells [113, 114]. Currently, the accuracy and specificity of AMACR in the 
detection of prostate cancer in biopsy specimens is regarded as an improvement over 
the serum PSA-test [115]. Its high expression and cancer cell specificity implies that 
AMACR may also be a candidate for the development of molecular probes that may 
facilitate the identification of prostate cancer using noninvasive imaging modalities (Table 
2) [111].
There have been many efforts to develop a body fluid-based assay for AMACR. First, 
an AMACR activity assay used on extracts derived from prostate needle biopsy 
specimen had 92.3% sensitivity and 89.2% specificity for prostate cancer detection 
(Table 2) [116]. Second, an AMACR immune reactivity assay showed 71.8% specificity 
and 61.6% sensitivity in distinguishing the sera of prostate cancer patients from those of 
healthy controls, and could be used in combination with serum PSA to reduce the 
number of unnecessary biopsies (Table 2) [117]. Third, a small study indicated that 
AMACR-based quantitative real-time PCR analysis on urine samples obtained after 
prostate massage has the potential to exclude the patients with clinically insignificant 
disease when AMACR mRNA expression is normalized for PSA [118]. Fourth, western 
blot analysis on urine samples obtained after prostate massage had a sensitivity of 
100%, a specificity of 58%, a positive predictive value (PPV) of 72%, and a negative 
predictive value (NPV) of 88% for prostate cancer (Table 2) [119]. These assays using 
AMACR mRNA for the detection of prostate cancer in urine specimen are promising. 
However, additional investigation is needed to validate the clinical usefulness of this 
biomarker.
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Hepsin
Using cDNA micro-array analysis, it has been shown that hepsin (HPN), a Type II 
transmembrane serine protease, is one of the most differentially overexpressed genes in 
prostate cancer compared with normal prostate and BPH tissues [120-122]. Using a 
quantitative real-time PCR analysis, it has been shown that hepsin is overexpressed in 
90% of prostate cancer tissues. In 59% of the prostate cancers, this overexpression was 
more than tenfold. There has also been a significant correlation between the 
upregulation of hepsin and tumor grade. Further studies must determine the tissue 
specificity of hepsin and the diagnostic value of this serine protease as a new serum 
marker.
Using a mouse model of nonmetastasizing prostate cancer, overexpression of hepsin 
was shown to cause disorganization of the basement membrane and promoted primary 
prostate cancer progression and metastasis to liver, lung, and bone [123]. Since hepsin 
is upregulated in advanced and more aggressive tumors, a role as a prognostic tissue 
marker is suggested in determining the aggressiveness of a tumor (Table 2) [124].
PSMA
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is 
expressed on the surface of prostate epithelial cells. The expression of PSMA appears to 
be restricted to the prostate. It has been shown that PSMA is upregulated in prostate 
cancer tissue compared with benign prostate tissues. No overlap in PSMA expression 
has been found between BPH and prostate cancer, indicating that PSMA is a very 
promising diagnostic marker [125](Table 2). Recently, it has been shown that high PSMA 
expression in prostate cancer cases correlated with tumor grade, pathological stage, 
aneuploidy and biochemical recurrence. Furthermore, increased PSMA mRNA 
expression in primary prostate cancers and metastasis correlated with PSMA protein 
overexpression [126]. Its clinical utility as a diagnostic or prognostic marker for prostate 
cancer has been hindered by the lack of a sensitive immunoassay for this protein. 
However, a combination of ProteinChip® (Ciphergen Biosystems) arrays and SELDI- 
TOF MS has led to the introduction of a protein biochip immunoassay for the 
quantification of serum PSMA. It was shown that the average serum PSMA levels for 
prostate cancer patients were significantly higher compared with those of men with BPH 
and healthy controls [127]. These findings implicate a role for serum PSMA to distinguish 
men with BPH from prostate cancer patients. However, further studies are needed to 
assess its diagnostic value.
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A combination of ProteinChip® arrays and SELDI-TOF MS has led to the introduction 
of a protein biochip immunoassay for the quantification of serum PSMA. It was shown 
that the average serum PSMA levels for prostate cancer patients were significantly 
higher compared with those of men with BPH and healthy controls [127]. These findings 
implicate a role for serum PSMA to distinguish men with BPH from prostate cancer 
patients. However, further studies are needed to assess its diagnostic value.
RT-PCR studies have shown that PSMA in combination with its splice variant PSM’ 
could be used as a prognostic marker for prostate cancer. In the normal prostate, PSM’ 
expression is higher than PSMA expression. In prostate cancer tissues, the PSMA 
expression is more dominant. Therefore, the ratio of PSMA to PSM’ is highly indicative 
for disease progression. Designing a quantitative PCR analysis which discriminates 
between the two PSMA forms could yield another application for PSMA in diagnosis and 
prognosis of prostate cancer (Table 2) [125, 128].
Because of its specific expression on prostate epithelial cells and its upregulation in 
prostate cancer, PSMA has become the target for therapies. The proposed strategies 
range from targeted toxins and radio nuclides to immunotherapeutic agents. First­
generation products have entered clinical testing [129].
5-catenin
8-catenin (p120/CAS), a p-catenin superfamily protein, has been shown to be highly 
discriminative between BPH and prostate cancer. In situ hybridization studies showed 
the highest expression of S-catenin transcripts in adenocarcinoma of the prostate and 
low to no expression in BPH tissue. The average overexpression of S-catenin in prostate 
cancer compared with BPH is 15.7 fold. Both quantitative PCR and in situ hybridization 
analysis could not find a correlation between S-catenin expression and Gleason score 
[125]. Increased S-catenin expression in human prostate cancer results in alterations of 
cell cycle and survival genes, thereby promoting tumor progression [130]. S-catenin was 
detected in cell-free human voided urine prostasomes. The S-catenin immunoreactivity 
was significantly increased in the urine of prostate cancer patients [131]. Further studies 
are needed to assess its potential utility in the diagnosis of prostate cancer.
PCA3
PCA3, formerly known as DD3, has been identified using differential display analysis. 
PCA3 was found to be highly overexpressed in prostate tumors compared with normal 
prostate tissue of the same patient using northern blot analysis [132]. Moreover, PCA3 
was found to be strongly overexpressed in more than 95% of primary prostate cancer
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specimens and in prostate cancer metastasis. Furthermore, the expression of PCA3 is 
restricted to prostatic tissue, that is, no expression has been found in other normal 
human tissues [133, 134]. The gene encoding for PCA3 is located on chromosome 
9q21.2. Open reading frame analysis revealed that the PCA3 exons are populated by an 
unusual number of stop codons. A gene that codes for proteins will typically possess one 
long open reading frame delimited by a stop codon. The multiplicity of stopcodons across 
the three reading frames of PCA3 and the lack of an extended open reading frame 
indicates that PCA3 does not encode a protein and functions as a non-coding RNA.
Recently, a time-resolved quantitative RT-PCR assay (using an internal standard and 
an external calibration curve) has been developed. The accurate quantification power of 
this assay showed a median 66-fold upregulation of PCA3 in prostate cancer tissue 
compared with normal prostate tissue. Moreover, a median upregulation of eleven-fold 
was found in prostate tissues containing less than 10% of prostate cancer cells. This 
indicated that PCA3 was capable of detecting a small number of tumor cells in a huge 
background of normal cells.
This hypothesis has been tested using the quantitative RT-PCR analysis on voided 
urine samples. These urine samples were obtained after DRE from a group of 108 men 
who were indicated for prostate biopsies based on a total serum PSA value of > 3 ng/ml. 
This test had 67% sensitivity and 83% specificity using prostatic biopsies as a gold­
standard for the presence of a tumor. Furthermore, this test had a negative predictive 
value of 90%, which indicates that the quantitative determination of PCA3 transcripts in 
urinary sediments obtained after DRE bears potential in the reduction of the number of 
invasive TRUS guided biopsies in this population of men [134].
The tissue-specificity and the high overexpression in prostate tumors indicate that 
PCA3 is the most prostate cancer-specific gene described so far. Gen-probe Inc. has the 
exclusive worldwide licence to the PCA3 technology and has successfully transferred the 
technology to its APTIMA® platform. APTIMA® uses transcription-mediated amplification 
(TMA), which is an RNA transcription amplification system using RNA polymerase and 
reverse transcriptase to drive the isothermal reaction. Multicentre studies using the 
validated PCA3 assay provided the first basis for the molecular diagnostics in clinical 
urological practice (Table 1 and 2). A review on PCA3 in the diagnosis of prostate cancer 
can be found in chapter 8.
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Table 1. Current biomarker-based tests and their sensitivity and specificity in the diagnosis of prostate cancer in the diagnostic 
prostate-specific antigen gray zone
Biomarker Application Method AUC Se Sp NPV Ref.
PSA Serum Hybritech tandem PSA 
assays or dual 
ProStatus assay
0.50-0.70 90 10-31 [24, 38, 
39, 47]
%fPSA Serum Hybritech tandem PSA 
assays or dual 
ProStatus assay
0.53-0.76 90 10-45 [24, 38,
39, 47, 51, 
68]
%sum-proPSA Serum Research use dual 
monoclonal antibody 
immunoassay
0.69 90 31 [39]
Combination of total Serum 
PSA, %fPSA and 
%sum-proPSA
Research use dual 
monoclonal antibody 
immunoassay
0.77 90 44 85 [38]
%[-2]proPSA Serum Research use dual 
monoclonal antibody 
immunoassay
0.64 90 21 [39]
hK2 Serum In-house-research
immunofluorometric
assay
0.68 90 20 [47]
fPSA/(tPSAxhK2) Serum Immunofluorometric
assay
0.75 88 57 85 [55]
hK2/fPSA Serum Immunofluorometric
assay
0.86 100 48 [51]
KLK11/tPSA Serum Immunofluorometric
assay
0.77 90 52 [68]
GSTP1 Urine MSP analysis 73 98 80 [91]
TMPRSS2-ERG + 
PCA3
Urine RT-PCR 73 93 [105]
TMPRSS2-ERG+
PCA3+
SPINK1+GOLPH2
Urine 0.76 66 76 [106]
PCA3 Urine Quantitative RT-PCR 
assay
0.72 67 83 90 [134]
AMACR Biopsy tissue IHC 97 100 [112]
Biopsy tissue 
extracts
AMACR activity assay 92 89 [116]
Serum AMACR immune 
reactivity assay
62 72 [117]
Urine AMACR western blot 
analysis
100 58 88 [119]
AUC: area under ROC curve, IHC: Immunohistochemistry, MSP: Methylation-specific PCR, NPV: negative predictive value Ref: References, RT:reverse 
transcription, Se: sensitivity, Sp: specificity
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Table 2. Biomarkers and their potential application in the detection of prostate cancer
Goal Biomarker Application Method Ref.
Discrimination of organ- hK2,fPSA/(tPSAxh K2) Serum Immunofluorometric [40, 43, 49,
confined disease from %[2]pro-PSA assays 50, 55, 73,
locally-advanced PCa [-5/-7]proPSA/%fPSA
KLK14
94, 95]
GSTP1 Urine MSP analysis
Discrimination between %[2]pro-PSA Serum Immunofluorometric [40, 43]
GS <7 and s7 [-5/-7]proPSA/%fPSA assays
Prediction of G3 tumors. hK2/fPSA (%hK2) 
fPSA/(tPSAxhK2)
Serum Immunofluorometric
Assays
[55]
Distinguish the more Hepsin Serum Immunofluorometric [40, 85, 86,
aggressive tumors from %[2]pro-PSA assays 88, 108,
the indolent ones.
124]
RASSF1A Urine MSP analysis
TMPRSS2-ERG Urine Quantitative RT-PCR
Reduction of the 50.8-kDa protein Serum Immunofluorometric [29, 38, 39,
number of unnecessary 
biopsies.
PSMA 
%KLK11 
%hK2 
fPSA
fPSA+ %KLK11 
KLK14
combination of tPSA, %fPSA and 
pro-PSA, %sum-proPSA, 
[-2]pro-PSA
Assays 51, 68, 74, 
78, 91, 97, 
105, 106, 
112, 116, 
117, 119, 
127, 134]
GSTP1 Urine MSP analysis,
combination of GSTP1 +
RASSF1A+RARB+APC+PCA3
Combination of PCA3+SPINK1+ Quantitative RT-PCR
GOLPH2 + TMPRSS2-ERG
TMPRSS2-ERG + PCA3
AMACR Tissue
Biopsy extracts
Serum
Urine
IHC
Activity assay 
Immune reactivity assay 
Western Blot analysis
Candidate for molecular AMACR Imaging modalities [111]
probe in imaging
modalities.
Prediction of disease PSMA/PSM’ Tissue, Blood Quantitative RT-PCR [125, 128]
progression
IHC: Immunohistochemistry, MSP: Methylation-specific PCR, PCa: prostate cancer, Ref: References, RT:reverse transcription
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RT-PCR-based detection of circulating tumor cells
With the introduction of the highly sensitive PCR technology, the detection of a single 
tumor cell in the huge background of predominantly normal cells became feasible to 
improve cancer diagnosis in blood samples. It is assumed that transcripts of epithelial 
cells do not normally occur in the blood circulation. Therefore, the detection of these 
transcripts in the serum or plasma indicates the presence of disseminated prostate 
cancer cells. In the two decades, many reports have been written on the RT-PCR-based 
detection of disseminated prostate cancer cells using PSA mRNA as target. However, 
remarkable differences were observed in the sensitivity of the RT-PCR-based assays 
since these assays were qualitative, not standardized, and difficult to reproduce in the 
various laboratories [135]. To enhance the sensitivity of these assays, researchers used 
nested PCR. This led to the amplification of illegitimate transcripts [136]. These are 
transcripts that have been produced and secreted at small amounts by any normal cell in 
the body, such as normal blood or epithelial cells. As a result, PSA mRNA transcripts 
were found in the serum of women and healthy controls [137]. As such, these RT-PCR- 
based methods were of limited value. New sensitive, quantitative, and more reproducible 
assays using exogenous internal standards for the detection of PSA and hK2 mRNA 
transcripts overcame this problem [138]. However, another problem arose when using 
organ-specific and not cancer-specific transcripts, such as PSA or hK2 mRNA. PSA 
mRNA transcripts were detected in the serum or plasma of men with and without 
prostate cancer after prostate biopsies. This lead to a false-positive indication for the 
presence of a disseminated cancer cell [139, 140]. However, the identification of highly 
overexpressed prostate cancer-specific genes combined with the validated quantitative 
RT-PCR assays could become valuable in the detection of disseminated cancer cells in 
serum or plasma.
Conclusions
Since there are no adequate therapeutic options for advanced prostate cancer, it is 
imperative that it is detected at an early stage when it is potentially curable. The 
screening tests for PSA show high sensitivity for prostate cancer detection. However, in 
the diagnostic gray zone, the specificity of PSA is only 20%, resulting in a negative 
biopsy rate of 70-80%. It has become clear that new markers are urgently needed to 
improve the specificity of PSA in the diagnostic gray zone.
Innovations in the field of molecular technology are rapidly growing. Recent 
technologies such as microarrays and proteomics have already provided new markers. 
In this review, several markers have been discussed that might have clinical utility in the
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early diagnosis of prostate cancer. The number of serum markers is rapidly growing due 
to the extensive human kallikrein family. By themselves they will not be able to improve 
the specificity for the early detection of prostate cancer. However, combined as a panel 
of markers, the specificity can be remarkably improved. Since prostate cancer is a 
heterogeneous disease, it becomes clear that a defined set of markers will become 
important in early prostate cancer diagnosis. Novel tests based on GSTP1 
hypermethylation and PCA3, which is highly overexpressed in prostate cancer, enabled 
the noninvasive detection of prostate cancer in body fluids such as urine or ejaculates. It 
becomes clear that through evaluation and clinical testing of the markers described 
herein, a greater insight onto their true diagnostic potential emerges.
Expert Opinion
The application of new technologies has shown that a large number of genes are 
upregulated in prostate cancer. For non-invasive screening tests, only those genes that 
are overexpressed in more than 95% of prostate cancer tissues compared with normal 
prostate or BPH will be important. Moreover, the upregulation of these genes in cancer 
should be more than ten-fold in prostate cancer compared with normal prostate to enable 
the detection of a single prostate cancer cell in a huge background of normal cells in 
body fluids. The close collaboration and communication between clinicians and 
researchers is essential in clinical testing of these markers to assess their true diagnostic 
potential and to evaluate the impact of these tests on the reduction of unnecessary 
biopsies and disease mortality.
Five year view
Despite the success of fPSA in cancer detection, several limitations remain. In the 
oncoming years, new assays will be developed for the measurements of the distinct 
forms of serum fPSA, particularly proPSA. The inclusion of proPSA can increase 
specificity of prostate cancer and provide information regarding the prognostic course of 
a patient. The combination of hK2 with several forms of PSA offers promising 
approaches for the discrimination of prostate cancer patients from men with BPH, and 
may be used in the prediction of organ-confined disease. Clinical studies using large 
patient groups will show the applicability of KLK11 in the reduction of the number of 
unnecessary biopsies. The combination of %fPSA values with %KLK11 appears 
especially promising. Large multi-center studies will show the real diagnostic application 
of these kallikreins and may lead to promising new serum-based tests. Another
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challenge of the oncoming years is to unravel the biological and physiological functions 
of KLK4, KLK11, KLK14 and KLK15.
In the next few years, the number of potential biomarkers will grow substantially, as 
will our understanding of the aetiology of prostate cancer. For diagnostic purposes, it is 
very important that the potential biomarkers are tested in terms of tissue-specificity and 
discrimination potential between prostate cancer, normal prostate and BPH. Until now, 
only telomerase, GSTP1 and PCA3 have been studied for their potential to reduce the 
number of biopsies. Ironically, TRUS-guided prostate biopsies are used as the gold 
standard in these studies. Therefore, many of the patients who are currently regarded as 
being negative for prostate cancer may become cancer patients in the near future. 
Consequently, follow-up data of these clinical studies will become important to achieve 
improved outcomes and management of prostate cancer.
To date, the most prostate cancer-specific gene is PCA3. As a urine marker PCA3 
has the potential to detect prostate cancer in men with a history of negative biopsies. 
The PCA3 test is now available to the urologist, which can be used as a reflex-test upon 
total PSA testing. The combination of PCA3 with TMPRSS2-ERG gene fusion data 
improved the sensitivity for prostate cancer diagnosis.
It is apparent that a biomarker panel will provide significantly more diagnostic 
information than any one biomarker. Therefore, future tests for prostate cancer diagnosis 
will trend towards the use of multiple markers, using multiplex assay formats. Since the 
detection of cancer cells directly is not only expected to be more specific for cancer but 
also a completely independent analysis for cancer compared to the surrogate markers in 
serum, it seems reasonable that both types of clinical diagnostic tests will be used 
effectively to provide much more accurate diagnostic and therapeutic decisions. 
Validated quantitative RT-PCR assays that are based on the detection of truly prostate 
cancer-specific genes may become important for the identification of patients with 
malignant disease. Innovations in new technologies will enable the development of more 
sensitive and accurate marker-based tests. The application of artificial neural networks 
and various logistic regression models may aid in the improvement of the positive 
predictive value of both serum and prostate cancer-specific markers.
Non-invasive marker-based assays used as screening tests in the early detection of 
prostate cancer are rapidly becoming reality.
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Abstract
Background. The time-resolved fluorescence (TRF)-based PCA3 test was shown to be 
a sensitive urine test for the detection of prostate cancer with potential to reduce the 
number of unnecessary biopsies. Recently, Gen-Probe Inc. translated this test to their 
transcription-mediated amplification (TMA) platform. This report describes the head-to- 
head comparison between these two PC.A3-based tests.
Methods. Urinary sediments were obtained after digital rectal examination from a cohort 
of 286 men admitted for prostate biopsies based on serum PSA levels between 3-15 
ng/ml. The PCA3 scores were determined using both quantitative tests and were 
correlated to biopsy results.
Results. ROC-curve analysis yielded an area under curve (AUC) of 0.648 and 0.682 for 
the TRF-based PCA3 test and TMA-based PCA3 test, respectively. For the TRF-based 
PCA3 test the sensitivity was 61%, the specificity was 68%, and the negative predictive 
value was 79%. For the TMA-based PCA3 test the sensitivity was 60%, the specificity 
was 68%, and the negative predictive value was 78%. In this study population the serum 
PSA test had an AUC of 0.555.
Conclusion. The user-friendly TMA-based PCA3 test and the more complex TRF-based 
PCA3 test perform similarly in the detection of prostate cancer cells in urinary sediments. 
The TMA-based PCA3 test is simple, fast and sensitive enough to be used in a clinical 
laboratory. The TMA platform is commercially available for several FDA-approved 
products, and its equipment is already present in many laboratories worldwide.
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Introduction
Because there are no adequate therapeutic options for advanced prostate cancer, 
early detection of prostate cancer is pivotal to increase the curative success rate for this 
disease. Although the routine use of serum prostate-specific antigen (PSA) testing has 
undoubtedly increased prostate cancer detection, one of its main drawbacks has been 
the lack of specificity that results in a high negative biopsy rate. Therefore, there is an 
urgent need for better biomarkers that can improve the specificity of prostate cancer 
diagnosis in the serum PSA gray zone between 3 and 15 ng/ml. Many candidate 
markers are currently being identified, however, only few are evaluated in multi-centre 
studies using standardized assays. One of the evaluated biomarkers is prostate cancer 
antigen 3 (PCA3). PCA3 is a prostate-specific noncoding RNA which is highly over­
expressed in more than 95% of primary prostate tumors [1]. To explore the diagnostic 
potential of PCA3, a dual time-resolved fluorescence (TRF)-based quantitative RT-PCR 
assay was developed. Hessels et al. used this TRF-based PCA3 test to evaluate the 
utility of PCA3 to detect prostate cancer cells in urinary sediments after digital rectal 
examination (DRE) [2]. Using this TRF-based PCA3 test it was shown that the median 
upregulation of PCA3 in prostate cancer tissue was 66-fold compared with adjacent non­
cancer prostate tissues. This was the first study that demonstrated the potential of a 
quantitative urinary PCA3 test to aid in the prediction of biopsy outcome [2]. Recently, 
the clinical performance of the TRF-based PCA3 test was confirmed in a Dutch 
multicenter study [3]. However, for implementation in clinical laboratories, a less 
intensive methodology is required for the accurate quantification of PCA3 mRNA 
transcripts that is as sensitive and robust as the TRF-based PCA3 assay. Recently, Gen­
Probe Inc. successfully transferred the TRF-based PCA3 test to its transcription- 
mediated amplification (TMA) platform [4]. This TMA-based PCA3 test has potential for 
worldwide implementation in clinical laboratories. In this study a head-to-head 
comparison was made between the TRF-based PCA3 test and the TMA-based PCA3 
test for the detection of prostate cancer cells in urinary sediments.
Materials and methods
Collection of urine samples after prostate massage
In the urological outpatient clinic of the Radboud University Nijmegen Medical 
Centre, first voided urine after DRE (20-30 ml first catch) was collected from a total of 
286 men with serum PSA levels between 3 and 15 ng/ml (extremes included) who were 
to undergo ultrasound-guided, transrectal, prostate biopsies as a result of local
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management. Beforehand, all men had received study information and had signed their 
informed consent.
The DRE was done according to a standard protocol: by applying firm pressure 
(enough to depress the surface) from the base to apex and from the lateral to the median 
line for each lobe. The men were asked to void, and the first voided urine was collected. 
The urine was collected in a container with 4 ml of 0.5 M EDTA pH 8.0, cooled to 4 °C 
and processed within 1 h. Upon centrifugation at 4°C and 700 x g for 10 min, urinary 
sediments were obtained. These urinary sediments were washed twice with ice-cold 
PBS (at 4°C and 700 x g for 10 minutes), snap-frozen in liquid nitrogen, and stored at 
-70°C. Twenty |ig of Escherichia coli (E.coli) tRNA was added to the urinary sediments 
(Roche Diagnostics, Almere, the Netherlands). Total RNA was extracted from these 
urinary sediments, using TRIzol® Reagent (Invitrogen™, Breda, the Netherlands).
Synthesis of PCA3 and IS-PCA3 RNA
The internal standard (IS)-PCA3 RNA was constructed using the “GeneEditor” in vitro 
site-directed mutagenesis system (Promega Corporation, Madison, WI, USA). Three 
substitutions (TCC to CGT) at positions 416 to 418 of the PCA3 cDNA (GenBank 
accession number AF103907) were introduced in the PCA3 cDNA construct pMB45. 
Mutations were confirmed by DNA sequence analysis.
Linearized pMB45 and pMB45-mutant plasmid DNA served as a template for in vitro 
transcription reactions using T3 RNA polymerase (Roche Diagnostics, Almere, the 
Netherlands). In vitro produced RNAs were DNase-I treated, purified by phenol 
extraction, precipitated and dissolved in diethylpyrocarbonate-treated water. The 
concentration and integrity of the RNAs were determined by agarose gel electrophoresis 
using RNA standards. The RNAs were stored in aliquots at -7 0  °C.
Calibration curves for PCA3 and PSA
Twelve-point calibration curves of both PCA3 and PSA were generated 
simultaneously. In vitro transcribed PCA3 RNA, IS-PCA3 RNA, PSA RNA and IS-PSA 
RNA were diluted in 0.2 mg/ml E.coli tRNA (Roche Diagnostics, Almere, the 
Netherlands). In twelve reaction vials, both IS-PCA3 RNA (5-103 copies) and IS-PSA 
RNA (5-103 copies) were mixed with a variable amount of PCA3 RNA (50 to 1-107 
copies) and PSA RNA (50 to 1-106 copies). For the quantification of PCA3 and PSA RNA 
in a sample, both IS-PCA3 and IS-PSA RNA (5-103 copies each) were added to 8 |il RNA 
of the sample. The reverse transcriptase reaction was performed using the first-strand 
cDNA synthesis kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). The RNA
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samples were heated for 10 min at 65°C followed by reverse transcription for 1 h at 
37oC, using 0.2 |ig of universal oligo-d(T )18 primer, 2 mmol/l DTT and 5 |il of a Bulk 1st 
strand reaction mixture.
Time-resolved fluorescence-based quantitative RT-PCR assay for PCA3
For PCR amplifications, the following PCA3-specific primers were used: forward, 5'- 
TGGGAAGGACCTGATGATACA-3' (nucleotides 97-117 of exon 1 of the PCA3 cDNA, 
GenBank accession number AF103907) and reverse, 5'-CCCAGGGATCTCTGTGCTT-3’ 
(nucleotides 459-477, spanning exons 3 and 4 of the PCA3 cDNA). Five |il of cDNA was 
amplified under a layer of mineral oil (Sigma-Aldrich, St Louis, MO, USA) in a 100 |il 
PCR reaction containing: 0.133 |imol/l reverse primer, 0.065 |imol/l biotinylated reverse 
primer, 0.4 |imol/l forward primer, 25 mmol/l deoxynucleotide triphosphates (Roche 
Diagnostics, Almere, the Netherlands), 2 Units of SuperTaq polymerase (HT 
Biotechnologie LTD, Cambridge, Cambridgeshire, UK) in buffer containing 1.5 mmol/l 
magnesium chloride, 10 mmol/l Tris-HCl (pH 8.3), 50 mmol/l potassium chloride and 
0.1% Triton X-100. The reaction mixtures were overlaid with mineral oil and 
thermocycling was performed on a Thermal Cycler (PerkinElmer Lifesciences Inc., 
Waltham, Massachusetts, USA) as follows: 95°C for 2 min followed by 35 cycles of 95°C 
for 1 min, 60°C for 1 min, 72°C for 1 min; followed by a final extension of 72°C for 10 
min.
Time-resolved fluorescence-based quantitative RT-PCR assay for PSA
To correct for the number of prostate cells present, the PSA mRNA transcripts were 
quantitatively determined in the same urinary sediments, using the quantitative RT-PCR 
protocol for PSA as described by Ylikoski et al. (1999) and modified by Hessels et al. [2, 
5]
Hybridization assay for PCA3
The PCR products were purified from mineral oil. Ten |il of each PCR product and 50 
|il of DELFIA® Assay buffer containing 1.5 mol/l NaCl were added to each well of a 
streptavidin-coated microtitration plate (Greiner Bio-One, Alphen aan de Rijn, the 
Netherlands) in triplicate. During an incubation at room temperature under slow shaking 
for 1 h, the biotinylated PCR products were captured to the streptavadin-coated wells. 
The wells were washed 3 times with DELFIA® Wash Solution. Then the double-stranded 
PCR products were denatured using 100 |il 50 mmol/l NaOH solution. After 5 min 
incubation at room temperature under slow shaking, the wells were washed 3 times with
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DELFIA® Wash Solution. For the target-specific detection, 30 pg/|il of a PCA3 Eu3+- 
labeled detection probe (5'(modC)2oCACATTTCCAGCCCCT-3') and 30 pg/|il of a Tb3+- 
labeled IS-PCA3 detection probe (5'(modC)2oCACATTCGTAGCCCCT-3') were used. 
During 2.5 h at 37°C, the probes were hybridized to the target of interest, followed by a 3 
times wash-step with DELFIA® Wash Solution at room temperature. After the addition of 
200 |il of DELFIA® Enhancement solution per well and incubation for 30 minutes at 
room temperature under slow shaking, the fluorescent signal obtained from the Eu3+ 
chelates was measured with a 1420 Victor™ Multilabel Counter. Then, 50 |il of DELFIA® 
(Tb3+) Enhancer Solution was added to each well, followed by incubation at room 
temperature under slow shaking for 5 min, and measurement of the fluorescent signal 
obtained from the Tb3+ chelates. All the DELFIA® reagents and the 1420 Victor™ 
Multilabel Counter were obtained from PerkinElmer Life Sciences (Waltham, 
Massachusetts, USA). The amount of PCA3 mRNA in the sample was calculated by 
comparing the PCA3/IS-PCA3 fluorescence ratio in the sample with that of the samples 
in the calibration curve.
The ratio PCA3/PSA was then calculated by dividing the number of PCA3 mRNA 
copies by the number of PSA mRNA copies obtained in a given sample. The PCA3 
score was defined as the ratio PCA3 mRNA/PSA mRNA x 1,000.
The TMA-based PCA3 test
The TMA-based PCA3 test (Gen-Probe Incorporated, San Diego, CA, USA) uses the 
following technologies: target capture, transcription mediated amplification, and 
hybridization protection. The components for the TMA-based PCA3 test include analyte- 
specific (PCA3 and PSA) target capture reagents, amplification reagents, probe 
reagents, as well as calibrators and controls. Eight |jl of RNA extracted from urinary 
sediments was dissolved in 2.6 ml of transport medium (STM), which stabilizes the 
mRNA. To determine the PCA3 score in a given sample, the TMA-based PCA3 test was 
run according to the protocol described by Groskopf et al. [4].
Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS, Cary, 
NC, USA) version 12.0.1 for Microsoft Windows. The nonparametric Mann-Whitney U 
test was used to test for differences in PCA3 score between men with a negative biopsy 
result and men with a positive biopsy result. A  P-value of <0.05 was considered 
significant.
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Results
TRF-based PCA3 test and correlation with biopsy results
Of the 286 men, 93 had prostate cancer in their biopsies, and the remaining had 
negative biopsies. The PCA3 scores obtained for both subject groups were summarized 
in a box plot (Fig. 1A). The median PCA3 score was 14 for the biopsy-negative 
population and 76 for the biopsy-positive population. This difference was highly 
significant (P < 0.0001), which was in agreement with previous data [2, 3].
No malignancy Prostate cancer No malignancy Prostate cancer
Fig. 1. Box plots showing the PCA3 scores in urinary sediments for both men with a negative and 
men with a positive biopsy result that were obtained using the TRF-based PCA3 test (A) and TMA- 
based PCA3 test (B). The median value (thick black horizontal line), outliers (open circles), and 
extremes (stars) are shown. The box length is the interquartile range and the whiskers extend to 
1.5x this distance.
The diagnostic efficacy of the TRF-based PCA3 test is visualized by a receiver- 
operating characteristic (ROC) curve, in which the test variable was the PCA3 score 
obtained from the urinary sediments and the state variable the biopsy result (Fig. 2). In 
the absence of an arbitrary cutoff value, we determined a cutoff value of 40 for prostate 
cancer diagnosis based on this ROC curve. A lower cutoff value would not have 
increased the sensitivity of the test, but would have resulted in a loss of specificity. A 
similar procedure was described earlier. The area under the curve (AUC), a measure of 
the diagnostic accuracy of a test, was 0.648 (95% confidence interval (CI), 0.578 -  
0.717). The diagnostic value of the serum PSA test is also visualized (Fig. 2); for serum 
PSA, the AUC was 0.555 (95% CI, 0.483 -  0.627). Using this cutoff of 40 for the 
detection of prostate cancer by the TRF-based PCA3 test, the sensitivity, specificity, and
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Fig. 2. The diagnostic efficacy of PCA3 gene-based analysis in urinary sediments is visualized by a 
ROC-curve. The ROC-curve for the TRF-based PCA3 test had an AUC-ROC of 0.648(95% CI: 
0.578-0.717). The ROC-curve for the TMA-based PCA3 test had an AUC-ROC of 0.682 (95% CI: 
0.615-0.750). The serum PSA test had an AUC-ROC of 0.555 (95% CI: 0.483-0.627). Based on 
these ROC-curves, a cutoff level of 40 was determined for the TRF-based PCA3 test and a cutoff of 
26 was determined for the TMA-based PCA3 test.
the negative predictive value was calculated. The sensitivity was 61%; the specificity was 
68%; and the negative predictive value was 79%.
TMA-based PCA3 test and correlation with biopsy results
To compare both PCA3 tests, the TMA-based PCA3 test was run on the same 
urinary sediments analysed using the TRF-based PCA3 test. The median PCA3 score 
was 9 for the biopsy-negative population, and 40 for the biopsy-positive population (Fig. 
1B). This difference was highly significant (P< 0.000001).
A  ROC curve was constructed and the AUC-ROC of the TMA-based PCA3 test was
0.682 (95% CI, 0.615 -  0.750) (Fig. 2). A cutoff value of 26 was determined based on 
this ROC curve. Using this cutoff value, the sensitivity was 60%, the specificity was 68%, 
and the negative predictive value was 78%.
TRF-based PCA3 test versus TMA-based PCA3 test
The positive and negative test results for both PCA3 tests were summarized in a 
table (Table 1). Using the defined threshold values, 228 out of 286 men (80%) were
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classified as either positive or negative by both tests. 89 men were shown to be positive 
for both tests of whom 46 (51%) had prostate cancer upon biopsy. Both tests were found 
to be negative for 139 men of whom 113 (81%) had a negative biopsy result.
However, 29 men were found to be positive for the TRF-based PCA3 test and 
negative for the TMA-based PCA3 test. Of these 29 men, 11 had prostate cancer in their 
prostate biopsy. Of the 28 men who were negative for the TRF-based PCA3 test and 
were found to be positive for the TMA-based PCA3 test, 10 men had prostate cancer in 
their prostate biopsy.
Comparison of two PCA3-based urine tests
Table 1: Concordance analysis of the TRF-based PCA3 test versus the TMA-based PCA3 test
TRF PCA3 score > 40 TRF PCA3 score < 40 Total
TMA PCA3 score > 26 89 28 117
TMA PCA3 score < 26 29 140 169
Total 118 168 286
PCA3: prostate cancer gene 3, TMA: transcription-mediated amplification, TRF: time-resolved fluorescence
Discussion
In this study, a head-to-head comparison was made between the TRF-based PCA3 
test and the TMA-based PCA3 test for the detection of prostate cancer cells in urinary 
sediments after DRE in men admitted for prostate biopsies based on serum PSA levels 
between 3-15 ng/ml. Both tests yielded median PCA3 scores that were significantly 
different between the biopsy-positive population and the biopsy-negative population. 
Although the accuracy of the TMA-based PCA3 test was slightly better than that of the 
TRF-based PCA3 test (AUC-ROC 0.682 versus 0.648), it yielded a sensitivity, a 
specificity and negative predictive value quite similar to those of the TRF-based PCA3 
test. In this study population the clinical performance of the serum PSA test had an AUC- 
ROC of only 0.555.
The TRF-based PCA3 test and the TMA-based PCA3 test are based on different 
methodologies, that is, RT-PCR and transcription-mediated amplification (TMA) of target 
RNA sequences. The TRF-based PCA3 test is based on RT-PCR, which is the most 
widely used method for the detection of low-level mRNA copy numbers in clinical 
specimens. In this test an internal standard was used. The internal standard corrects for 
variations during the entire assay procedure from reverse transcription to the detection of 
amplification products by the hybridization assay. The detection method, TRF, is 
considered as one of the most sensitive, non-radioactive techniques [6]. With an
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extraordinarily wide dynamic range, this method is able to detect as few as 50 up to as 
much as 1107 copies of PCA3 mRNA in a given sample [2, 7].
The TMA-based PCA3 test is based on: target capture (TC), transcription mediated 
amplification (TMA) and a hybridization protection assay (HPA). The TC technology 
allows the purification of the mRNA of interest from potential amplification inhibitors 
through the hybridization of the target mRNA to a complementary capture sequence. The 
resulting complex is then captured by poly-T oligonucleotides on magnetic particles. The 
magnetic particles are captured from the sample by a magnet and are washed to remove 
potential amplification inhibitors. TMA, an RNA transcription amplification system using 
RNA polymerase and reverse transcriptase to drive the isothermal reaction, amplifies the 
captured sequence. In contrast to RT-PCR, TMA amplifies RNA and produces RNA 
amplicons. In 15-30 minutes, up to 10 billion RNA amplicons can be generated. In the 
hybridization protection assay, the amplified products are detected using acridinium- 
ester-labeled probes. A luminometer determines the fluorescent signal as Relative Light 
Units (RLUs) [4].
The dynamic range of the TMA-based PCA3 test is smaller compared with that of 
the TRF-based PCA3 test. The TMA-based PCA3 test is able to detect as few as 233 up 
to 129,800 copies of PCA3 mRNA in a given sample. Because of the difference in 
methodology for amplification and detection, the PCA3 scores obtained with both tests 
were not similar. Using the TRF-based PCA3 test the median number of PCA3 mRNA 
transcripts found in the biopsy-negative population was 93 versus 337 for the biopsy 
positive population. Using the TMA-based PCA3 test the median number of PCA3 
mRNA transcripts found in the biopsy-negative population was 165 versus 744 for the 
biopsy-positive population. Thus, the number of PCA3 mRNA transcripts were almost 2­
fold higher for both biopsy-negative and biopsy-positive populations using the TMA- 
based PCA3 test. Using the TRF-based PCA3 test the median number of PSA mRNA 
transcripts found in the biopsy-negative population was 4,099 versus 4,248 for the 
biopsy-positive population. Using the TMA-based PCA3 test the median number of PSA 
mRNA transcripts found in the biopsy-negative population was 12,678 versus 13,101 for 
the biopsy-positive population. Thus, the number of PSA mRNA transcripts were almost 
3-fold higher for both biopsy-negative and biopsy-positive populations using the TMA- 
based PCA3 test. This explains why the PCA3 scores were lower for the TMA-based 
PCA3 test compared with the TRF-based test as was shown in the boxplot (Fig. 1.).
The TRF-based PCA3 test is a very sensitive test that can detect as few as 50 
PCA3 and PSA transcripts in a sample. The TMA-based PCA3 test has a higher limit of 
detection (233 PCA3 and 8545 PSA mRNA transcripts). The different set of calibrators
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used in both tests may account for some differences of quantification. However, 
especially in case of PSA, the amplification efficiency of the TMA-based PCA3 test 
seems to be more efficient than the thermal cycling amplification of the TRF-based PCA3 
test. The latter could be partly due to eliminating inhibition of amplification due to the use 
of TC.
Both tests were positive for 89 samples and negative for 140 samples (80% 
concordance). However, in 57 samples (20%) the TMA-based PCA3 test and the TRF- 
based PCA3 test yielded discordant results using the determined threshold values. In the 
majority of these cases the values were not clustered around the determined threshold 
values of the used test. Thus, the different results cannot be explained by the test 
variability. In almost half of the discordant cases the number of PCA3 mRNA copies was 
below the limit of detection using both tests. However, in the cases where the number of 
PCA3 mRNA transcripts were below the limit of detection in the TRF-based PCA3 test, 
the result of the TMA-based PCA3 test was above the limit of detection and vice versa. 
In these cases the sensitivity of both tests could account for the discordance. Further 
research is warranted to unravel the cause for the other discordant results.
The quantitative TMA-based PCA3 test was already shown to be a robust and user- 
friendly assay [4]. Importantly, this study shows that its diagnostic performance is 
equivalent to that of the TRF-based PCA3 test, and that the difference in technology has 
no impact on its diagnostic accuracy. The TRF-based PCA3 test can be completed in 9 
days, starting from RNA extraction to calculation of the number of PCA3 and PSA mRNA 
copies in a given sample. Next to twelve calibrators and three control samples, 33 
patient samples can be analyzed in triplicate.
The major advantages of the TMA-based PCA3 test over the TRF-based PCA3 test 
are its simplicity and the fact that the risk of contamination is minimized since the TMA- 
based PCA3 test is carried out in a single-tube format. PCA3 and PSA mRNAs are 
quantified using similar protocols and reagents, with components specific for the two 
analytes. Next to 5 calibrators and 2 control samples, 40 patient samples can be 
analyzed simultaneously for PCA3 and PSA in duplicate within 6 hours, which is a key 
point when used for clinical purposes. For clinical purposes, the specimen-processing 
procedure has been simplified using urine samples instead of urinary sediments. The 
analytical performance of the TMA-based PCA3 assay has been extensively studied in 
post-DRE urine specimens, showing a robust performance of the test within and across 
sites [8]. This technology is simple, fast and sensitive enough to be used in a clinical 
laboratory.
Comparison of two PCA3-based urine tests
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Conclusion
The fast and user-friendly TMA-based PCA3 test performs as well as the existing, 
labour intensive, and complex TRF-based PCA3 test. The TMA platform is commercially 
available for several FDA-approved products, and its equipment is already present in 
many laboratories worldwide. The CE-marked version of the TMA-based PCA3 test was 
launched at the end of 2006, and is now commercially available in Europe and the US 
under the trade name Progensa™ PCA3.
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Abstract
Background. PCA3 is the most prostate cancer-specific gene described to date. To 
assess the clinical utility of PCA3, a time-resolved fluorescence-based, quantitative RT- 
PCR analysis for PCA3 was developed.
Methods. The diagnostic potential of PCA3 was determined by quantitative 
measurement of PCA3 transcripts in non-malignant and malignant prostate specimens. 
Moreover, PCA3 transcripts were determined quantitatively in urinary sediments 
obtained after prostatic massage. A cohort of 108 men, admitted for prostate biopsies 
based on a PSA of >3 ng/ml, was studied.
Results. Prostate tumors showed a 66-fold upregulation of PCA3 (median 158.4-105 
copies/pg tissue) when compared with benign prostate tissue (median 2.4-105 copies/pg 
tissue). This upregulation was found in more than 95% of prostate cancer specimens 
studied. These data revealed that specimens with less than 10% of cancer cells could be 
accurately discriminated from non-cancer tissues. Hence, detection of a small fraction of 
prostate cancer cells in a background of normal cells seemed feasible. Therefore, this 
PCA3-based RT-PCR assay was used for the identification of prostate cancer in urinary 
sediments obtained after prostatic massage. From 108 men with a serum PSA value >3 
ng/ml, 24 men were shown to have prostate cancer upon biopsy. O f these 24 men, 16 
were shown to be positive for PCA3, indicating a sensitivity of the assay of 67%. 
Furthermore, a negative predictive value of 90% was calculated.
Conclusion. The quantitative RT-PCR assay for PCA3 described, bears great promise 
as a tool for molecular urine analysis. It has great potential in reducing the number of 
unnecessary biopsies. A multi-center study using this PCA3-based assay can provide 
the basis for the utility of molecular diagnostics in clinical urological practice.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy affecting the Western 
male population. It is the second leading cause of cancer related deaths in men [1]. 
Because the incidence of prostate cancer increases with age, the number of newly 
diagnosed cases continues to rise as the life expectancy of the general population 
increases. Prostate cancer can be cured by radical surgery or radiation therapy if the 
disease is localized within the prostate [2-5]. However, if the disease has spread locally 
or distantly, no curative treatment is available and these patients will suffer from a poor 
prognosis [6, 7]. Therefore, early diagnosis of the disease can increase the cure rate for 
prostate cancer. Although serum PSA measurement is regarded as the best 
conventional serum tumor marker available, there is little doubt that it has great 
limitations as well. The threshold above which biopsies are indicated has decreased now 
to a serum PSA value of 3 ng/ml, resulting in a negative biopsy rate of 70-80%. This can 
readily be explained by the fact that PSA is not specific for prostate cancer. One 
approach to improve diagnostic accuracy of tests for prostate cancer and to reduce the 
number of biopsies is to identify prostate cancer-specific genes.
Recently, a number of such genes have been identified and their usefulness in the 
diagnosis and prognosis of prostate cancer is under investigation. Elevated expression 
of prostate-specific membrane antigen (PSMA), an integral transmembrane glycoprotein, 
has been correlated with poor prognosis and especially with more aggressive metastatic 
disease [8]. Overexpression of NKX3.1, an androgen-regulated homeobox gene, has 
been found in prostate tumors [9]. Increased expression of prostate stem cell antigen 
(PSCA) has been correlated with higher Gleason grade and bone metastasis [10]. 
Expression of prostate tumor inducing gene-1 (PTI-1) has been found in human prostate 
carcinomas, but not in normal prostate or benign prostatic hyperplasia (BPH) [11]. It has 
been shown that prostate-specific transcript-1 (PCGEM-1) exhibits a significant prostate 
tumor-associated overexpression [12]. Other prostate-specific genes are SAM pointed 
domain containing ets transcription factor (PDEF) [13], transmembrane serine 2 protease 
(TMPRSS2) [14], prostase (KLK4) [15] and prostate cancer gene 3 (PCA3)[16, 17] . So 
far, diagnosis based on the expression of these prostate-specific genes has not been 
described.
PCA3 is the most prostate cancer-specific gene described so far. PCA3 is strongly 
overexpressed in more than 95% of primary prostate cancer specimens and in prostate 
cancer metastasis [16, 17]. Furthermore, the expression of PCA3 is restricted to prostatic 
tissue, i.e. no expression in other normal human tissues was found. The gene encoding 
PCA3 is located on chromosome 9q21.2. Open reading frame analysis revealed that the
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PCA3 exons are populated by an unusual number of stop codons. A gene that codes for 
proteins will typically possess one long open reading frame delimited by a stop codon. 
The multiplicity of stop codons across the three reading frames of PCA3 and the lack of 
an extended open reading frame indicates that PCA3 does not encode a protein and 
functions as a non-coding RNA.
To evaluate the potential usefulness of PCA3 as a diagnostic marker for prostate 
cancer, a time-resolved fluorescence-based quantitative RT-PCR assay (using an 
internal standard and an external calibration curve) has been developed. The sensitivity 
and specificity of this time-resolved fluorescence-based quantitative RT-PCR assay for 
PCA3 have been validated on a large panel of well-characterized normal and malignant 
prostate specimens.
This study was undertaken to determine whether this PCA3-based RT-PCR assay is 
applicable as a non-invasive diagnostic test for prostate cancer. The target group 
consisted of men who where indicated for prostate biopsies because of a serum PSA 
value above 3 ng/ml. Voided urine samples were collected from these men after prostatic 
massage. The PCA3-based RT-PCR assay was then used for the identification of 
prostate cancer cells in these urinary sediments. For diagnostic purposes the sensitivity, 
specificity and negative predictive value of this test were determined.
Materials and methods
Tissue specimens
Radical prostatectomy specimens were obtained from the Canisius Wilhelmina 
Hospital Nijmegen and the Radboud University Nijmegen Medical Center. Normal 
prostate, BPH and prostate tumor specimens were obtained from fresh prostates. 
Gleason scores and TNM classification of these tumors were determined at the 
department of Pathology of both hospitals. The specimens were snap frozen in liquid 
nitrogen, processed by step sectioning and at regular intervals a Hematoxilin & Eosin 
staining was performed to determine the percentage of normal, BPH and tumor cells in 
the tissue sections. Total RNA from these tissue specimens was isolated by the LiCl- 
urea method [18].
Collection of urine samples after prostate massage
Voided urine samples were collected from a cohort of 108 consecutive patients that 
were admitted for prostatic biopsies based on serum PSA levels above 3 ng/ml. After 
rectal examination of the prostate, urine was collected. The urine samples were coded 
and immediately cooled on ice. Upon centrifugation at 4°C and 700g for 10 minutes,
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urinary sediments were obtained. These urinary sediments were washed twice with ice- 
cold phosphate-buffered saline (at 4°C and 700g for 10 minutes), snap-frozen in liquid 
nitrogen, and stored at -70°C. The urinary sediments were spiked with 20 |ig of E.coli 
tRNA as a carrier (Roche Diagnostics). Total RNA was extracted from these urinary 
sediments, using TRIzol® Reagent (Invitrogen).
Time-resolved fluorescence-based quantitative RT-PCR assay for PCA3
The PCA3 transcripts were quantitatively determined in the urinary sediments, using 
the time-resolved based quantitative RT-PCR protocol for PCA3. Briefly, in vitro 
transcribed PCA3 RNA and internal standard (IS) PCA3 RNA were used as templates for 
cDNA synthesis using the first-strand cDNA synthesis Kit (Amersham). PCA3 and IS- 
PCA3 RNA were diluted in 0.2 mg/ml E.coli tRNA (Roche Diagnostics), that was used as 
carrier RNA. For the preparation of a calibration curve, 5 1 0 3 copies of IS-PCA3 RNA 
were mixed with a variable amount (50 to 1 1 0 7 copies) of PCA3 RNA. For the 
quantification of PCA3 RNA in a sample, 5 1 0 3 copies of IS-PCA3 RNA were added to 
each RNA sample before the reverse-transcriptase reaction. The RNA samples were 
heated for 10 minutes at 65°C followed by reverse transcription for 1 hour at 37oC, using
0.2 |ig of universal oligo-d(T )18 primer, 2 mM DTT and 5 |il of a Bulk 1st strand reaction 
mixture (Amersham).
For PCR amplifications, the following PCA3-specific primers were used: forward, 5'- 
TGGGAAGGACCTGATGATACA-3' (nucleotides 97-117 of exon 1 of the PCA3 cDNA, 
GenBank #AF103907) and reverse, 5'-CCCAGGGATCTCTGTGCTT-3' (nucleotides 
459-477, spanning exons 3 and 4 of the PCA3 cDNA). After 35 cycles of PCR, the 
amplification products were quantified by the time-resolved fluorescence-based 
hybridization assays on streptavidin-coated microtitration wells (Greiner Bio-One). For 
the target-specific detection a PCA3 detection probe (30 pg/|il) labeled with Eu3+ and a 
IS-PCA3 detection probe (30 pg/|il) labeled with Tb3+ were used. The amount of PCA3 
RNA in the sample was calculated by comparing the PCA3/IS-PCA3 fluorescence ratio 
in the sample with that of the samples in the calibration curve.
Time-resolved fluorescence-based quantitative RT-PCR assay for PSA
PSA transcripts were also quantitatively determined in the same urinary sediments, 
using the quantitative RT-PCR protocol for PSA as described by Ylikoski et al. (1999) 
[19]. Different PSA-specific primers were used for PCR: forward, 5'- 
AGCATTGAACCAGAGGAGTTCT-3' (nucleotides 4024-4042 of exon 3 and 4186-4188 
of exon 4 of the PSA cDNA, GenBank #M27274) and reverse, 5'-CCCGAGCAG
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GTGCTTTTG-3' (nucleotides 4307-4322 of exon 4 and 5699-5700 of exon 5 of the PSA 
gene).
Statistical analysis
Using the Statistical Package for Social Sciences (SPSS) the data were summarized 
in a Receiver Operating Characteristic curve (ROC) to visualize the efficacy of PCA3 as 
a marker. In this curve the sensitivity (true positives) was plotted on the Y-axis against 1- 
specificity (false positives) on the X-axis. In this curve all observed values were 
considered as arbitrary cutoff values. The Area Under Curve (AUC) and its 95% 
confidence interval was calculated as a measure for the discriminative efficacy of the 
tested marker. If the marker has no discriminative value, the AUC value is close to 0.5. In 
this case the AUC will be close to the diagonal in the curve. If a marker has strong 
discriminative power, the ROC curve will be close to the upper left corner (AUC is close 
to 1).
Results
Quantification of PCA3 mRNA expression in tissue specimen
The quantitative RT-PCR assay was used to evaluate the potential usefulness of 
PCA3 as a diagnostic marker for prostate cancer. First we determined the prostate- 
specificity of PCA3 by measuring the number of PCA3 transcripts in the cDNA obtained 
from several normal tissues of breast, bladder, duodenum, heart, liver, lung, kidney, 
prostate, seminal vesicle, skin, stomach, testis and peripheral blood leukocytes. All 
samples, except prostate, were negative for PCA3. These data (not shown) were in 
concordance with earlier published data [16, 17].
Next, PCA3 mRNA expression was determined in the following tissue specimens: 
BPH (n=8), normal prostate (n=4), prostate tumor containing equal or less than 10% of 
prostate cancer cells (n=13), prostate tumor containing more than 10% of prostate 
cancer cells (n=27) in order to evaluate the specificity of PCA3 as a prostate tumor 
marker. There was no difference in the expression of PCA3 mRNA between non- 
malignant prostate tissue and BPH tissue and therefore both were included in the group 
of non-malignant controls. In prostate tumors, containing more than 10% of prostate 
cancer cells, the median upregulation of PCA3 was 66-fold (median, 158.4105; range, 
7 .0105 -  994.0 105) compared with the PCA3 mRNA expression in non-malignant 
controls (median, 2.4-105; range 0.2-105 -  10.1 • 105) (Fig. 1). Even in prostate tumors 
containing less than 10% of prostate cancer cells, the average upregulation of PCA3 was 
11-fold (median 25 .3105; range 6 .6105 -  166.0 105) compared with the expression in
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Fig. 1. The expression of PCA3 RNA (x 1105 copies/ |jg tissue RNA) in non-malignant prostate 
(benign), prostate tissue containing equal to or less than 10% tumor cells (<10% PCa) and prostate 
tissue containing more than 10% tumor cells (>10% PCa). The median expression (the thick black 
horizontal line in the different tissue specimen) and outliers (open circles) are shown. One extreme 
of 993 105 copies per microgram tissue in the group of >10% PCa is not shown.
non-malignant controls. In seven human radical prostatectomy specimens the PCA3 
expression in tumor areas was compared with the PCA3 expression in the adjacent non­
neoplastic prostate tissue from the same patients. Using the quantitative PCA3 RT-PCR 
analysis a 6 to 1500-fold upregulation of PCA3 was found in these prostate tumors 
compared with the adjacent non-neoplastic prostate tissue (Table 1).
Table 1. Comparison of PCA3 mRNA expression between non-malignant prostate and prostate 
tumor tissue of the same patient
Patient Sample code PCA3 mRNA copies/|jg tissue RNA (1 • 104)
NPr PCa NPr PCa Ratio T/N
1 128 129 100 590 6
2 674 673 76 630 8
3 127 126 7 113 16
4 663 664 31 2965 96
5 234 235 74 9940 134
6 120 118 18 2648 147
7 162 163 2 2973 1487
NPr: normal prostate tissue, PCa: prostate tumor tissue
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When selected prostate tumor and normal prostate tissue specimens were analyzed 
for PCA3 expression, the AUC-ROC value was 0.98 (95% CI: 0.94-1.00), indicating that 
the PCA3-based assay is very specific and may have strong diagnostic value.
Quantification of PCA3 transcripts in urinary sediments after prostate massage
The described quantitative RT-PCR assay was used to evaluate the potential 
usefulness of PCA3 as a diagnostic tool for the detection prostate cancer cells in a high 
background of non-malignant cells. The PSA mRNA expression has been shown to be 
relatively constant in normal prostate cells and only a weak (~1.5-fold) downregulation of 
PSA expression in prostate cancer cells has been reported [20]. Therefore, PSA 
transcripts were quantitatively determined to correct for the number of prostate cells 
present in urinary sediments. The PCA3/PSA ratio was then used as a diagnostic tool for 
the accurate identification of prostate cancer cells in urinary sediments obtained after 
prostate massage.
A cohort of 108 consecutive patients that were admitted for prostatic biopsies, based on 
serum PSA levels of more than 3 ng/ml, was tested. After prostate massage voided urine 
samples were collected and PCA3 transcripts and PSA transcripts were quantitatively 
determined in these urinary sediments. From the cohort of 108 biopsies, 24 biopsies 
were positive for prostate cancer while the other 84 biopsies were negative (Table 2a 
and 2b). To visualize the diagnostic efficacy of the PCA3-based RT-PCR assay of urine 
samples in the absence of an arbitrary cutoff value the data were summarized using a 
Receiver Operating Characteristic curve (ROC) (Fig. 2). The AUC-ROC was 0.717 (95% 
CI: 0.58-0.85). Based on this ROC curve a cutoff level of 200-10'3 was determined. 
H igher cutoff values would not increase the sensitivity of this test but would only result in 
a loss of specificity. Fourteen out of 84 men who had negative biopsies had higher 
PCA3/PSA ratios than this cutoff value. This indicated that using this cutoff value, the 
specificity of this PCA3 -based RT-PCR assay was 83%. More important, of the 24 men 
who had positive biopsies, 16 had a positive PCA3/PSA value. This indicated that the 
PCA3-based RT-PCR assay used for the detection of prostate cancer in urinary 
sediments after prostate massage had a sensitivity of 67%. Moreover, the negative 
predictive value of PCA3 measurements is 90%.
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Fig. 2 . To visualize the diagnostic efficacy of the PCA3-based assay of urine samples in the 
absence of an arbitrary cutoff value the data were summarized using a ROC. Based on this ROC 
curve, a cutoff level of 20010-3 was determined (arrow). Higher cutoff values would not increase the 
sensitivity of this test but would only result in a loss of specificity.
Discussion
Prostate cancer is the most commonly diagnosed cancer and the second cause of 
cancer deaths in the Western male population. Only if the disease is still confined to the 
prostate it can be cured by radical surgery or radiation therapy. To reduce the mortality 
rate, there have been numerous efforts to detect this malignancy in an early stage. After 
its discovery twenty years ago, PSA has been considered to be the most valuable tool in 
the early detection, staging and monitoring of prostate cancer [21]. PSA turned out to be 
not prostate cancer-specific since elevated serum PSA levels were detected in patients 
with BPH and prostatitis. One of the limitations of PSA as a tumor marker is that there is 
a substantial overlap in serum PSA values between men with BPH and prostate cancer.
Currently, upon an elevated PSA level of more than 3 ng/ml the conventional 
diagnostic approach are the traditional sextant transrectal ultrasound (TRUS) guided 
prostate biopsies. Moreover, extension of the diagnostic set to ten biopsies is 
recommended by most academic centers. This invasive approach often leads to non­
representative biopsy specimens in which prostate cancer is detected in only about a 
third of the patients with elevated PSA levels [22]. Repeated biopsies reveal the 
presence of prostate cancer in another 10-20% of the cases. There is an urgent need to
73
Table 2A. PCA3/PSA ratios in urinary sed im en ts  obtained after DRE
Sample
number
Urine
code
Serum PSA 
[ng/ml] Pathology
PCA3/PSA 
(x 1-10'3)
Sample
number
Urine
code
Serum PSA 
[ng/ml] Pathology
PCA3/PSA 
(x 1-10'3)
1 D05 15.7 Chronic inflammation 0 29 D38 6.9 Chronic inflammation 33
2 D12 8.7 Chronic inflammation 0 30 D54 5.9 Chronic inflammation and atrophy 33
3 D15 12.2 Chronic inflammation 0 31 D56 15.4 No abnormalities 35
4 D65 9.2 Chronic inflammation 0 32 D49 >3.0 Chronic inflammation and atrophy 40
5 D67 5.5 No abnormalities 0 33 D100 6.8 Atypia 41
6 D104 8.0 Atypia and chronic inflammation 0 34 D24 8.5 No abnormalities 41
7 D110 11.1 No abnormalities 0 35 D46 8.6 Atrophy 41
8 D81 8.5 Chronic inflammation and atrophy 3 36 D11 20.3 Chronic inflammation and atrophy 42
9 D106 18.0 Atypia and chronic inflammation 4 37 D09 4.2 Chronic inflammation 46
10 D04 4.6 No abnormalities 8 38 D41 6.5 No abnormalities 49
11 D20 5.1 Atrophy 8 39 D31 7.4 Chronic inflammation and atrophy 50
12 D94 12.2 No abnormalities 8 40 D17 14.0 Chronic inflammation 52
13 D114 10.4 Chronic inflammation and atrophy 16 41 D73 5.6 Chronic inflammation and atrophy 55
14 D27 16.7 Chronic inflammation 16 42 D35 35.1 Chronic inflammation and atrophy 57
15 D80 5.5 No abnormalities 16 43 D02 8.3 Chronic inflammation and atrophy 59
16 D97 6.7 Chronic inflammation and atrophy 17 44 D13 6.9 Chronic inflammation and atrophy 61
17 D78 >3.0 No abnormalities 17 45 D30 2.3 No abnormalities 65
18 D58 9.5 Chronic inflammation 18 46 D52 6.8 Chronic inflammation 76
19 D109 8.4 No abnormalities 19 47 D01 9.9 Atrophy 78
20 D26 9.9 Chronic inflammation 20 48 D74 7.6 Chronic inflammation and atrophy 82
21 D14 6.8 No abnormalities 24 49 D75 15.6 No abnormalities 82
22 D95 13.4 Chronic inflammation and atrophy 25 50 D111 7.8 Chronic inflammation 83
23 D44 21.6 Chronic inflammation and atrophy 25 51 D06 12.0 No abnormalities 84
24 D39 9.4 Atrophy 27 52 D69 2.7 Chronic inflammation 95
25 D92 3.5 BPH 27 53 D21 9.1 No abnormalities 100
26 D23 1.1 No abnormalities 28 54 D112 53.9 Atypia 101
27 D79 15.5 Chronic inflammation 30 55 D08 CO 03 No abnormalities 105
28 D48 7.6 No abnormalities 32 56 D22 9.1 Chronic inflammation and atrophy 105
BPH: benign prostatic hyperplasia, PC A3: prostate cancer gene 3, PSA: prostate-specific antigen
Table 2B. PCA3/PSA ratios in urinary sed im en ts  obtained after DRE
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Sample
number
Urine
code
Serum PSA 
[ng/ml]
Pathology
PCA3/PSA 
(x 1-10'3)
Sample
number
Urine
code
Serum PSA 
[ng/ml]
Pathology
PCA3/PSA 
(x 1-10'3)
57 D40 6.1 PIN l-ll 105 85 D10 48.3 PCa: Gleason 4+4=8 0
58 D28 7.2 No abnormalities 109 86 D70 6.1 PCa:Gleason 3+3=6 17
59 D91 10.2 Atrophy 119 87 D98 30.2 PCa:Gleason 3+3=6 18
60 D43 6.4 Chronic inflammation and atrophy 121 88 D71 27.6 PCa: Gleason 3+4=7 18
61 D53 12.3 Chronic inflammation and atrophy 121 89 D59 8.9 PCa: Gleason 4+4=8 23
62 D37 7.4 Chronic inflammation 130 90 D16 7.7 PCa:Gleason 3+3=6 38
63 D51 3.9 No abnormalities 132 91 D03 11.2 PCa:Gleason 3+3=6 48
64 D105 10.1 Chronic inflammation and atrophy 135 92 D84 12.8 PCa:Gleason 3+3=6 138
65 D19 11.0 No abnormalities 137 93 D07 18.2 PCa: Gleason 3+4=7 202
66 D88 13.9 No abnormalities 161 94 D42 9.2 PCa: Gleason 3+4=7 217
67 D107 13.5 Chronic inflammation and atrophy 165 95 D101 9.3 PCa: Gleason 3+4=7 267
68 D36 4.8 Chronic inflammation and atrophy 169 96 D50 6.5 PCa:Gleason 3+3=6 307
69 D60 12.4 Atrophy 180 97 D93 19.1 PCa:Gleason 3+3=6 343
70 D33 12.0 Chronic inflammation and atrophy 199 98 D102 11.6 PCa:Gleason 3+3=6 447
71 D108 0.3 Chronic inflammation and atrophy 248 99 D96 6.8 PCa:Gleason 3+3=6 474
72 D18 9.6 No abnormalities 296 100 D57 10.5 PCa:Gleason 3+3=6 511
73 D76 10.8 No abnormalities 298 101 D29 18.2 PCa: Gleason 3+4=7 552
74 D47 10.8 Cystic/atypia 328 102 D62 7.0 PCa: Gleason 4+3=7 641
75 D61 10.4 Chronic inflammation 376 103 D99 29.5 PCa:Gleason 3+3=6 680
76 D87 14.3 Chronic inflammation 441 104 D113 4.1 PCa 900
77 D103 8.4 No abnormalities 477 105 D63 6.5 PCa: Gleason 3+4=7 1761
78 D89 40.7 No abnormalities 500 106 D82 6.7 PCa:Gleason 3+3=6 1777
79 D115 7.0 Chronic inflammation and atrophy 621 107 D85 7.6 PCa:Gleason 3+3=6 2221
80 D64 4.5 No abnormalities 640 108 D90 15.4 PCa:Gleason 3+3=6 3070
81 D68 4.5 Chronic inflammation 935
82 D72 11.9 Atrophy 1187
83 D66 11.2 No abnormalities 2140
84 D55 16.4 Atrophy 3340
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PIN: prostate intra-epitheiial neoplasia, PCa: prostate cancer, PCA3: prostate cancer gene 3, PSA:prostate-specific antigen
detect prostate cancer at an early stage using non-invasive procedures. The recent 
discoveries of genes that are not only prostate-specific but are also overexpressed in 
prostate tumors are of special interest for the development of new diagnostic tools.
One of the new prostate tumor-specific genes is PCA3 [16]. To evaluate the 
usefulness of PCA3 as a marker for the detection of neoplastic prostate cells, a time- 
resolved fluorescence-based quantitative RT-PCR assay was developed based on the 
principle of the quantitative RT-PCR for PSA mRNA recently described by Ylikoski and 
colleagues [19, 23]. The results of the accurate quantification of PCA3 transcripts in 
normal tissue specimens showed that PCA3 was exclusively expressed in the prostate. 
This was in concordance with earlier published data [16, 17]. The accurate quantification 
power of this assay allowed the determination of the median upregulation of PCA3 in 
prostate tumors. In the radical prostatectomy specimens of 7 patients the PCA3 
expression in tumor areas was compared with the PCA3 expression in the adjacent non­
neoplastic prostate tissue. A 6 to 1500-fold upregulation of PCA3 was found in the 
prostate tumors compared with the adjacent non-neoplastic prostate tissue. In the non­
matched group of tissue specimens a median 66-fold upregulation of PCA3 in prostate 
cancer was found. These data are in agreement with the 10-100 fold overexpression of 
PCA3 in tumor areas compared with adjacent non-neoplastic prostate tissue, based on 
Northern blot analysis [16].
The epithelial cells of the prostate express PCA3. The percentage of epithelial cells 
per microgram tissue may vary per specimen. However, comparison of the tissue 
specimens of the normal prostates and the tissue specimens containing less than 10% of 
tumor cells used in this study reveals that the number of epithelial cells were comparable 
in both tissue groups. The median upregulation of PCA3 of 11-fold in 13 prostate tissue 
samples containing less than 10% of tumor cells indicated that the PCA3 expression is 
truly upregulated by the small amount of cancerous epithelial cells in an overall benign 
tissue sample. This is encouraging since the PCA3-based RT-PCR assay is then 
capable to detect a few malignant cells in a background of predominantly non-malignant 
cells without the need for microdissection. This was in concordance with the data 
obtained from the recently developed real-time quantitative RT-PCR method [17]. The 
combined data and the fact that PCA3 is not expressed in leukocytes (often present in 
bodily fluids) indicate that this quantitative RT-PCR assay for PCA3 bears great promise 
as diagnostic tool. As such it could be applicable in the detection of malignant prostate 
cells in blood, urine or ejaculates obtained from patients who are suspected for having 
prostate cancer. To test this hypothesis the PCA3 transcripts have been quantitatively 
determined in sediments from voided urine samples obtained after prostate massage. 
The reasoning behind this test is that the manipulation of the prostate would transport
Chapter 4
76
the cancer cells via the prostatic ductal system into the prostatic urethra. As was 
reported before, the first portion of a voided urine sample contains the highest 
concentration of prostatic and urethral secretions [24]. Clements et al. showed that the 
results were comparable between ejaculate and urethral washings [25]. Therefore, 
voided urine sample collection was elected since it is a more acceptable specimen for 
men to give rather than ejaculate. In urinary sediments not only prostate cancer cells but 
also non-neoplastic prostate cells are present. To normalize the test for the number of 
prostate cells PSA has been used as a “housekeeping” gene. The PSA mRNA 
expression has been shown to be relatively constant in normal prostate cells and only a 
weak (~1.5-fold) downregulation of PSA expression in prostate cancer cells has been 
reported [20]. Since PCA3 showed a 66-fold upregulation in prostate tumors compared 
with non-neoplastic prostate tissue, due to this downregulation of ~1.5-fold in prostate 
tumors the PCA3/PSA ratio will increase.
The PCA3/PSA ratio was then used as a diagnostic tool for the accurate identification 
of prostate cancer cells in urinary sediments obtained after prostate massage. A cohort 
of 108 consecutive patients that were admitted for prostatic biopsies, based on a serum 
PSA level of more than 3 ng/ml, was tested. After extensive prostate massage voided 
urine samples were collected and PCA3 transcripts and PSA transcripts were 
quantitatively determined. Biopsy specimens were used as the gold standard for prostate 
cancer detection. From the cohort of 108 biopsies, 24 biopsies were positive for prostate 
cancer while the other 84 biopsies were negative.
To visualize the diagnostic efficacy of the PCA3-based RT-PCR assay of urine 
samples in the absence of an arbitrary cutoff value, the data were summarized using a 
ROC. ROC curves are useful in optimizing a cutoff value to discriminate between a 
positive and a negative test. Based on this ROC curve, a cutoff level of 200-10'3 was 
determined. According to this ROC curve higher cutoff values would not increase the 
sensitivity of this test but would only result in a loss of specificity.
Fourteen out of 84 men with negative biopsies had higher PCA3/PSA ratios than this 
cutoff value, indicating that the specificity of this PCA3-based RT-PCR test was 83%. As 
was stated earlier, biopsies often lead to non-representative biopsy specimens in which 
prostate cancer is detected in only about a third of the patients with elevated PSA levels 
and repeated biopsies will reveal the presence of prostate cancer in another 10-20% of 
the cases [22]. Due to the low sensitivity of the sextant biopsies, our gold standard, the 
AUC-ROC was 0.72 (95% CI: 0.58-0.85). Therefore, follow-up using repeated biopsies of 
these fourteen patients is of great interest. It may confirm that the positive PCA3/PSA 
ratios may precede the histological diagnosis of prostate cancer. Eventually, this follow- 
up may increase AUC-ROC value of this test.
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Almost all of the men with negative biopsies had chronic inflammation in their 
histological specimens. Since the negative predictive value of PCA3 measurements is 
90%, it shows that this benign prostatic disease does not upregulate the PCA3/PSA 
ratios. This is also in concordance with the fact that PCA3 is not expressed by 
leukocytes present in these specimens.
More important, of the 24 patients with positive biopsies, 16 had a positive 
PCA3/PSA value, indicating that the PCA3-based RT-PCR assay of urine samples has a 
sensitivity of 67%. PSA mRNA expression was detected in the 8 samples with low 
PCA3/PSA values. This indicated that the cells present in these urinary sediments were 
of prostatic origin. Since the PCA3 expression was low in these specimens, it appears 
that these cells were of normal prostatic origin. This suggests that no malignant prostate 
cells were released into the urine upon DRE. As was shown by Meid et al., generally 
small and well differentiated prostate tumors do not slough easily and, thus, they become 
difficult to detect [26]. Therefore, the technique of DRE is currently standardized to aid 
the release of malignant prostate cells in the urine.
Recently several groups reported on the detection of prostate cells in voided urine 
after prostatic massage. The use of telomerase activity for the detection of prostate 
cancer cells after prostatic massage tested on a small group of 36 specimens showed a 
58% sensitivity and 100% specificity [26]. The negative predictive value of this test was 
17%. The DNA-based detection method targeting promoter hypermethylation of the 
gluthathione-S-transferase P1 (GSTP1) gene, the most common DNA alteration 
associated with prostate cancer, was tested on a group of 92 specimens [27]. This test 
showed a 73% sensitivity and 98% specificity in the detection of prostate cancer. The 
negative predictive value of this test was 80%.
The PCA3 -based RT-PCR assay described was tested on voided urine samples 
collected after prostate massage from 108 men who were indicated for prostate biopsies 
based on a serum PSA value of more than 3 ng/ml. Using biopsies as the gold standard 
for prostate cancer, this test showed a sensitivity of 67% and specificity of 83% at a 
cutoff value for PCA3/PSA of 200-10'3. Compared with the other two tests described, this 
test has the highest negative predictive value of 90%. Moreover, the here presented test 
is quantitative and has a high inter- and intra assay reproducibility. This indicates that 
this test bears great potential in the reduction of the number of invasive TRUS guided 
biopsies in this population of men.
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Conclusion
The time-resolved fluorescence-based quantitative RT-PCR assay for the 
determination of PCA3 transcripts bears great promise as non-invasive diagnostic tool. 
The combined data presented here show that the quantitative determination of PCA3 
transcripts in urinary sediments, obtained after prostatic massage, has a high negative 
predictive value. This will have great impact for the reduction of the number of biopsies. 
Thus, multi-center studies using the validated PCA3-based assay can provide the first 
basis for the utility of molecular diagnostics in clinical urological practice.
Acknowledgements
The authors would like to thank Yvonne van Aarssen for urine sample collection, Dr 
Gerald Verhaegh for critically reading the manuscript and all patients that gave their 
consent to participate in this study.
References
1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 
1999;49:8-31.
2. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic 
adenocarcinoma: long-term results. J Urol 1990;144:1180-1184.
3. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical 
retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-1836.
4. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) 
results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J 
Urol 1994;152:1850-1857.
5. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical 
retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 
1997;24:395-406.
6. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on 
progression following radical prostatectomy: a study of 196 cases with long-term followup. J 
Urol 1993;150:135-141.
7. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. 
Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research 
Team. JAMA 1993;269:2633-2636.
8. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, 
Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH. 
Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific 
antigen and prostate specific membrane antigen. Cancer 1996;78:809-818.
9. Xu LL, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, Srivastava S. 
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in 
primary prostate cancer. J Urol 2000;163:972-979.
10. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, 
Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high gleason score, 
advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-1296.
11. Sun Y, Lin J, Katz AE, Fisher PB. Human prostatic carcinoma oncogene PTI-1 is expressed in 
human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res 1997;57:18-
23.
12. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn 
IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S. PCGEM1, a
79
Chapter 4
prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 2000 Oct 
24;97(22): 12216-21 2001;97:12216-12221.
13. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, 
Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA. PDEF, a novel prostate 
epithelium-specific ets transcription factor, interacts with the androgen receptor and activates 
prostate-specific antigen gene expression. J Biol Chem 2000;275:1216-1225.
14. Lin B, Ferguson C, White JT, Wang S, Vessella R, True Ld , Hood L, Nelson PS. Prostate- 
localized and androgen-regulated expression of the membrane-bound serine protease 
TMPRSS2. Cancer Res 1999;59:4180-4184.
15. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K. Molecular cloning and 
characterization of prostase, an androgen-regulated serine protease with prostate-restricted 
expression. Proc Natl Acad Sci U S A 1999;96:3114-3119.
16. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, 
Debruyne FM, Ru N, Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in 
prostate cancer. Cancer Res 1999;59:5975-5979.
17. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, 
Schalken JA. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. 
Cancer Res 2002;62:2695-2698.
18. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs 
from total myeloma tumor RNA. Eur J Biochem 1980;107:303-314.
19. Ylikoski A, Sjoroos M, Lundwall A, Karp M, Lovgren T, Lilja H, Iitia A. Quantitative reverse 
transcription-PCR assay with an internal standard for the detection of prostate-specific antigen 
mRNA. Clin Chem 1999;45:1397-1407.
20. Meng FJ, Shan A, Jin L, Young CY. The expression of a variant prostate-specific antigen in 
human prostate. Cancer Epidemiol Biomarkers Prev 2002;11:305-309.
21. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we 
have learned and where we are going. J Urol 1999;162:293-306.
22. Djavan B, Remzi M, Schulman C, Marberger M, Zlotta A. Repeat prostate biopsy: who, how and 
when? A review. Eur Urol 2002;42(2):93-103.
23. Ylikoski A, Karp M, Lilja H, Lovgren T. Dual-label detection of amplified products in quantitative 
RT-PCR assay using lanthanide-labeled probes. Biotechniques 2001;30:832-836, 838, 840.
24. Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey T. An analysis of urinary prostate specific 
antigen before and after radical prostatectomy: evidence for secretion of prostate specific 
antigen by the periurethral glands. J Urol 1993;149:783-786.
25. Clements JA, Rohde P, Allen V, Hyland VJ, Samaratunga ML, Tilley WD, Lavin MF, Gardiner 
RA. Molecular detection of prostate cells in ejaculate and urethral washings in men with 
suspected prostate cancer. J Urol 1999;161:1337-1343.
26. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity for 
the detection of prostatic cancer cells after prostatic massage. J Urol 2001 ;165:1802-1805.
27. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K. DNA-based 
detection of prostate cancer in urine after prostatic massage. Urology 2001 ;58:335-338.
80
Chapter S
♦
k .
The time-resolved fluorescence-based PCA3 
test on urinary sediments after DRE
Dutch m ulticenter validation of the diagnostic  
performance
Daphne Hessels and Martijn P.M.Q. van Gils 1*, Onno van Hooij1 , Sander A. Jannink1 
W. Pim Peelen1, Suzanne L.J. Hanssen1, J. Alfred W itjes1 , Erik B. Cornel2,
Herbert F.M Karthaus3, Geert A.H.J. Smits4, Gerard A. Dijkman5, Peter F.A.Mulders1, 
Jack A. Schalken1
*Both authors contributed equally to this work
1 Department of Urology, Radboud University Nijmegen Medical Centre, The Netherlands
2 Department of Pathology, ZGT Hengelo, Hengelo, The Netherlands
3 Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
4 Department of Urology, Alysis Healthcare Group (Rijnstate), Arnhem, The Netherlands
5 Department of Urology, Amphia Hospital, Breda, The Netherlands
Published in:
Clin Cancer Res 2007;13:939-943
Chapter 5 
Abstract
Background. To improve the specificity in prostate cancer diagnosis and to prevent 
unnecessary prostate biopsies, especially in the serum PSA gray zone between 3 and 
15 ng/ml, the implementation of prostate cancer-specific markers is urgently needed. 
The recently discovered prostate cancer gene 3 (PCA3) is such a promising prostate 
cancer marker. In a previous single institution study, the PCA3 urine test clearly proved 
to be of diagnostic value. Therefore, the diagnostic performance of the PCA3 urine test 
was validated in a multicenter study.
Methods. The first voided urine after digital rectal examination was collected from a total 
of 583 men with serum PSA levels between 3 and 15 ng/ml who were to undergo 
prostate biopsies. We determined the PCA3 score in these samples and correlated the 
results with the results of the prostate biopsies.
Results. 534 men (92%) had an informative sample. The area under the receiver 
operating characteristic curve, a measure of the diagnostic accuracy of a test, was 0.66 
for the PCA3 urine test and 0.57 for serum PSA. The sensitivity for the PCA3 urine test 
was 65%, the specificity was 66% (versus 47% for serum PSA), and the negative 
predictive value was 80%.
Conclusion. In this multicenter study, we validated the diagnostic performance of the 
PCA3 urine test in the largest group studied thus far using a PCA3 gene-based test. This 
study shows that the PCA3 urine test, when used as a reflex test, can improve the 
specificity in prostate cancer diagnosis and could prevent many unnecessary prostate 
biopsies.
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Introduction
Nowadays, prostate cancer is by far the most common cancer in men in the United 
States (excluding basal and squamous cell skin cancers and in situ carcinoma except 
urinary bladder). In 2006, prostate cancer will be diagnosed in ~ 234,460 American men, 
and 27,350 American men will die of this disease [1]. In Europe, in 2002, an estimated 
225,227 men were newly diagnosed with prostate cancer, and about 83,066 died from 
this disease; for the Netherlands these numbers were 7,112 and 2,529 respectively 
(www-dep.iarc.fr) [2].
Serum prostate-specific antigen (PSA) is regarded as the standard diagnostic 
prostate cancer marker. Prostate cancer awareness, leading to widespread use of PSA 
testing, has led to a stage shift, i.e., a lower tumor stage and grade at the time of 
diagnosis. However, PSA is not cancer specific, resulting in a high negative biopsy rate. 
Moreover, its use is associated with certain drawbacks, e.g., the diagnosis of clinically 
irrelevant tumors and potential overtreatment [3].
As a result, there is an urgent need for prostate cancer-specific markers that can 
improve the specificity in prostate cancer diagnosis and can prevent unnecessary 
prostate biopsies, especially in the serum PSA gray zone between 3 and 15 ng/ml, in 
which nowadays many newly diagnosed men are.
Prostate cancer gene 3 (PCA3) is a prostate-specific non-coding mRNA which is 
highly overexpressed in more than 95% of primary prostate cancer specimens and 
prostate cancer metastases [4, 5]. Hessels et al. found that the median upregulation of 
PCA3 in prostate cancer tissue compared with normal prostate tissue was 66-fold [6]. 
Moreover, a median 11-fold upregulation was found in prostate tissues containing < 10% 
of prostate cancer cells. As PCA3 is a noncoding mRNA, a dual time-resolved 
fluorescence (TRF) -based reverse transcription-PCR (RT-PCR) assay was developed to 
identify it as a diagnostic prostate cancer marker in urinary sediments after digital rectal 
examination (DRE). This second-generation test showed a negative predictive value of 
90% in a population of men, admitted for prostate biopsies based on a serum PSA value 
> 3 ng/ml. Therefore, PCA3 clearly showed to have diagnostic value and great potential 
in reducing the number of unnecessary biopsies [6]. Using the first generation uPM3™ 
test, a qualitative nucleic acid sequence-based amplification (NASBA) technology, two 
independent studies confirmed these results [7, 8]. Earlier this year, Groskopf et al. 
introduced the quantitative automated probe transcription-mediated amplification PCA3 
urine test. This is a third-generation PCA3 assay that uses transcription-mediated 
amplification, a RNA transcription amplification system using RNA polymerase and 
reverse transcriptase to drive the isothermal reaction. The latter allows the reaction to be
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carried out in a single tube format [9].
Because of the promising results of our previous single institution study [6], the aim 
of this study was to validate the diagnostic performance of the TRF-based PCA3 urine 
test in a multicenter setting. Therefore, we correlated the PCA3 score in urinary 
sediments after DRE with the presence of prostate cancer in subsequent prostate 
biopsies. Here, the results of the TRF-based PCA3 urine test are reported in a group of 
583 men, the largest group studied thus far, using a PCA3 gene-based test.
Materials and methods
Collection of urine samples after prostate massage
In the urological outpatient clinics of five Dutch hospitals (one university hospital and 
four community hospitals), the first voided urine after DRE was collected from a total of 
583 men with serum PSA levels between 3 and 15 ng/ml (extremes included) who were 
to undergo ultrasound-guided, transrectal, prostate biopsies as a result of local 
management. Beforehand, all men had received study information and had signed their 
informed consent. As part of standard clinical practice, both serum PSA and the fraction 
of free serum PSA had already been determined in most men. All other samples and 
data were collected prospectively.
The DRE was done according to a standard protocol: by applying firm pressure to the 
prostate (enough to depress the surface) from the base to apex and from the lateral to 
the median line for each lobe. The men were asked to void, and the first voided urine 
was collected.
Following urine collection, the urologist measured the prostate by transrectal 
ultrasonography and did the prostate biopsy according to a standard protocol (at least 
three biopsies from the left peripheral zone, at least three biopsies from the right 
peripheral zone, one biopsy from the left transition zone, and one biopsy from the right 
transition zone, plus additional biopsies from other areas suspicious for prostate cancer 
when present). All biopsy cores were treated lege artis and examined for the presence of 
prostate cancer.
The first voided urine after DRE was collected in a coded container with 4 ml 0.5 M 
EDTA. All samples from the four community hospitals were immediately cooled to 4°C 
and were mailed in batches with cold packs to the laboratory in the university hospital. 
The samples were processed within 48 h after the sample was acquired to guarantee 
good sample quality. The samples taken at the university hospital were processed within 
1 h. Upon centrifugation at 4°C and 700 x g for 10 minutes, urinary sediments were 
obtained. These urinary sediments were washed twice with ice-cold PBS (at 4°C and
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700 x g for 10 min), snap-frozen in liquid nitrogen, and stored at -70°C. The urinary 
sediments were added to 20 |jg of Escherichia coli (E.coli) tRNA as a carrier (Roche 
Diagnostics, Almere, the Netherlands). Total RNA was extracted from these urinary 
sediments, using TRIzol Reagent (Invitrogen, Breda, the Netherlands).
Time-resolved fluorescence-based quantitative RT-PCR assay for PSA
To correct for the number of prostate cells present, the PSA mRNA transcripts were 
quantitatively determined in the urinary sediments using the dual TRF-based, 
quantitative RT-PCR protocol for PSA described by Ylikoski et al. [10, 11] and modified 
by Hessels et al. [6].
Time-resolved fluorescence-based quantitative RT-PCR assay for PCA3
Similarly, the PCA3 mRNA transcripts were quantitatively determined in the same 
urinary sediments using a dual TRF-based, quantitative RT-PCR protocol for PCA3. 
Briefly, in vitro transcribed PCA3 RNA and internal standard (IS) PCA3 RNA were used 
as templates for cDNA synthesis using the first-strand cDNA synthesis Kit (Amersham, 
Buckinghamshire, United Kingdom). PCA3 and IS-PCA3 RNA was diluted in 0.2 mg/ml 
E. coli tRNA (Roche Diagnostics, Almere, the Netherlands), which is used as carrier 
RNA. For the preparation of a calibration curve, 5,000 copies of IS-PCA3 RNA were 
mixed with a variable amount (50 to 10,000,000 copies) of PCA3 RNA. For the 
quantification of PCA3 RNA in a sample, 5,000 copies of IS-PCA3 RNA were added to 
each RNA sample before the reverse transcriptase reaction. The RNA samples were 
heated for 10 minutes at 65°C followed by reverse transcription for 1 h at 37°C, using 0.2 
mg of universal oligo-d(T)18 primer, 2 mmol/L DTT and 5 ml of a bulk first-strand 
reaction mixture (Amersham, Buckinghamshire, United Kingdom). For PCR 
amplifications, the following PCA3-specific primers were used: forward, 5'- 
TGGGAAGGACCTGATGATACA-3' (nucleotides 97-117 of exon 1 of the PCA3 cDNA, 
GenBank accession number AF103907) and reverse, 5'-CCCAGGGATCTCTGTGCTT-3’ 
(nucleotides 459-477, spanning exons 3 and 4 of the PCA3 cDNA). After 35 cycles of 
PCR, the amplification products were quantified by the TRF-based hybridization assays 
on streptavidin-coated microtitration wells (Greiner Bio-One, Alphen aan de Rijn, the 
Netherlands). For the target-specific detection, a PCA3 detection probe (30 pg/ml) 
labeled with Eu3+ and an IS-PCA3 detection probe (30 pg/ml) labeled with Tb3+ were 
used. The amount of PCA3 mRNA in the sample was calculated by comparing the 
PCA3/IS-PCA3 fluorescence ratio in the sample with that of the samples in the 
calibration curve. The ratio PCA3/PSA mRNA was then calculated by dividing the
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number of PCA3 mRNA copies by the number of PSA mRNA copies obtained in a given 
sample. The PCA3 score was defined as the ratio PCA3/PSA mRNA x 1,000.
Statistical analysis
Data were analyzed using the Statistical Package for the Social Sciences (SPSS, 
Chicago, IL) version 12.0.1 for Microsoft Windows. To test for differences in PCA3 score 
between men with a negative biopsy result and men with a positive biopsy result, we 
used the two-tailed Mann-Whitney U test. We also used the two-tailed Mann-Whitney U 
test to test for differences in PCA3 score the biopsy-negative university hospital 
population and the biopsy-negative community hospital population, as well as between 
the biopsy-positive university hospital population and the biopsy-positive community 
hospital population. A P-value <0.05 was considered significant.
Results
The total number of urine samples that could be analyzed successfully (i.e. was 
positive for PSA mRNA expression) was 534 out of the 583 that were collected. 
Therefore, the analytical performance of the PCA3 urine test was 92% (534/583) overall; 
95% (295/312) in the university hospital; and 88% (239/271) in the community hospitals.
The mean age at the time of biopsy of the 534 men in the study population was 
(mean ± SD) 64.3± 7.2 years; the mean serum PSA value was 7.49 ± 2.93 ng/ml; the 
mean fraction of free serum PSA (determined in 173 / 534 = 32%) was 0.19 ± 0.11; the 
mean total prostate volume (measured in 250 / 534 = 47%) was 48.2 ± 28.4 ml.
Of the 534 men who yielded informative specimens, 174 (33%) had prostate cancer 
in their biopsies, and the remaining had negative biopsies. The PCA3 scores obtained 
for both subject groups were summarized in a boxplot (Fig. 1). The median PCA3 score 
for men with a negative biopsy result was 24 (range 0 -  1,862); the median PCA3 score 
for men with a positive biopsy result was 90 (range 0 -  4,088). The difference between 
both groups was highly significant (P = 1'10'9).
The diagnostic efficacy of the PCA3 test is visualized by a receiver-operating 
characteristic (ROC) curve, in which the test variable was the PCA3 score and the state 
variable the biopsy result (Fig. 2). In the absence of an arbitrary cutoff value, we 
determined a cutoff value of 58 for prostate cancer diagnosis based on this ROC curve. 
A lower cutoff value would not have increased the sensitivity of the test, but would have 
only resulted in a loss of specificity. A  similar procedure was described earlier [6]. The 
area under the curve (AUC), a measure of the diagnostic accuracy of a test, was 0.66 
(95% confidence interval (95% CI), 0.61 - 0.71) for the PCA3 test. The diagnostic value
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of the serum PSA test is also visualized (Fig. 2); for serum PSA, the AUC was 0.57 (95% 
CI, 0.52 - 0.63). For the serum free PSA test, the AUC was 0.58 (95% CI, 0.48 - 0.68; 
data not shown).
Using this cutoff of 58 for the detection of prostate cancer by the PCA3 urine test, we 
calculated the sensitivity, specificity, and the negative predictive value. The sensitivity 
was 65%; the specificity was 66%; and the negative predictive value was 80% (Table 1). 
For the serum PSA test at the same sensitivity (65%), the specificity was 47% (Fig. 2). A 
higher PCA3 score also correlated with a higher probability of a positive biopsy result 
(Fig. 3).
The PCA3 urine test; a Dutch multicenter validation
I T
“ I
No m alignancy Prostate cancer
Fig. 1. Boxplot (also known as a ‘box-and-whisker diagram') showing the PCA3 scores in urinary 
sediments after DRE for both men with a negative and men with a positive biopsy result. The 
median value (thick black horizontal line), outliers (open circles), and extremes (stars) are shown. 
The box length is the interquartile range and the ‘whiskers' extend to 1.5 times this distance.
Table 1. TRF-based PCA3 urine test results versus biopsy results
Prostate cancer No malignancy Total
PCA3 score > 58 113 122 235
PCA3 score < 58 61 238 299
Total 174 360 534
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The diagnostic performance of the TRF-based PCA3 urine test was compared 
between the university hospital population and the community hospitals population. In 
the university hospital, the median PCA3 score in men with a negative biopsy was 11 
(range, 0 -  1,779); the median PCA3 score in men with a positive biopsy was 73 (range, 
0 -  1,432). The AUC for the PCA3 test was 0.65 (95% CI, 0.58 - 0.72). Using the cutoff 
value of 58 (determined in the total multicenter population), the sensitivity for the 
detection of prostate cancer of the PCA3 urine test in the university hospital population 
was 59%, the specificity was 74%, and the negative predictive value was 79%. The AUC 
for the serum PSA test was 0.55 (95% CI, 0.48 - 0.62).
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Fig-2. Receiver-operating characteristic curve for the PCA3 score (top line) in urinary sediments 
after DRE and serum PSA (middle line) in the detection of prostate cancer, using biopsy 
histopathology as standard of reference. Dotted lines, determined cutoff value of 58.
In the four community hospitals, together, the median PCA3 score in men with a 
negative biopsy was 39 (range 0 -  1,862); the median PCA3 score in men with a positive 
biopsy was 107 (range 0 -  4,088), and the AUC for the PCA3 test was 0.67 (95% CI,
0.60 - 0.75). Again, the cutoff value of 58 was used, and in the community hospital 
population, the sensitivity was 72%, the specificity was 56%, and the negative predictive 
value was 80%. The AUC for the serum PSA test was 0.61 (95% CI, 0.53 - 0.68).
The differences in the PCA3 score between the biopsy-negative university hospital 
population and the biopsy-negative community hospital population (P  < 0.001 ), as well
88
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as between the biopsy-positive university hospital population and the biopsy-positive 
community hospital population (P < 0.01 ) were significant.
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Fig. 3. Diagram of the probability of a positive biopsy result for different ranges of the PCA3 score. 
Bottom, both the number of men with prostate cancer and the total number of men per range.
Discussion
Because of the promising results of our previous single institution study, the aim of 
this study was to validate the diagnostic performance of the TRF-based PCA3 urine test 
in a multicenter setting. Therefore, the PCA3 score in urinary sediments after DRE was 
correlated with the presence of prostate cancer in subsequent prostate biopsies. In our 
previous study, the sensitivity for the detection of prostate cancer by the PCA3 test in 
urine was 67%, the specificity was 83% and the negative predictive value was 90% [6]. 
In this study, these values were 65%, 66% and 80%, respectively. The high negative 
predictive value in particular suggests that the PCA3 test can be used to reduce the 
number of unnecessary biopsies. We have summarized the results of all reports on 
PCA3 gene-based urine testing, including our present study (Table 2). Most test 
performance characteristics in this multicenter study are somewhat lower than in the 
other studies, in particular when compared with our previous study. A possible 
explanation for this could be the fact that 55% of our study population consisted of 
mostly prescreened men who were referred to a university hospital. In this population the 
AUC for the PCA3 urine test was lower than in the community hospitals population and
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consequently brought down the overall test performance. Noteworthy is the fact that in 
the university hospital population, the PCA3 urine test still did much better than the 
serum PSA test because the latter was no better than the flip of a coin.
Formally, it was statistically incorrect to calculate the sensitivity and specificity for the 
serum PSA test because a serum PSA value between 3 and 15 ng/ml was a requirement 
to enter the study. However, for reasons of comparison, we showed that at an equal 
sensitivity of 65%, the specificity for the serum PSA test was only 47%, compared with 
66% for the PCA3 urine test. This suggests that the PCA3 test can be used improve the 
specificity in prostate cancer diagnosis.
Table 2. The performance in prostate cancer diagnosis of PCA3 gene-based analysis in urine
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samples following DRE
PCA3 urine 
test method
Total 
number of 
urine 
samples 
obtained
Number of 
informative 
urine 
samples
AP
%
Number of 
men with 
prostate 
cancer
(%)
Se
%
Sp
%
NPV
%
AUC Ref
TRF-based NA 108 NA 24 (22) 67 83 90 0.72 [6]
uPM3™ 517 443 86 152 (34) 66 89 84 0.86 [7]
uPM3™ 201 158 79 62 (39) 82 76 87 0.87 [8]
APTIMA® 70 68 97 16 (24) 69 79 89 0.75 [9]
TRF-based 583 534 92 174 (33) 65 66 80 0.66 This study
NA: not applicable, AP: analytical performance, Se: sensitivity, Sp: specificity, NPV: negative predictive value, AUC: area under the
receiver operating characteristic curve, Ref: references
Overall analytical performance of 92% indicates that the transport and processing of 
the urine samples in a multicenter setting is feasible. The difference in analytical 
performance of the PCA3 urine test between the university hospital (95%) and the 
community hospitals (88%) could not be attributed to RNA degradation that could have 
occurred during transport because the median copy numbers of PCA3 and PSA mRNA 
in the samples from the community hospitals were higher when compared with the 
samples from the university hospital (data not shown).
The median PCA3 scores in both the biopsy-negative and the biopsy-positive groups 
of the community hospitals were significantly higher than the ratios in both groups of the 
university hospital, respectively. As a result, when using the cutoff value that was 
determined in the total multicenter study population, the sensitivity of the TRF-based 
PCA3 urine test was higher (72%) for the study population of the community hospitals 
when compared with the sensitivity for the study population of the university hospital
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(59%). Consequently, the specificity was lower (56% versus 74%). The differences 
observed were not attributable to RNA degradation during transport. A possible 
explanation is the difference in study population between the university and the 
community hospitals. A clue in this direction is the fact that the serum PSA test did better 
in the community hospitals study population, with an AUC of 0.61 instead of 0.55 for the 
university hospital study population. The median serum PSA value was also significantly 
higher in the community hospital study population (data not shown). Therefore, the 
university hospital study population could have been more prescreened. The variance in 
the median value of the PCA3 score between different study populations and the fact 
that a higher score correlated with a higher probability of a positive biopsy result also 
suggest that it would be better to use the result of the PCA3 urine test as a continuous 
risk variable instead of strictly applying a certain cutoff value, resulting in a test with a 
dichotomous result.
In the group of men with a negative biopsy outcome there were several men with a 
high PCA3 score (the outliers, 25/360=7%; and extremes, 18/360=5% in Fig. 1). We 
speculate that in this group, there is a substantial number of men who actually have 
prostate cancer, but in whom it was missed on biopsy. It is well known that some 10-20% 
of men with a previous negative biopsy will be diagnosed with prostate cancer upon 
repeat biopsy [12]. Moreover, several men included in the study published by Hessels et 
al. [6] who had negative biopsies but a positive PCA3 urine test were shown to have 
prostate cancer upon repeated biopsies (unpublished data). The follow-up data of our 
study population will have to show if indeed the PCA3 urine test was able to predict the 
presence of prostate cancer.
Conclusion
In conclusion, this Dutch multicenter study showed that to improve the specificity in 
prostate cancer diagnosis and reduce the number of unnecessary biopsies, the TRF- 
based PCA3 urine test is of value as a reflex-test in the serum PSA gray zone between 3 
and 15 ng/ml. At a cutoff value of 58, the sensitivity for the detection of prostate cancer 
by the PCA3 test in urine was 65%, the specificity was 66% (compared with 47% for the 
serum PSA test), and the negative predictive value was 80%. A higher ratio PCA3 score 
correlated with a higher probability of a positive biopsy result.
The PCA3 urine test; a Dutch multicenter validation
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Abstract
Background. PCA3 urine tests have shown to improve the specificity in prostate cancer 
diagnosis, and have thus the potential to reduce the number of unnecessary prostate 
biopsies and to predict repeat biopsy outcomes. In this study, PCA3 was correlated with 
clinical stage, biopsy Gleason score, radical prostatectomy Gleason score, tumor 
volume, and pathological stage to assess its potential as predictor of prostate cancer 
aggressiveness.
Methods. In this study, 351 men admitted for prostate biopsies based on serum PSA 
levels >3 ng/ml, an abnormal digital rectal examination (DRE), and/or a family history of 
prostate cancer were included. Post-DRE urinary sediments from 336 men were tested 
using a transcription- mediated amplification-based PCA3 test, and assay results were 
correlated with clinical stage and biopsy Gleason score. In a sub-cohort of 70 men that 
underwent radical prostatectomy, the PCA3 ratio's were correlated to the radical 
prostatectomy Gleason score, tumor volume, and pathological stage.
Results. In this patient cohort we could not find a correlation between PCA3 and clinical 
stage, biopsy Gleason score, radical prostatectomy Gleason score, tumor volume, and 
pathological stage.
Conclusion. The predictive value of PCA3 for prostate cancer aggressiveness features 
as reported in earlier studies cannot be confirmed in our study. Experimental differences 
(urine sediments versus whole urine) and cohort may explain this. The exact place of 
PCA3 as prognostic test for prostate cancer remains the subject of investigation.
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Introduction
Prostate cancer is the most frequently diagnosed malignancy in the Western male 
population. In Europe, prostate cancer was diagnosed in 345,900 men and was the 
cause of death in 87,400 men in 2006 [1]. The high incidence of prostate cancer can be 
attributed to the increased life expectancy of Western males and the implementation of 
serum prostate-specific antigen (PSA) testing. The introduction of serum PSA in clinical 
practice has led to the detection of prostate cancer at a potentially curable stage. There 
is objective indication that PSA-based (opportunistic) screening has led to an increase in 
prostate cancer diagnosis and overtreatment [2]. Many of the detected prostate tumors 
are clinically insignificant, that is, in the absence of screening these tumors would not 
have been diagnosed within the patient's lifetime. This is best illustrated by an increased 
'incidence mortality ratio' after the introduction of PSA-based screening [3, 4]. Currently, 
it is difficult to predict which tumor will show aggressive behavior and which tumor will 
not. Therefore, overtreatment of localized prostate cancer is a serious clinical issue and 
there is an urgent need for better biomarkers that can distinguish indolent from clinically 
significant prostate cancer. The ideal biomarker would be detectable using non-invasive 
methods, that is, by means of a blood or urine test. Many candidate biomarkers are 
currently being identified, however, only few are evaluated in multi-centre studies using 
standardized assays. One of the evaluated biomarkers is prostate cancer gene 3 
(PCA3). PCA3 is a prostate-specific non-coding RNA which is highly overexpressed in 
more than 95% of primary prostate tumors, with a median 66-fold upregulation compared 
with adjacent non-cancer prostate tissues [5-7]. The feasibility of PCA3 gene-based 
molecular tests for the detection of prostate cancer cells in the urine has been 
demonstrated [7-9]. Recently, a quantitative PCA3 urine test with the potential for 
general use in clinical settings was developed [10]. PCA3 gene-based testing on urine 
samples has improved specificity in the detection of prostate cancer, and can thus lead 
to a reduction in the number of unnecessary prostate biopsies, since it more accurately 
predicts repeat biopsy outcomes [7, 11, 12].
Limited data are available on the relationship between PCA3 and prostate cancer 
features. We hypothesize that less differentiated prostate cancer cells are more invasive 
and are more likely to mobilize and shed into the prostatic ductal system. This would 
result in a higher fraction of prostate cancer cells in the first voided urine after digital 
rectal examination (DRE) and thus a higher ratio of PCA3 to total prostate mRNA in the 
specimen. In this study we correlated the PCA3 ratio in urinary sediments after DRE to 
the biopsy Gleason score and clinical stage in 351 men admitted for prostate biopsies 
based on serum PSA levels >3 ng/ml, an abnormal DRE, and/or a family history of
PCA3’s value predicting adverse prostate cancer features
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prostate cancer. Moreover, in patients who underwent a radical prostatectomy, the 
correlation of the PCA3 ratio with prostatectomy Gleason score, tumor volume, and 
pathological stage was assessed as well.
Materials and methods 
Specimen source
At the urological outpatient clinic of the Radboud University Nijmegen Medical 
Centre, first voided urine samples were collected after DRE (20-30 ml first catch) from 
351 men scheduled for prostate biopsies based on serum PSA levels >3 ng/ml, 
abnormal DRE, and/or a family history of prostate cancer. A good urologic DRE of three 
strokes per lobe was performed by applying firm pressure from the base to apex and 
from the lateral to the median line for each lobe. Urine specimens were collected 
between July 2003 and September 2006 as part of a multicenter study previously 
described [11]. Men were included with one or more previous negative biopsies. A 
consent form approved by the institutional review board was signed by all participants.
After urine specimen collection, the urologist performed prostate biopsies according 
to a standard protocol (at least three biopsies from the left peripheral zone, at least three 
biopsies from the right peripheral zone, one biopsy from the left transition zone, one 
biopsy from the right transition zone, plus additional biopsies from other areas suspicious 
for prostate cancer when present).
Prostate biopsies and radical prostatectomy specimens were evaluated at the 
Department of Pathology of the Radboud University Nijmegen Medical Centre and in 
case prostate cancer was present the Gleason score was determined. If more than one 
tumor was reported in a set of biopsies or radical prostatectomy specimen, the highest 
Gleason score was used for evaluation of the predictive value.
Collection of urine samples after prostate massage
Urinary sediments were obtained and total RNA was extracted as previously 
described [11]. Six pL of extracted RNA was dissolved in 2.6 ml of detergent-based 
stabilization buffer (sample transport medium; STM). The PCA3 mRNA and PSA mRNA 
levels were quantified as previously described using the PCA3 test [10]. PSA mRNA 
expression has been shown to be relatively constant in normal prostate cells and 
prostate cancer cells. Therefore, the PSA mRNA expression is used to normalize for 
non-cancerous prostate cells; the overall result was defined as the ratio PCA3 
mRNA/PSA mRNA x 1,000.
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Data analysis
The performance of the PCA3 test was evaluated in terms of sensitivity and 
specificity by comparing the PCA3 ratio to biopsy results. The diagnostic accuracy of the 
PCA3 test was compared to that of serum PSA. The relationship between PCA3 and 
biopsy Gleason score, clinical stage, prostate volume, radical prostatectomy Gleason 
score, significant versus indolent prostate cancer, and tumor volume was also assessed. 
Indolent prostate cancer was defined as organ confined cancer with a tumor volume 
<0.5 cm3 and the absence of a Gleason grade 4 or 5 disease. Significant prostate cancer 
was defined as all cancers not meeting the criteria for indolent prostate cancer. Data 
were analyzed using the Statistical Package for Social Sciences (SPSS, Chicago, USA) 
version 12.0.1 for Windows. The non-parametric Mann-Whitney U test or the non- 
parametric Kruskal-Wallis test was used to assess significance levels.
Results
Diagnostic performance of the PCA3 assay
The total number of urine sediments that could be analyzed successfully (i.e., had 
adequate concentrations of PCA3 mRNA and PSA mRNA to calculate the PCA3 ratio) 
was 96% (336 of 351). In Table 1 the characteristics of the 336 men in the study are 
presented. Of the 336 men with a PCA3 ratio, 134 men (40%) were found to have 
prostate cancer upon biopsy. These men were significantly older and had a significantly 
higher serum PSA, higher PCA3 ratio and lower prostate volume than the men with 
negative biopsies. Eighty-one percent of these men had a biopsy Gleason score of 6-7.
In Table 2 the relationship between PCA3 ratio and clinical variables is shown. The 
median PCA3 ratio was 18 for the biopsy-negative population and 50 for the biopsy- 
positive population. The difference between the two populations was highly significant 
(P<1 -10-11). Men with higher prostate volumes had significantly higher serum PSA levels 
(P<2.3-10-5) (data not shown). In contrast, the PCA3 ratio was independent of prostate 
volume (P=0.448) and serum PSA (P=0.097) (Table 2).
The Area under the curve (AUC) of the Receiver Operating Characteristics (ROC) 
was 0.72 (95% CI: 0.66-0.77) for the PCA3 ratio and 0.65 (0.59-0.71) for serum PSA 
(data not shown). A PCA3 ratio cutoff of 35 provided the optimal balance between 
sensitivity (61%) and specificity (74%). In comparison, at the same sensitivity the 
specificity of serum PSA was 60%.
PCA3’s value predicting adverse prostate cancer features
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Table 1. Characteristics of the study population
Men with negative biopsy (n=202) Men with positive biopsy (n=134)
P-value
Total study population (n=336)
Median Mean Range Median Mean Range Median Mean Range
Age (years) 63 62 38-83 65 65 4 9 -8 3 0.005 64 63 3 8 -8 3
Serum PSA [ng/ml] 5.9 7.8 0 .1 4 -6 3 8.3 27.4 1.2 -1619 3.8- 1er5' 7.0 15.6 0.14-1619
Serum PSA <3 [ng/ml] 22 (11%) 4 (3%) 26 (8%)
Serum PSA 3-10 [ng/ml] 139 (69%) 80 (60%) 219 (65%)
Serum PSA > 1 0  [ng/ml] 41 (20%) 50 (37%) 91 (27%)
Prostate volume [ml] 53 59 12 -2 3 0 40 48 1 2 -2 0 5 1.2* 1er4" 46 55 1 2 -2 3 0
PC A3 ratio 18 49 1 - 2827 50 94 0 .2 -1355 1.4-10“" ' 25 67 0.2 - 2827
Biopsy GS:
Minimal Cancer 2 (1.5%)
4 2 (1.5%)
5 7 (5.2%)
6 72 (54%)
7 (3+4) 31 (23%)
7 (4+3) 5 (3.7%)
8 7 (5.2%)
9 7 (5.2%)
10 1 (0.7%)
O =r Q) T3 
t t CD
CT>
GS: Gleason Score, PC A3: prostate cancer gene 3, PSA: prostate-specific antigen 
Mann-Whitney U test
The correlation between PCA3 ratio and biopsy Gleason score
The Gleason score could be determined in 132/134 men with prostate cancer­
positive biopsies (Table 1). In two men the Gleason score could not be determined. In 
one of these men the amount of prostate cancer in his biopsies was too small for 
Gleason score determination and in the other the prostate tumor in his biopsies was 
classified as a high-grade small-cell neuro-endocrine carcinoma. Men with clinical stage 
T2 had a higher median PCA3 ratio than men with clinical stage T1c, although this 
difference was not significant (P=0.088). No difference was observed between the PCA3 
ratios of men with biopsy Gleason score <7 and men with biopsy Gleason score >7 
(P=0.622) (Table 2).
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Table 2. Relationship between PCA3 ratio and clinical variables
PCA3 in: N Median Mean P-value
All 336 25 67
Men with:
Negative biopsy 202 18 49 1.4-10-11*
Positive biopsy 134 50 94
Serum PSA:
< 3 (ng/ml) 26 24 36 0.097#
3-10 (ng/ml) 219 23 69
> 10 (ng/ml) 91 32 73
Prostate volume:
<30 (ml) 55 25 59 0.448*
30-50 (ml) 132 27 69
>50 (ml) 148 23 69
cT1c 50 38 71 0.088*
cT2 58 56 122
Biopsy GS < 7 81 52 99 0.622*
Biopsy GS > 7 51 38 88
GS, Gleason score;PCA3, prostate cancer gene 3;PSA,prostate-specific antigen 
Mann-Whitney U test 
*Kruskal Wallis test
The correlation between PCA3 ratio and radical prostatectomy Gleason score
Of the 134 men with a positive biopsy result, 70 underwent a radical prostatectomy. 
Tables 3 and 4 list the clinical and pathological characteristics of these patients. Radical 
prostatectomy Gleason score did not equal the biopsy Gleason score in 50% (35/70). 
There was upgrading in 41% (29 men) and downgrading in 9% (6 men) of the cases. 
There was no correlation between PCA3 ratio and tumor volume (P=0.680). In this 
cohort, the PCA3 ratio could not discriminate low volume/low grade prostate cancer 
(insignificant prostate cancer) from significant prostate cancer (P=0.496). The PCA3 ratio
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could not discriminate tumors with Gleason score >7 from those with Gleason score <7 
(P=0.199). Furthermore, the PCA3 ratio could not predict extra capsular extension in this 
patient cohort (P=0.765).
Table 3. Characteristics of radical prostatectomy population
N Median Mean Range
Age (years) y0 B2 B1 49^0
Serum PSA (ng/ml) y0 y.2 10.0 2.1-42.S
Serum PSA < 3 (ng/ml) 2 3%
Serum PSA 3-10 (ng/ml) 49 y0%
Serum PSA > 10 (ng/ml) 19 2y%
Prostate volume (ml) y0 3S 44 1S-112
Biopsy GS:
Minimal Cancer 1 (1.4%)
4 2 (2.9%)
5 5 (7.1°/o)
B 44 (B2.9%)
y (3+4) 14 (20.0%)
y (4+3) 2 (2.9%)
S 1 (1.4%)
9 1 (1.4%)
GS: Gleason score, PSA: prostate-specific antigen
Table 4. Relationship between PCA3 ratio and pathological variables
PCA3 in: N Median Mean P-value
All y0 42 93
Tumor volume: 5B
< 0.5 (ml) 10 4y 105 0.BS0#
0.5-2 (ml) 13 33 BS 0.S04* (<0.5 ml vs 0.5-2.0 ml)
> 2 (ml) 33 52 11B 0.42S* (<0.5-2.0 ml vs >2.0 ml)
Insignificant PCa 5 42 44 0.49B*
Significant PCa 54 45 109
Prostatectomy GS
4 1 42
5 y 20 241
6 21 32 54
7 30 54 100
8 4 99 9B
9 5 42 44
<7 29 32 99 0.199*
>7 39 52 92
Pathological stage
pT2 40 53 10S 0.7B5*
pT3 2S 3S yy
GS: Gleason score, PCa: prostate cancer, PCA3: prostate cancer antigen 3,PSA: prostate-specific antigen 
Mann-Whitney U test 
#Kruskal Wallis test
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Discussion
In this study we investigated the correlation between the PCA3 ratio and clinico- 
pathological features known to be associated with prostate cancer aggressiveness. 
Independent predictors of pathological stage and prognosis are clinical stage, serum 
PSA and Gleason grade. The Gleason scoring system is regarded as the most powerful 
prognostic factor in prostate cancer [13]. Men who have organ-confined disease and a 
Gleason score 7 tumor have significant worse outcome after radical prostatectomy and 
radiotherapy than men with a Gleason score <6 tumor [14]. Differentiation between 
Gleason score <6 and >7 is important for treatment decision. However, the 50% grade 
migration seen in his study indicates the need for better predictors of pathological stage 
and cancer aggressiveness. Several studies have shown that PCA3 was superior to 
serum PSA testing for predicting biopsy outcome [12, 15]. Two reports have shown a 
correlation between urinary PCA3 and prostatectomy Gleason score, tumor size, 
prostate cancer significance, or extra capsular extension [16, 17].
In this study, we were unable to confirm a correlation between PCA3 and clinico- 
pathological features. It was shown that a good urologic DRE of three strokes per lobe 
provided an informative rate of >94% which was equivalent to a more aggressive 
procedure (massage) [18]. In this study the DRE was performed according to a standard 
protocol involving three strokes per lateral lobe of the prostate. We used post-DRE 
urinary sediments, while previous studies that showed a positive correlation utilized post- 
DRE whole urine specimens. An advantage of using a urinary sediment over a whole 
urine sample may be that clinical data can be correlated to all the cells and cell 
fragments that were present in the collected urine. When using whole urine samples, 
only part of the total urine sample (2.5 ml) is analyzed. Therefore, if post-DRE whole 
urine specimens would have been used, the results obtained for this patient cohort might 
have been different. The advantage of whole urine is that the specimen processing 
procedure can be simplified, and the processed urine sample can be shipped overnight 
at room temperature. Because of this simplified procedure, whole urine is preferred 
above urine sediment.
The inconsistency of results might be also explained by differences among subject 
groups. In a recent Dutch multicentre study we observed that the study population is 
important for performance characteristics [11]. The current study is based on men 
admitted for prostate biopsies because of elevated serum PSA values (>3 ng/ml), an 
abnormal DRE, and/or a family history of prostate cancer. Some of these patients had a 
history of one or more negative biopsies. The median serum PSA value in our cohort is 
higher (7.2 ng/ml) when compared with the median serum PSA values in recent studies
PCA3’s value predicting adverse prostate cancer features
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(4.7 ng/ml [16] and 4.8 ng/ml [17]). In several studies it was shown that PCA3 can 
improve specificity in the diagnosis of prostate cancer when compared with serum PSA 
[12, 15]. The PCA3 assay performance was shown to be similar at all serum PSA levels 
[15]. In our study cohort, the PCA3 ratio was also significantly higher in the biopsy- 
positive population compared with the biopsy-negative population (P<1 10-11). The PCA3 
ratio was independent of prostate volume, confirming previous data [15]. A PCA3 cutoff 
value of 35 provided an optimal balance between sensitivity (61%) and specificity (74%). 
The AUC of 0.72 (95% CI: 0.66-0.77) for PCA3 was higher than that for serum PSA 
(0.65 (95% CI: 0.59-0.71)). In this patient cohort, PCA3 had a higher specificity (74%) 
compared with that of serum PSA (60%) in the diagnosis of prostate cancer.
The previous reports on the relationship between PCA3 and prostate cancer tumor 
features were performed in the US. Recently, it was shown that despite a stage 
migration to lower stages in the US, the fraction of Gleason score 7 cancer increased, 
whereas in Europe the patients with Gleason score 6 increased [19]. In an analysis of 
11,350 men treated with radical prostatectomy it was shown that patients from the US 
were younger and had lower serum PSA values at presentation [19]. In our study cohort 
the median age of men diagnosed with prostate cancer is 65 years, and 62 years for 
men scheduled for prostatectomy. In the US studies, the median age of the patient 
cohort scheduled for radical prostatectomy is ~59 years [16, 17]. The observed 
differences are consistent with opportunistic screening and prostate cancer detection in 
the US versus low to no penetration of screening in the Netherlands.
In our cohort, 62% of men with prostate cancer had a biopsy Gleason score <6, 
whereas in previous studies on the predictive value of PCA3, the number of men with 
biopsy Gleason score < 6 was lower (41-55%) [16, 17]. These data are in concordance 
with recent findings in which patients in the US had a higher rate of palpable cancer and 
a higher rate of biopsy Gleason score 7-10 than their European counterparts [19]. 
Furthermore, we observed a disappearance of biopsy Gleason score < 5 in the US study 
cohort [16, 17]. It has been shown that the grade interpretation of pathologists in the US 
has shifted towards higher biopsy grades compared with 10 years ago [20]. There is an 
increasing incidence in detection of moderately differentiated prostate cancer at biopsy 
and a decreasing incidence in well and poorly differentiated prostate cancer at biopsy 
[21]. The less universal adherence of the Europeans to the recommendations for grading 
of biopsy specimens may account for the fact why no decrease in biopsy Gleason score 
< 5 was observed in the European cohort. However, these findings may have clinical 
implications, since prediction tools developed in the US may perform differently in 
European patients due to the grade migration described above [19].
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Our study confirms the findings by Nakanishi et al. that there is no correlation 
between PCA3 ratio and clinical stage. In the biopsy population of our patient cohort no 
significant difference was found between PCA3 ratio and biopsy Gleason score <7 
versus >7 (P=0.622). Although previous studies did not find a significant correlation 
between PCA3 ratio and biopsy Gleason score either, there was an important difference 
between the data. In our patient cohort, biopsy Gleason score <7 had a higher median 
PCA3 ratio (52) compared to biopsy Gleason score >7 (38). In the studies by Deras et al. 
and Nakanishi et al., biopsy Gleason score 6 had a lower median PCA3 ratio compared 
to biopsy Gleason score >7 (38 versus 41 and 48 versus 55 respectively) [15, 17]. Again, 
it should be noted that we determined the PCA3 ratios in urinary sediments. Therefore, 
the PCA3 ratios cannot be compared at the level of absolute values with those 
determined in whole urine.
A hint in the direction that patient cohort may account for differences came from a 
recent European study [22]. In the multicentre study by Haese et al., only men were 
included who had one or two previous negative biopsies and who were scheduled for 
repeat biopsy. In their patient cohort, PCA3 did correlate with biopsy Gleason score and 
clinical stage, and was significantly higher in significant prostate cancer compared with 
indolent prostate cancer. Therefore, in men with one or two previous negative biopsies 
scheduled for repeat prostate biopsy, PCA3 may aid in the decision which patients need 
a repeat biopsy and may be indicative of the significance of prostate cancer.
We also analyzed the corresponding radical prostatectomy specimen, in which the 
Gleason score can be determined more accurately. In our patient cohort, 52% of men 
with prostate cancer were scheduled for radical prostatectomy. Seventy-four % of these 
men had biopsy Gleason score <7 and 26% had biopsy Gleason score >7. In the study 
by Nakanishi et al., 41% had a biopsy Gleason score <7 and 59% had biopsy Gleason 
score >7. It is unclear whether this reflects systematic differences in Gleason grading or 
that US surgeons are more willing to operate on higher risk patients [19].
In our study population, the prostatectomy Gleason score did not match the biopsy 
Gleason score in 50% of the cases. Upgrading occurred in 41% of the men and 
downgrading in 9% of the men. Twenty-nine men had prostatectomy Gleason score <7, 
whereas 39 men had prostatectomy Gleason score >7. The median PCA3 ratio for 
prostatectomy Gleason score <7 was lower than the median PCA3 ratio for 
prostatectomy Gleason score >7, although this difference was not significant (32 versus 
52, P=0.199).
In the study by Nakanishi et al., biopsy Gleason score did not equal the 
prostatectomy Gleason score in 41% of the cases (upgrading in 31 men and 
downgrading in 8 men). Only 15 men had prostatectomy Gleason score 6, whereas 81
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men had prostatectomy Gleason score >7. The PCA3 ratio was significantly higher in 
patients with prostatectomy Gleason score >7 compared with those who had 
prostatectomy Gleason score 6 tumors (P=0.005)[17].
In the radical prostatectomy population of the study by Whitman et al., 42 men had 
Gleason score 6 and 30 Gleason score >7 prostate cancer. The median PCA3 ratio for 
prostatectomy Gleason score 6 was less than the median PCA3 ratio for Gleason score 
>7 prostate cancer, but the difference was not significant (21 versus 31, P=0.22). 
Furthermore, the median PCA3 ratio was 25 and this was relatively lower compared with 
other studies. Whitman et al. suggested that patient population could account for the 
observed differences. Their population consisted of a relative high percentage (25%) of 
men with black ethnicity. Black men represent a group at a particularly high risk for 
developing prostate cancer. Significant differences in the frequency of risk alleles in 
these men have been identified and might, in part, explain an increased susceptibility to 
prostate cancer.
In our patient cohort, the number of patients with extra capsular extension was higher 
(40%) compared with the study by Nakanishi et al. (18%) and Whitman et al. (29%). An 
explanation for a higher rate of pT3 stage at prostatectomy compared with other studies 
is the inclusion of patients with a higher pre-operative serum-PSA (26% of men had 
serum PSA values > 10 ng/ml)[23]. We could not find a correlation between PCA3 and 
extra capsular extension in this cohort. Whitman et al. suggested that the increased 
frequency of pT3 disease observed in their study cohort could have been the result of 
increased detection from analyzing the prostate in whole mounted sections with smaller 
intervals [16]. In contrast to our study and the study by Nakanishi et al., men with pT3 
disease had a higher median PCA3 ratio compared with patients without extra capsular 
extension (49 versus 19, P=0.02)[16].
Conclusion
When combining the results from all the studies on the predictive value of PCA3 for 
adverse clinico-pathological features, yet unexplained discrepancies are revealed. Four 
variables may explain these differences. First, there are systematic differences in 
Gleason grading, which is best illustrated by the paradoxical high fraction of Gleason 
score 7 cancers in US cohorts. Second, it should be stressed that due to the original 
study design urine sediments were analyzed, which may have yielded different results 
than whole urine utilized in other studies. Third, the number of radical prostatectomy 
specimen in this study was relatively small. Perhaps a larger study could better 
differentiate the data. Fourth, our patient cohort had relatively few men with a favorable
Chapter 6
104
PCA3’s value predicting adverse prostate cancer features
prognostic outcome. Therefore, the predictive value of PCA3 for adverse prostate cancer 
features should be studied in a larger patient cohort with different risk categories. Further 
studies are needed to assess the exact position of PCA3-based testing in the clinical 
management of prostate cancer.
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Abstract
Background. Early detection of prostate cancer can increase the curative success rate 
for prostate cancer. We studied the diagnostic usefulness of TMPRSS2-ERG fusion 
transcripts as well as the combination of prostate cancer gene 3 (PCA3) RNA and 
TMPRSS2-ERG fusion transcripts in urinary sediments after digital rectal examination 
(DRE).
Methods. A total of 78 men with prostate cancer-positive biopsies and 30 men with 
prostate cancer-negative biopsies were included in this study. After DRE, the first voided 
urine was collected, and urinary sediments were obtained. We used semiquantitative 
reverse transcription-PCR (RT-PCR) analysis followed by Southern blot hybridization 
with a radiolabeled probe for the detection of TMPRSS2-ERG fusion transcripts in these 
urinary sediments. A quantitative RT-PCR assay for PCA3 was used to determine the 
PCA3 score in the same sediments.
Results. TMPRSS2-ERG fusion transcripts can be detected in the urine after DRE with 
a sensitivity of 37%. In this cohort of patients, the PCA3-based assay had a sensitivity of 
62%. When both markers were combined, the sensitivity increased to 73%. Especially in 
the cohort of men with persistently elevated serum PSA levels and a history of negative 
biopsies, the high positive predictive value of 94% of TMPRSS2-ERG fusion transcripts 
could give a better indication which patients require repeat biopsies.
Conclusion. In this report, we used for the first time the combination of the prostate 
cancer-specific biomarkers TMPRSS2-ERG and PCA3, which significantly improves the 
sensitivity for prostate cancer diagnosis.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy and the second 
leading cause of cancer-related deaths in the Western male population. It is estimated 
that prostate cancer will be diagnosed in 218,890 American men in 2007 [1]. The high 
incidence of prostate cancer can be attributed to the increased life expectancy of 
Western males and the implementation of serum prostate-specific antigen (PSA) testing. 
Although the introduction of serum PSA in clinical practice has led to detection of 
prostate cancer at a potentially curable stage, it has also led to the diagnosis of clinically 
insignificant prostate tumors. Another drawback of the serum PSA test is its low 
specificity, especially in the serum PSA gray zone of 3 to 15 ng/ml, resulting in a 
negative biopsy rate of 70 to 80%. Therefore, there is an urgent need for better 
biomarkers that can distinguish indolent from clinically significant prostate cancer and 
can reduce the number of unnecessary biopsies.
Differential gene expression analysis has been successfully used to identify prostate 
cancer-specific biomarkers by comparing malignant with non-malignant prostate tissues. 
Recently, a new biostatistical method called cancer outlier profile analysis (COPA) was 
used to identify genes that are differentially expressed in a subset of prostate cancers 
[2]. COPA identified strong outlier profiles for v-ets erythroblastosis virus E26 oncogene 
(ERG) and ets variant gene 1 (ETV1) in 57% of prostate cancer cases [3]. This was in 
concordance with the results of a study where prostate cancer-associated ERG over­
expression was found in 72% of prostate cancer cases [4]. In >90% o f the cases that 
overexpressed either ERG or ETV1, a fusion of the 5'-untranslated region of the 
prostate-specific and androgen-regulated transmembrane-serine protease gene 
(TMPRSS2) with these ETS family members was found. Recently, another fusion 
between TMPRSS2 and an ETS family member has been described, the TMPRSS2- 
ETV4 fusion, although this fusion is sporadically found in prostate cancers [5]. These 
fusions can explain the aberrant androgen-dependent overexpression of ETS family 
members in subsets of prostate cancer because TMPRSS2 is androgen-regulated [3]. 
The discovery of the TMPRSS2-ERG fusion transcript and the fact that ERG is the most 
frequently overexpressed proto-oncogene described in malignant prostate epithelial cells 
suggests its role in prostate tumorigenesis. As such, it may have impact not only on 
improved diagnosis but also on the treatment of prostate cancer.
For the diagnosis of prostate cancer, ideally, biomarkers should be detectable using 
noninvasive methods, e.g., by means of a blood or urine test. Recently, attention was 
focused on prostate cancer gene 3 (PCA3), a noncoding RNA that is prostate specific 
and highly overexpressed in prostate cancer [6]. Independent studies have shown that a
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PCA3-based urine test can improve the specificity in prostate cancer diagnosis and 
could thus aid in reducing biopsies [7, 8]. Because prostate cancer is a heterogeneous 
disease, the use of a panel of markers can further improve the diagnosis of this disease.
A recent study done on a cohort of 19 prostate cancer patients showed that the 
detection of TMPRSS2-ERG fusion transcripts in the urine of prostate cancer patients is 
feasible [9]. For the first time, we report on the diagnostic usefulness of TMPRSS2-ERG 
fusion transcripts in combination with PCA3 in urinary sediments in patients who were to 
undergo prostate biopsies based on serum PSA levels >3 ng/ml and/or an abnormal 
digital rectal examination (DRE).
Materials and methods
Specimen source
In the urological outpatient clinic, the first voided urine after DRE was collected 
prospectively from men who were admitted for prostate biopsies based on serum PSA 
levels > 3 ng/ml and/or abnormal DRE. All men had received study information, and they 
had signed their informed consent. In this study, a total of 108 patients were included, of 
whom 78 (72%) had prostate cancer upon biopsy. This patient population does not 
represent the typical patient population having a prostate biopsy based on elevated 
serum PSA levels in which the percentage of prostate cancer positive men is about 30%. 
The serum PSA values ranged from 1.1 to 1619.0 ng/ml.
The DRE was done by applying firm pressure to the prostate from the base to apex 
and from the lateral to the median line of each lobe. The men were asked to void, and 
the first 30 ml of urine was collected. Following urine collection, the urologist measured 
prostate volume by transrectal ultrasonography and did the prostate biopsy according to 
a standard protocol (at least three biopsies from the left peripheral zone, at least three 
biopsies from the right peripheral zone, one biopsy from the left transition zone, and one 
biopsy from the right transition zone, plus additional biopsies from other areas when 
suspicious for prostate cancer). All biopsy cores were examined for the presence of 
prostate cancer by a pathologist.
Collection of urine samples after prostate massage
After collection, the urine samples were immediately cooled on ice. Upon 
centrifugation at 4 °C and 700 x g for 10 minutes, urinary sediments were obtained. 
These urinary sediments were washed twice with ice-cold phosphate-buffered saline 
(PBS). Upon centrifugation at 4 °C and 700 x g for 10 minutes, the sediments were snap 
frozen in liquid nitrogen and stored at -70°C . The urinary sediments were spiked with 20
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|ig of Escherichia coli (E. coli) tRNA as a carrier (Roche Diagnostics), and total RNA was 
extracted using the TRIzol® Reagent (Invitrogen™). The PCA3 score was determined in 
all urinary sediments as described previously [10, 11].
Reverse transcription-PCR analysis
Total RNA was DNase treated and used for reverse transcription with SuperScript™ 
II RNase H- Reverse Transcriptase (Invitrogen™). The cDNA synthesis was done in a 30 
|il reaction volume, which contained 4 pl RNA, 300 units of reverse transcriptase, 1x first­
strand buffer, 10 mmol/l of DTT, 1 mmol/l of each deoxynucleotide triphosphate (dNTP), 
and 1 nmol random hexamers.
Primer pairs were designed with a forward primer in exon 1 of TMPRSS2, T2-F1: 5'- 
CGC GAG CTA AGC AGG AG-3' (position 1-17, GenBank™ database accession 
number NM_005656), and reverse primers in exon 4 of ERG, ERG-R4: 5'-GTC CAT 
AGT CGC TGG AGG AG-3', and exon 6 of ERG, ERG-R6: 5'-CCA TAT TCT TTC ACC 
GCC CAC TCC-3' (respectively, positions 315-334 and 636-659, GenBank™ database 
accession number NM_004449). For each sample a control PCR was done with primers 
for the housekeeping gene p2-microglobulin B2M-for: 5'-AGC AGA GAA TGG AAA GTC 
AAA-3' and B2M-rev: 5'-TGC TGC TTA CAT GTC TCG-3' (respectively, positions 162­
182 and 409-426, GenBank™ database accession number NM_004048). About 2 |il of 
cDNA sample was amplified in a 25 |il PCR reaction containing 25 pmol of each primer, 
150 |imol/l of each dNTP (Roche Diagnostics), 0.02 units of SuperTaq polymerase (HT 
Biotechnologie LTD) in buffer containing 1.5 mmol/l magnesium chloride, 10 mmol/l Tris- 
HCl (pH 8.3), 50 mmol/l potassium chloride, and 0.1% Triton X-100. PCR amplification 
for TMPRSS2-ERG transcripts was done on a Thermal Cycler (Eppendorf AG) as 
follows: 95°C for 2 minutes followed by 40 cycles at 94°C for 45 seconds, 64°C for 45 
seconds and 72 °C for 45 seconds, followed by a final extension of 10 minutes at 72°C. 
The same conditions were used for PCR amplification of p2-microglobulin with the 
exception that 26 amplification cycles were done and an annealing temperature of 60°C 
was used.
Detection of the PCR products
Amplified PCR products were separated on a 2% agarose gel and blotted onto 
Hybond™-N+ membranes (GE Healthcare) using blot buffer containing 0.5 mol/l NaOH 
and 1.5 mol/l NaCl. A probe was constructed by cloning the TMPRSS2-ERG (T2- 
F1/ERG-R4) PCR-fragment into the pCR-Blunt vector (Invitrogen™), verified by
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sequence analysis and labeled by random prime labeling using [a -32P]dATP, 10 mCi/ml, 
3,000 Ci/mmol (GE Healthcare).
Hybridization of the Southern blots was done as has been described previously [12]. 
Briefly, the blots were preincubated in hybridization buffer (7% SDS; 1% bovine serum 
albumin; 0.5 mol/l sodium phosphate buffer (pH 7.4); 1 mmol/l EDTA; 100 pg/ml salmon 
sperm DNA) for 1 hour at 65 °C. The radiolabeled probe was added to a maximum of 
1 1 0 6 cpm/ml and the blots were hybridized for 3 h at 65°C.
Blots were washed at high stringency with buffers containing 1% SDS, 1 mmol/l 
EDTA, and 0.5 mol/l sodium phosphate (wash buffer 1) and 0.1 mol/l sodium phosphate 
(wash buffer 2) for 15 minutes each at 65°C. Specific hybridization signals were 
visualized by autoradiography using X-ray films (GE Healthcare).
Statistical analysis
The Pearson X2 test was used to test the hypothesis that the presence of TMPRSS2- 
ERG fusion transcripts in urinary sediments is related to Gleason score determined in 
prostate biopsy specimen.
Results
TMPRSS2-ERG fusion transcripts can be detected in urine after DRE
Urinary sediments were obtained after DRE from 78 men with prostate cancer­
positive biopsies and 30 men with prostate cancer-negative biopsies. All 108 urine 
samples were positive for the housekeeping gene p2-microglobulin, used as a control for 
cDNA synthesis, indicating that all samples contained cells (data not shown). All samples 
were positive for PSA mRNA, quantitatively determined in all of these specimens as 
described previously, indicating that cells of prostate origin were present in these urinary 
sediments (data not shown) [10].
After reverse transcription-PCR (RT-PCR) amplification of TMPRSS2-ERG fusion 
transcripts, a heterogeneous pattern of PCR products was observed on agarose gel 
electrophoresis (Fig. 1A). After Southern blotting and hybridization with a radiolabeled 
probe specific for TMPRSS2-ERG fusion transcripts containing TMPRSS2 exon 1 or 
ERG exon 4, only specific bands remained visible (Fig. 1B). Bidirectional sequence 
analysis confirmed that the PCR products that did not hybridize to the probe were not 
TMPRSS2-ERG-related and that the PCR products that did hybridize represent the 
actual TMPRSS2-ERG fusion transcripts (Fig. 1B and Fig. 2).
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Fig. 1. Detection of TMPRSS2-ERG fusion transcripts in urinary sediments after DRE. (A) RT-PCR 
analysis on RNA extracted from 18 urinary sediments with a forward primer located in TMPRSS2 
exon 1 and a reverse primer located in ERG exon 4. The PCR products were separated by agarose 
gel electrophoreses. Lane 1, M: 100 bp DNA ladder (Promega); lanes 2-19, urinary sediments; lane 
20, negative control. (B) Autoradiogram of the Southern-blot from agarose gel shown in figure A, 
hybridized with a 32P-labeled probe specific for TMPRSS2-ERG fusion transcripts. The most 
common fusion transcript from TMPRSS2 exon 1 to ERG exon 4 can be seen in lanes 3-5, 8, 10, 
13, 15 and 17 (a, 180 bp). In lane 3, a variant fusion transcript is present of TMPRSS2 exon 2 and 
ERG exon 4 (b, 251 bp). A fusion between TMPRSS2 exon 1 and ERG exon 2 can be seen in 
lanes 7 and 18 (c, 368 bp). Lane 18 contains the same fusion transcript as in lane 7, together with a 
fusion transcript of TMPRSS2 exon 2 and ERG exon 2 (d, 439 bp). The nature of all fusion 
transcripts were confirmed by sequence analysis.
Fig. 2. Partial chromatogram of sequence analysis of the TMPRSS2-ERG fusion transcripts found 
in the urinary sediments. In the chromatogram the ERG sequence is underlined
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When we did semi-quantitative RT-PCR on RNA extracted from 29 primary prostate 
cancer tissue specimens, we found that TMPRSS2-ERG fusion transcripts were 
detected in 59% of the cases (data not shown). The urinary sediments of 29 of the 78 
(37%) prostate cancer patients and 2 of the 30 men with negative biopsies (7%) 
harboured TMPRSS2-ERG fusion transcripts (Table 1). The transcript TMPRSS2 exon 1 
fused with ERG exon 4 was found in 27 of 31 (87%) fusion transcript-positive cases 
(Table 2). In the urinary sediments of three prostate cancer patients, this transcript was 
found together with variant fusion transcripts. These variant fusion transcripts are 
TMPRSS2 exon 1 fused with ERG exon 2 and TMPRSS2 exon 2 fused with ERG exon
4. In four prostate cancer patients, only variant fusion transcripts were found: TMPRSS2 
exon 1 fused with ERG exon 2 or 3, and TMPRSS2 exon 2 fused with ERG exon 2 or 4 
(Table 2). Using the Pearson's X2 test, no relationship was found between the presence 
of TMPRSS2-ERG transcripts in urinary sediments and Gleason score in prostate biopsy 
specimens (two-sided P=0.511;Table 3). In the total cohort of patients, the analysis for 
TMPRSS2-ERG fusion transcripts in urinary sediments had a sensitivity of 37%, a 
specificity of 93%, a negative predictive value of 36%, and a positive predictive value of 
94% for the detection of prostate cancer (Table 1).
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Table 1. Diagnostic performance of TMPRSS2-ERG fusion transcripts in urinary sediments
PCa NPr
TMPRSS2-ERG positive 29 2 31 Sensitivity 0.37
TMPRSS2-ERG negative 49 28 77 Specificity 0.93
78 30 108 NPV 0.36
PPV 0.94
PCa: prostate cancer-positive biopsies, NPr: negative biopsies, NPV: negative predictive value, PPV: positive 
predictive value
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Table 2. Overview of TMPRSS2-ERG fusion transcripts determined in urinary sediments
Patient Serum PSA 
ng/ml
PCA3 test 
result
Gleason score 
in biopsies
TMPRSS2-ERG 
fusion transcripts
17 10.4 - no malignancy 1 ^  4
47 1.1 + no malignancy 1 ^  4
70 6.4 + 2 + 3 = 5 1 ^  4
89 4.7 - 2 + 3 = 5 1 ^  4
4 7.6 + 3 + 3 = 6 1 ^  4
44 7.3 + 3 + 3 = 6 1 ^  4
52 3.4 + 3 + 3 = 6 1 ^  4
67 5.0 + 3 + 3 = 6 1 ^  4
79 17.6 - 3 + 4 = 7 1 ^  4
88 7.4 + 3 + 4 = 7 1 ^  4
90 11.4 - 3 + 4 = 7 1 ^  4
95 96.7 - 3 + 4 = 7 1 ^  4
96 22.5 - 3 + 4 = 7 1 ^  4
100 4.7 + 3 + 4 = 7 1 ^  4
61 6.6 - 4 + 3 = 7 1 ^  4
106 11.8 - 4 + 3 = 7 1 ^  4
110 122.0 + 4 + 3 = 7 1 ^  4
2 73.6 + 4 + 4 = 8 1 ^  4
46 82.1 + 5 + 3 = 8 1 ^  4
71 85.6 + 4 + 5 = 9 1 ^  4
104 12.6 + 4 + 5 = 9 1 ^  4
103 103.0 + 5 + 4 = 9 1 ^  4
109 12.4 + 5 + 4 = 9 1 ^  4
54 16.0 + 5 + 5 = 10 1 ^  4
68 9.1 - 3 + 3 = 6 1/2 ^  4
62 4.9 + 3 + 3 = 6 1 ^  2/3/4
15 9.8 + 3 + 4 = 7 1 ^  4 + 1 ^  2/3/4
27 16.3 + 3 + 2 = 5 1 ^  4 + 1/2 ^  4
40 8.3 + 3 + 5 = 8 1 ^  4 + 1/2 ^  4
43 7.6 - 5 + 4 = 9 1 ^  2/3/4 + 1 ^  3/4
102 7.1 + 4 + 5 = 9 1 ^  2/3/4 + 1/2 ^  2/3/4
Table 3. Prognostic value of TMPRSS2-ERG fusion transcripts in urinary sediments of prostate
cancer patients
TMPRSS2-ERG negative TMPRSS2-ERG positive
n(%) n(%)
Number of cases 49 29
Gleason score <7 18 (37) 9 (31)
Gleason score =7 20 (41) 10 (34)
Gleason score >7 11 (22) 10 (34)
Note: No significant relationship was found between the presence of TMPRSS2-ERG fusion transcripts in 
urinary sediments and Gleason score determined in prostate biopsies (P=0.511).
TMPRSS2-ERG and PCA3 in prostate cancer diagnosis
To evaluate whether TMPRSS2-ERG fusion transcript analysis could be of additional 
value to the PCA3 test, the PCA3 score was determined as described previously [10]. In
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the absence of an arbitrary cutoff value, we determined from a Dutch multicenter study a 
cutoff value of 58 for prostate cancer diagnosis based on a receiver-operating 
characteristic curve [11]. In the study described here, samples with higher values than 
this cutoff were considered as positive PCA3 test results. A total of 48 urinary sediments 
of 78 men with prostate cancer had a positive PCA3 test, indicating a sensitivity of 62% 
(Table 4A).
In the total cohort of patients, the urinary sediments of 21 men were found positive 
for both PCA3 and TMPRSS2-ERG fusion transcripts (Table 4B). Twenty of these men 
(95%) had prostate cancer upon biopsy (Table 4A). The urinary sediments of 21 prostate 
cancer patients (27%) were negative for both markers. In the total cohort, 28 of the 41 
men (44%) who had a positive PCA3 test but were negative for TMPRSS2-ERG fusion 
transcripts had prostate cancer upon biopsy. A total of 9 of the 10 men (90%) who had a 
negative PCA3 test but were positive for TMPRSS2-ERG fusion transcripts had prostate 
cancer. These data are summarized in Tables 4A and 4B.
The PCA3 test alone detected 48 prostate cancer patients. Combined with 
TMPRSS2-ERG fusion transcripts, the number of prostate cancers detected increased to 
57. This indicates that the sensitivity of the combined tests is 73%.
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Table 4A. Concordance analysis of TMPRSS2-ERG versus PCA3 in prostate cancer patients
PCA3 positive PCA3 negative
TMPRSS2-ERG positive 20 9 29
TMPRSS2-ERG negative 28 21 49
48 30 78
Table 4B. Concordance analysis of TMPRSS2-ERG versus PCA3 in all patients
PCA3 positive PCA3 negative
TMPRSS2-ERG positive 21 10 31
TMPRSS2-ERG negative 41 36 77
62 46 108
Discussion
Gene-fusions have been predominantly found in hematological malignancies 
(leukemias and lymphomas) and soft-tissue tumors (Ewing's sarcomas) and have been 
far less frequently described in epithelial cancers, which account for 80% of cancer-
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related deaths [2]. Recently, fusions of the 5'-untranslated region of TMPRSS2 with the 
ETS transcription factors ERG, ETV1 and ETV4 have been reported in prostate cancer, 
which is one of the most common epithelial tumor types [3, 5]. A small study on 19 
patients with prostate cancer showed that TMPRSS2-ERG fusion transcripts could be 
detected in urinary sediments with a sensitivity of 42% [9]. In this study, urinary 
sediments obtained from 108 men who were indicated for prostate biopsies based on 
serum PSA levels >3 ng/ml and/or abnormal DRE, TMPRSS2-ERG fusion transcripts 
were detected in 37% of men with prostate cancer-positive biopsies.
In previous studies on RNA extracted from radical prostatectomy tissue samples, the 
frequency of TMPRSS2-ERG fusion transcripts, determined either by fluorescence in situ 
hybridization (FISH) or a RT-PCR-based approach, was 40 to 59% [3, 13-16]. In our 
cohort of 29 radical prostatectomy specimens, TMPRSS2-ERG fusion transcripts were 
detected in 59% of the cases (data not shown). These observations suggest that ~50% 
of the prostate cancers harbor TMPRSS2-ERG fusion transcripts.
There can be several explanations for the lower frequency of TMPRSS2-ERG fusion 
transcripts observed in urinary sediments compared with radical prostatectomy tissue 
samples. One explanation could be that most of the previous studies are based on 
radical prostatectomy tissue specimens. For the detection of TMPRSS2-ERG fusion 
transcripts in the urine, we are dependent on the ability of prostate cancer cells to be 
mobilized in the urine. To gain insight whether the urinary sediments contained prostate 
cancer cells, we compared the TMPRSS2-ERG results with PCA3 results in these 
specimen. PCA3-based assays using different amplification methods for the detection of 
PCA3 RNA transcripts have shown their diagnostic value [7, 8, 10, 11]. Because PCA3 is 
strongly overexpressed in more than 95% of primary prostate cancer specimens, only 
5% of cancers should be false-negative [6, 17]. We found a higher false-negative rate of 
27% for both markers; it suggests that this is due to the fact that no or very few cancer 
cells were released into the urine upon DRE. This is in agreement with the hypothesis of 
Tinzl et al. [7] that false negative samples may represent a subgroup of prostate tumors 
that have less tendency to invade in the prostate ductal system and, thus, shed less cells 
in the urine.
An alternative explanation could be that we restrict ourselves to the fusion transcripts 
that were described most frequent containing TMPRSS2 exon 1 and ERG exon 4 [14]. In 
the urinary sediments, the most frequently observed fusion transcript was TMPRSS2 
exon 1 fused with ERG exon 4 (87%) either alone or in combination with other fusion 
types (Table 2 and Fig. 2). This is comparable with the findings of Wang et al. [14], who 
detected this fusion transcript also in 86% of the cases. Several studies have reported on
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the expression of variant transcripts in which TMPRSS2 exon 1 is fused with ERG exon 
5 [14, 18]. In individual samples, this fusion transcript usually occurs together with the 
most commonly expressed transcript (TMPRSS2 exon 1 and ERG exon 4). Using a 
reverse primer in ERG exon 6, we confirmed for 29 radical prostatectomy tissue 
specimens (data not shown) that the transcript of TMPRSS2 exon 1 fused with ERG 
exon 5 was indeed found together with the most commonly expressed transcript. 
Therefore, it did not lead to the detection of additional prostate cancers. These findings 
indicate that the exclusion of the transcript TMPRSS2 exon 1 fused with ERG exon 5 
would not be the major reason for the observed lower sensitivity.
Recently, there have been reports on the prognostic value of TMPRSS2-ERG fusion 
transcripts. The Gleason scoring system, in which primary and secondary cancer growth 
patterns are identified and summed, is regarded as one of the most powerful 
prognosticators in prostate cancer. It was shown that the expression of TMPRSS2-ERG 
fusion transcripts is associated with higher Gleason scores [19, 20]. Moreover, a 
statistically significant association between TMPRSS2-ERG fusion transcripts and 
prostate cancer-specific death was found [20]. In our study, we could not confirm that the 
urine-based TMPRSS2-ERG analysis is associated with a higher Gleason score 
(P=0.511). An explanation could be that we used prostate biopsy tissue specimen to 
determine the Gleason score, whereas in other studies, radical prostatectomy tissue 
specimens or TURP material was used. The fact that prostate cancer is a heterogeneous 
disease can result in undergrading of the Gleason score in biopsies. It is therefore most 
likely that the Gleason score of many of these cancers will be upgraded at surgery. 
Therefore, it would be interesting to compare these results with the final Gleason score 
after radical surgery.
Because prostate cancer is a heterogeneous disease, it becomes clear that a 
combination of markers will become important in early prostate cancer diagnosis [21]. 
The urinary sediments of prostate cancer patients that were found positive for PCA3 but 
negative for TMPRSS2-ERG fusion transcripts and vice versa support this idea. Nine 
prostate cancers could be detected in case the negative PCA3 urine test was combined 
with TMPRSS2-ERG fusion transcripts (Table 2). The combination of both markers 
remarkably increased the sensitivity for the detection of prostate cancer from 62% (PCA3 
test alone) to 73%.
The combination of both markers could be of special value in men who have 
persistently elevated serum PSA values, but a history of negative biopsies. Several men 
included in the study published by Hessels et al. [10] who had a positive PCA3 test but 
negative biopsies were shown to have prostate cancer upon repeated biopsies 
(unpublished data). In this study, there are two men with negative biopsies who were
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positive for TMPRSS2-ERG fusion transcripts. One of them is also positive for PCA3. 
Since the positive predictive value (PPV) of TMPRSS2-ERG fusion transcript analysis is 
94%, this indicates that these two men have a probability of 94% of having prostate 
cancer. Because the urinary sediments in this study were collected prospectively, follow- 
up data on these evaluated patients are rather short. However, the results of this study 
suggest that if both tests are combined, a better indication can be given which patients 
need a repeat biopsy and, as such, could aid the diagnosis of prostate cancer as a reflex 
test to serum PSA. Follow-up data will show in time whether PCA3-based and 
TMPRSS2-ERG-based diagnostics can detect prostate cancers before prostate cancer 
is diagnosed by biopsy.
Conclusion
In summary, we show that the noninvasive detection of TMPRSS2-ERG fusion 
transcripts is feasible in urinary sediments obtained after DRE. This is the first report 
where two novel prostate cancer-specific biomarkers are combined for the diagnosis of 
prostate cancer. The combination of TMPRSS2-ERG fusion transcripts and PCA3 RNA 
transcripts remarkably improves the sensitivity without compromising specificity for the 
detection of prostate cancer. This combination could be of special value in men who 
have persistently elevated serum PSA values but a history of negative biopsies. The high 
positive predictive value of TMPRSS2-ERG fusion transcript analysis could aid the 
clinician to decide which patient needs a repeat biopsy.
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Abstract
Although the routine use of serum PSA testing has undoubtedly increased prostate 
cancer detection, one of its main drawbacks has been its lack of specificity, which results 
in a high negative biopsy rate. Consequently, a large population of men with chronically 
elevated serum PSA and one or more negative biopsies has emerged. More accurate 
tests are needed that can help identify which patients are at high risk of developing 
prostate cancer, and for whom repeat prostate biopsies are mandatory. To improve the 
specificity of prostate cancer diagnosis, prostate cancer-specific markers, such as 
prostate cancer gene 3 (PCA3), are needed. The strong association between PCA3 
mRNA overexpression and malignant transformation of prostate epithelium indicates its 
potential as a biomarker. Quantification of PCA3 mRNA levels in urine was found to help 
predict the outcome of prostate biopsies. The intensive and time-consuming reverse- 
transcriptase polymerase chain reaction PCA3 urine test has been translated 
successfully into the fast and easy transcription-mediated amplification (TMA)-based 
PCA3 test. This test is the first RNA-based molecular diagnostic assay in body fluids for 
prostate cancer that is available to urologists. This review describes the translation of the 
molecular marker PCA3 from the research laboratory to clinical practice.
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Introduction
Annually, 186,320 men in the US and 345,900 men in Europe are newly diagnosed 
with prostate cancer and around 28,660 US and 87,400 European men die from this 
disease [1, 2]. Early detection of prostate cancer relies on serum PSA testing or digital 
rectal examination (DRE). Since its first clinical application, serum PSA has been the 
most valuable tool in the detection, staging and monitoring of this disease. Although the 
routine use of serum PSA testing has undoubtedly increased prostate cancer detection, 
one of its main drawbacks has been its lack of specificity that results in a high negative 
biopsy rate. This is especially true in patients with serum PSA values between 3-10 
ng/ml, in whom the negative biopsy rate is approximately 60-75% [3]. This specificity is 
low because an elevated serum PSA level is not a prostate cancer-specific event; it can 
also be detected in men with benign prostatic hyperplasia (BPH) and prostatitis. 
Although prostate biopsy is considered the gold standard for prostate cancer diagnosis, 
this method has its limitations and associated morbidities. Methods to enhance PSA 
specificity have assisted clinicians in deciding which patients should undergo biopsy, but 
have not necessarily improved diagnostic accuracy of facilitated optimal therapeutic 
decision-making. More-accurate tests that can stratify patients according to their risk of 
developing prostate cancer, and identify those who require repeat prostate biopsy, are 
needed. Implementation of prostate cancer-specific markers in body fluids is needed in 
order to improve the specificity of prostate cancer diagnosis. A number of these 
biomarkers have been identified, but one of the biomarkers that has been critically 
evaluated and clinically investigated for its diagnostic potential is prostate cancer gene 3 
(PCA3) [4, 5], This review is an overview of PCA3, from its identification and its 
systematic and critical evaluation to a fully translated molecular assay in body fluids that 
is a valuable tool in predicting biopsy outcome.
Identification and characterization
In 1999, a new prostate-specific gene was identified using differential display 
analysis, a technique to compare mRNA expression patterns of tumor and adjacent non­
neoplastic tissue in radical prostatectomy specimens [6]. Using Northern blot analysis, 
DD3 (differential display clone 3) was found to be highly overexpressed in prostate 
tumors compared with normal prostate tissue from the same patient. In accordance with 
current human genome nomenclature, it has been renamed PCA3 to reflect its 
association with prostate cancer. Low PCA3 expression was observed in normal prostate 
and BPH tissue. High overexpression of PCA3 was observed in 95% of the primary 
prostate cancer specimens studied. Using reverse-transcriptase polymerase chain
The use of PCA3 in the diagnosis of prostate cancer
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reaction (RT-PCR), PCA3 was found to be prostate-specific as no expression could be 
detected in other normal human tissues, in tumors originating from the breast, cervix, 
endometrium, ovary and testis, or in cell lines originating from bladder, kidney and 
ovarian cancers. PCA3 expression was demonstrated in only two prostate cancer cell 
lines, LNCaP and 22Rv1 [6].
The gene encoding PCA3 maps to chromosome 9q21-22 and consists of four exons. 
Molecular characterization of the PCA3 transcription unit revealed that alternative 
polyadenylation at three different positions in exon 4 gives rise to three different-sized 
transcripts. In addition, alternative splicing occurs, in which exon 2 (present in only 5% of 
the transcripts) is skipped. The most frequently found transcript, which accounts for 
approximately 60% of all cDNA clones analyzed, contains exons 1, 3, 4a and 4b (Fig. 1) 
[6]. Open reading frame analysis revealed that the PCA3 exons are populated by an 
unusual number of stop codons. A gene that codes for proteins will typically possess one 
long open reading frame delimited by a stop codon. The multiplicity of stop codons 
across the three reading frames of PCA3 and the lack of an extended open reading 
frame indicates that PCA3 does not encode a protein and functions as a non-coding 
RNA.
Chapter 8
Fig. 1. Structure of the PCA3 transcription unit. The gene encoding PCA3 maps to chromosome 
9q21-22 and consists of four exons. Alternative polyadenylation at three different positions in exon 4 
(indicated 4a, 4b, and 4c) gives rise to three different-sized transcripts. Alternative splicing occurs, 
by which exon 2 (present in only 5% of the transcripts) is skipped. The most frequently found 
transcript contains exon 1, 3 and 4a and 4b [6].
124
The use of PCA3 in the diagnosis of prostate cancer
Diagnostic utility of PCA3
The strong association of PCA3 overexpression with malignant transformation of 
prostate epithelium has identified its potential use as biomarker for the diagnosis of 
prostate cancer; however, in the absence of a protein product, the only substrate or 
target molecule that can be used is mRNA. RNA is prone to degradation, especially in 
biological fluids, which can lead to a decreased sensitivity of any RNA-based test. Thus, 
a good clinical RNA-based test will rely on the robustness of sample collection and 
having a high degree of sensitivity for its target.
In 2002, a real-time RT-PCR analysis for the quantification of PCA3 mRNA in tissue 
specimens was developed [7]. In 2003, Hessels et al. established a sensitive quantitative 
RT-PCR technique that used dual time-resolved fluorescence, an exogenous internal 
control and an external calibration curve [8]. Both techniques confirmed that PCA3 
mRNA expression is restricted to the prostate and that it is present in normal prostate 
and BPH tissue at low, quantifiable levels. The median upregulation of PCA3 mRNA in 
prostate cancer was 66-fold compared with normal prostate tissue. Using receiver 
operating characteristic (ROC) curves, both techniques revealed that PCA3 has a high 
sensitivity and specificity for prostate cancer in tissue specimens (area under curve 
(AUC) of 0.94 and 0.98, respectively) (Fig. 2a) [7-9]. Moreover, in prostate tissue 
specimens that contained <10% prostate cancer cells, the median upregulation of PCA3
0 0.25 0.50 0.75 1.00 0 0.25 0.50 0.75 1.00
Specificity Specificity
Fig. 2. Sensitivity and specificity of PCA3 testing for detecting prostate cancer. 2a. ROC analysis 
demonstrated that PCA3 has a high sensitivity and specificity for prostate cancer in tissue 
specimens (AUC= 0.94 [95%CI: 0.89-0.99]) [9]. 2b. rO c  analysis was used to visualize the 
diagnostic efficiency of the quantitative RT-PcR-based PCA3 test (AUC= 0.66 [95% CI:0.61-0.71]) 
and serum PSA (aUc= 0.57 [95% CI:0.52-0.63]) in urinary sediments collected after DRE [13].
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was 11-fold. This demonstrates that PCA3 is able to detect a small number of prostate 
cancer cells in a background of predominantly non-malignant cells, without the need for 
microdissection [8]. The combined data and the fact that PCA3 is not expressed in 
leukocytes (often present in body fluids) indicate the great utility of PCA3 as a minimally 
invasive diagnostic tool to detect prostate cancer cells in body fluids [7]. The RT-PCR- 
based PCA3 test developed by Hessels et al. was used to evaluate the utility of PCA3 to 
detect prostate cancer cells in urinary sediments after DRE [8]. The reasoning behind 
this was that manipulation of the prostate would transport the cancer cells via the 
prostatic ductal system into the urethra. The first portion of voided urine following DRE 
contains the highest concentration of prostatic and urethral secretions [10]. However, 
urinary sediments contain non-neoplastic prostate cells and urothelial cells as well as 
tumor cells. PSA mRNA was used to normalize for the number of prostate cells as its 
expression was shown to be relatively constant in both normal prostate cells and 
prostate cancer cells [11]. Both PCA3 and PSA mRNA levels were quantified in urinary 
sediments following DRE [8]. The PCA3 score is the ratio of PCA3/PSA mRNAs 
multiplied by 1,000. In a cohort of 108 men admitted for prostate biopsies based on 
serum PSA levels > 3 ng/ml, 24 men were found to have prostate cancer upon biopsy. 
Using prostate biopsy as the gold standard, ROC analysis yielded an AUC of 0.72 (95% 
CI:0.58-0.85). The RT-PCR-based PCA3 assay had 67% sensitivity and 83% specificity 
for detecting prostate cancer [8]. For comparison, the serum PSA test specificity was 
22%. This study was the first to demonstrate the potential of a quantitative PCA3-based 
urine test to aid in the prediction of biopsy outcome. This test can also be performed on 
prostatic fluid after DRE, resulting in similar sensitivity and specificity data to that 
obtained from urine [12]. In a Dutch multicenter study that examined urinary sediments 
following DRE in 583 men with serum PSA levels in the range 3-15 ng/ml, the AUC was
0.66 (95% CI: 0.61-0.71) for PCA3 and 0.57 (95% CI: 0.52-0.63) for serum PSA (Fig. 
2b) [13]. Here, the test had a sensitivity of 65% and a specificity of 66% (versus 65% 
sensitivity and 47% of serum PSA), confirming that a PCA3 test can improve the 
specificity of prostate cancer diagnosis.
A TMA-based PCA3 test
Although the urinary RT-PCR-based test demonstrated the potential of PCA3 in the 
diagnosis of prostate cancer, the methodology used was too intensive and tim e­
consuming for widespread implementation in clinical laboratories, restricting its use to 
research laboratories. Moreover, the procedure for collecting and stabilizing specimens 
under standardized conditions had to be defined. Gen-Probe Inc, therefore, translated
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the initial RT-PCR-based urine PCA3 test to its transcription-mediated amplification 
(TMA) platform [14]. This technology is simple, fast and sensitive enough to be used in a 
clinical laboratory. The TMA platform is commercially available for several FDA-approved 
products, and its equipment is already present in many laboratories worldwide.
Sampling and methods
The TMA platform is composed of sample preparation, amplification and detection. 
This technology uses the first voided urine that is collected after a DRE consisting of 
three strokes per prostate lobe. The specimen-processing procedure is simplified using 
urine samples instead of urinary sediments. Cells are lysed and RNA is stabilized by 
mixing the urine sample with an equal volume of detergent-based stabilization buffer. 
The processed urine sample can be shipped overnight at room temperature to testing 
laboratories, or can be stored frozen for longer time periods. The PCA3 and PSA 
mRNAs are quantified using similar protocols and reagents, with components specific for 
the two analytes. The target RNAs are purified via capture onto magnetic particles 
coated with target-specific oligonucleotides, amplified using TMA, and the amplification 
products are detected with chemiluminescent DNA probes in a hybridization protection 
assay. All assay steps occur in a single tube and the test can be completed within 6 
hours [14].
Assay results
The analytical performance of the TMA-based PCA3 assay has been extensively 
studied. Post-DRE specimens provided informative rates (number of specimens with 
sufficient RNA for analysis) of >95% in several studies, compared with 80% using first 
morning voided urine or 74% using pre-DRE specimens [15]. This demonstrates that any 
manipulation of the prostate will shed enough cells in the urine to provide an informative 
specimen. The intra-run and inter-run coefficients of variance for PCA3 and PSA mRNA 
quantification were low (<13% and <12%, respectively) [14]. These data have been 
confirmed, and the variation between research sites was shown to be low (<9%), 
demonstrating a robust performance of the test both within and across sites [15, 16].
The accuracy and ease of use of the TMA-based PCA3 test will be key factors in its 
implementation in clinical practice. The yield of RNA (that is, having sufficient prostate 
cells) in a sample determines the utility of the test and is, therefore, also very important. 
The success of the TMA-based test is due to the simplified specimen processing 
procedure that utilizes the whole urine instead of urine sediments, as well as 
improvements to mRNA capture (which removes inhibitory substances in the first step of 
the assay) and amplification technology [14]. If, however, the RNA yield in the specimen
The use of PCA3 in the diagnosis of prostate cancer
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is insufficient, patients must return to provide another urine sample. This is inconvenient 
for the health care system and the patient, who will also need a repeat DRE.
PCA3 as a predictor of biopsy outcome
In 2006, the quantitative TMA-based PCA3 assay was applied to urine samples 
collected after DRE from men scheduled for prostate biopsy (pre-biopsy population), 
men who had undergone radical prostatectomy, and healthy men with no risk factors for 
prostate cancer [14]. The median PCA3 scores for men in the pre-biopsy group found to 
have positive biopsies, those in the pre-biopsy group with negative biopsies and healthy 
men were significantly different (P<0.01), confirming previous data [8, 13]. The greatest 
diagnostic accuracy in the pre-biopsy population was obtained using a PCA3 score cutoff 
of 50. This assay had 69% sensitivity and 79% specificity for prostate cancer detection. 
At the same sensitivity, the specificity of serum PSA measurement was 60% in this 
cohort. Although a different methodology was used, the clinical performance was similar 
to the previously reported quantitative RT-PCR-based PCA3 test (Table 1) [8, 13]. Three 
independent studies confirmed these results using a PCA3 score of 35 as the cutoff [17­
19]. Furthermore, they demonstrated that, for men with elevated serum PSA levels and 
one previous negative biopsy, the risk of positive biopsy findings correlated with PCA3 
scores (Fig. 3). Deras et al. demonstrated that men with a PCA3 score <5 had a positive 
biopsy rate of 14%, whereas 69% of men with a PCA3 score >100 had prostate cancer 
upon biopsy. The analytical performance and diagnostic accuracy of PCA3 was 
independent of the serum PSA level and of whether the individual underwent a first
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Table 1. Results for PCA3-based urine testing using different methodologies in predicting biopsy 
outcome
Study PC/43-based Number AUC Se Sp PPV NPV
test of (%) (%) (%) (%)
methodology patients
Hessels et al. (2003) [8] QRT-PCR 108 0.72 67 83 53 90
Van Gils et al. (2007) [13] QRT-PCR 583 0.66 65 66 48 80
Groskopf et al. (2006) [14] TMA 70 0.75 69 79 50 89
Marks et al. (2007) [17] TMA 233 0.68 58 72 43 83
Deras et al. (2008) [18] TMA 570 0.69 54 74 58 74
Haese et al. (2008) [19] TMA 470 0.66 47 72 39 78
AUC: area under curve, NPV: negative predictive value, PPV: positive predictive value, QRT-PCR: quantitative 
reverse-transcriptase polymerase chain reaction, Se: sensitivity, Sp: specificity, TMA: transcription-mediated 
amplification
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5-19 20-34 35-49 50-100 >100 
(205) (101) (62) (90) (54)
PCA3 score (number of subjects)
Fig. 3. The correlation of PCA3 score (determined with the TMA-based PCA3 test) with the 
percentage of men with positive prostate biopsies. The probability of a positive prostate biopsy 
increases with increasing PCA3 scores [18].
biopsy or repeat biopsy. PCA3 scores were independent of prostate volume and showed 
no correlation with biopsy Gleason score [18].
The ratio of uncomplexed PSA to total PSA (%fPSA) is often used to improve the 
specificity of prostate cancer detection. In the study by Haese et al., PCA3 had a better 
diagnostic accuracy than %fPSA for predicting repeat biopsy outcome [19]. Using a 
PCA3 score cutoff of 35, PCA3 had a sensitivity of 47% and a specificity of 72%. In 
comparison, the specificity of %fPSA (cutoff 25%) was only 23%. Three independent 
studies demonstrated that, in men undergoing repeat biopsy, PCA3 was superior to 
either serum PSA or %fPSA testing for predicting biopsy outcome [17-19].
Combination of PCA3 with other factors
The combination of new prostate cancer biomarkers such as PCA3 with other 
diagnostic factors might help to more accurately predict whether cancer is found on 
prostate biopsies. Logistic regression analysis has shown that the combination of PCA3 
with factors such as serum PSA, prostate volume and DRE findings could increase the 
diagnostic accuracy to an AUC of 0.75, compared to 0.69 for PCA3 alone or 0.55 for 
serum PSA alone [18]. Thus, a combination of biomarkers with other diagnostic
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indicators of prostate cancer can indeed increase diagnostic accuracy. This was 
confirmed by Ankerst et al. by using the Prostate Cancer Prevention Trial (PCPT) risk 
calculator [20]. In the PCPT risk calculator, six risk factors (serum PSA, DRE, first- 
degree family history of prostate cancer, biopsy history, age and black ethnicity) are 
combined for estimating the risk of developing prostate cancer and the risk of developing 
high grade disease (Gleason score > 7). Incorporation of PCA3 in this risk calculator 
resulted in a significant improvement in the diagnostic accuracy of the original model. 
When applied to individual patients, the incorporation of PCA3 into the risk calculator 
refined the estimate of prostate cancer risk; a low PCA3 score indicated a decreased risk 
for the patient, and a high PCA3 score indicated an increased risk of developing prostate 
cancer. Using the case of 65-year-old man, the original PCPT risk calculator estimated a 
risk of 26.5%. When a low PCA3 score was included, the risk decreased to 16.9%, 
whereas a high PCA3 score increased the risk to 43.1% [20]. These data show that new 
biomarkers like PCA3 can be successfully incorporated into risk calculators, resulting in 
improvements in prostate cancer detection.
PCA3 and TMPRSS2-ERG gene fusions
Because prostate cancer is a heterogeneous disease, the use of a panel of 
biomarkers can further improve diagnostic accuracy. Fusions of the 5'-untranslated 
region of the TMPRSS2 gene with the ETS transcription factors ERG, ETV1, and ETV4 
have been reported in prostate cancer [21, 22]. Hessels et al. showed that non-invasive 
detection of TMPRSS2-ERG fusion transcripts is feasible in urinary sediments obtained 
after DRE using an RT-PCR-based research assay [23]. Owing to the high specificity of 
the test (93%), the combination of TMPRSS2-ERG fusion transcripts with PCA3 
improved the sensitivity from 62% (PCA3 alone) to 73% (combined) without 
compromising the specificity for detecting prostate cancer.
Laxman et al. demonstrated that SPINK1, GOLPH2 and TMPRSS2-ERG were, like 
PCA3, independent predictors of prostate cancer upon repeat biopsy [24]. By combining 
PCA3 with these markers in a quantitative, multiplexed RT-PCR analysis, the ROC AUC 
value improved from 0.66 (PCA3 alone) to 0.76. This multiplexed, urine-based assay had 
66% sensitivity and 76% specificity for detecting prostate cancer in repeat biopsies.
PCA3 as a prognostic indicator
The association of PCA3 score with prostatectomy tumor volume and other clinical 
and pathological features was assessed by Van Gils et al. in 2008 [25]. They correlated 
the PCA3 score in urinary sediments after DRE in 62 men with the prognostic
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parameters that are assessed in radical prostatectomy specimens; no significant 
correlation was found between PCA3 Score and Gleason Score (P= 0.90), pathological 
tumor stage (P= 0.59), or total tumor volume (P= 0.96).
More encouraging results were found by Nakanishi et al. [26]. Their study population 
consisted of 59 men scheduled for prostate biopsies because of serum PSA values >2.5 
ng/ml and/or an abnormal DRE, and 83 men diagnosed with prostate cancer that were 
scheduled for a radical prostatectomy. In the biopsy population, no significant difference 
was found between PCA3 score and biopsy Gleason score 6 versus Gleason score > 7 
tumors, confirming previous results [18]. However, the PCA3 score was significantly 
correlated with tumor volume (P=0.008) and Gleason score (6 versus > 7) in 
prostatectomy specimens (P=0.005). Furthermore, the PCA3 score was significantly 
lower in men with clinically insignificant prostate cancer (dominant tumor volume <0.5 ml 
and Gleason score < 6) compared to the PCA3 score in clinically significant prostate 
cancer (P=0.007) (Fig. 4). These data indicate that the PCA3 score could be effective in 
helping to determine which men are candidates for active surveillance.
The use of PCA3 in the diagnosis of prostate cancer
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Nonsignificant Significant 
Prostate cancer classification
Fig. 4. PCA3 score and clinical relevance of prostate cancers. The PCA3 score was found to be 
significantly higher in clinically significant prostate cancers (n= 85; Gleason score > 7, and/or 
volume >0.5 ml) versus nonsignificant prostate cancers (n= 11; Gleason score < 6 and volume <0.5 
ml) (P=0.007). Error bars represent standard error of average [26].
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A European multicenter study consisting of 463 men with one or two negative 
biopsies confirmed that patients with clinically significant prostate cancer had higher 
PCA3 scores than those with clinically insignificant prostate cancer (P=0.0059) [19]. In 
this cohort, men with clinical stage T2 tumors had a significantly higher PCA3 score than 
men with clinical stage T1c tumors (P=0.005). PCA3 has also been found to be an 
independent predictor of extracapsular extension (P=0.01) and of a low tumor volume 
(<0.5 ml) (P=0.04) [27]. Combined with Gleason score >6 and pre-operative serum PSA 
level, the ROC AUC improved from 0.73 for PCA3 alone to 0.90 for predicting 
extracapsular extension. A PCA3 score cutoff of 47 resulted in 57% sensitivity, 94% 
specificity and a positive predictive value of 80% for predicting extracapsular extension. 
Thus, PCA3 may be indicative of clinical stage and prostate cancer significance [26].
The results indicating a correlation between PCA3 and cancer aggressiveness 
should be regarded as preliminary. The inconsistency in results between PCA3 and 
pathological tumor features might be explained by differences among the study 
population or in the pathological evaluation of the specimens. The only way to find out its 
true predictive value is through validation in definitive trials.
PCA3:clinical and future applications
A summary of the potential uses of the PCA3 score in clinical practice is given in 
Table 2. PCA3 measurement can be a useful test when considering the need for a 
repeat biopsy, especially in men with chronically elevated serum PSA values because of 
chronic inflammation or prostatitis. PCA3 can help to stratify men according to their risk 
of having prostate cancer. A negative biopsy and a low PCA3 score might indicate a 
more conservative follow-up is appropriate. Based on preliminary data regarding the 
prognostic value of PCA3, a negative prostate biopsy accompanied by a high PCA3 
score might indicate the need for advanced imaging modalities to locate a clinically 
significant prostate cancer. If a patient has prostate cancer but the PCA3 score is low, 
active surveillance might be considered for a clinically insignificant tumor. When both the 
biopsy is positive and the PCA3 score is high, there is a high likelihood of finding 
clinically significant prostate cancer, and the urologist might decide to recommend 
intervention. The information in Table 2 raises the question of what PCA3 score should 
be used as the cutoff value in these different clinical applications. With regard to the 
identification of men with an increased probability of having a positive repeat biopsy, a 
PCA3 score cutoff of 35 provided an optimal balance between sensitivity and specificity 
in a pre-biopsy population in several studies [17-19]. A low PCA3 score indicates a low 
probability of cancer; however, it does not exclude clinically significant prostate cancer in
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Table 2. The possibilities of the TMA-based PCA3 test in clinical practice
PCA3
score
+ Biopsy
result
Course of action to consider Established prognostic 
factor
Low + Negative Conservative follow-up PSA kinetics
High + Negative Advanced imaging PSA kinetics
(e.g. contrast-anhanced MRI)
Low + Positive Active surveillance Clinical stage + grade;
PSA kinetics
High + Positive Intervention Clinical stage + grade
the biopsy. This was shown in the study by Haese et al. A  PCA3 score cutoff of 35 
avoided 67% of unnecessary biopsies, while 21% of clinically significant cancers would 
have gone undetected [19]. If a PCA3 score of 20 had been used, 44% of the 
unnecessary biopsies would have been avoided while only 9% of clinically significant 
cancers would not have been detected.In their cohort, the PCA3 score cutoff of 20 
worked best for both avoiding unnecessary biopsies and minimizing the risk of leaving 
significant prostate cancer undetected. Whitman et al. found a median PCA3 score of 26 
in their pre-prostatectomy cohort [27]. Based on the defined PCA3 score cutoff of 35, half 
of the prostate cancers in their patient cohort would not have been detected in a pre­
biopsy population. Whether this difference in observation is due to the high percentage 
(25%) of black men in their patient cohort is unclear. Black men represent a group at a 
particularly high risk for developing prostate cancer. Significant differences in the 
frequency of risk alleles in these men have been identified and might, in part, explain an 
increased susceptibility to prostate cancer; however, this observation indicates that 
PCA3 score might be more useful in both diagnostic and prognostic applications as a 
continuous variable in combination with other clinical and/or pathological data [18, 20].
Efforts to further validate and expand the clinical utility of the TMA-based PCA3 test 
continue. Potential applications include the use of PCA3 prior to first prostate biopsy, 
detecting local recurrence following radical prostatectomy or radiation therapy, or 
monitoring patients receiving drug therapies that affect serum PSA levels (for example, 
5a-reductase inhibitors).
The challenge remains to identify markers that can help to identify potentially life- 
threatening prostate cancer at a curable stage. Prostate cancer is a heterogeneous 
disease and, therefore, a panel of biomarkers including PCA3 and TMPRSS2-ERG gene 
fusions will yield more clinical information than any single test.
At the tissue level, PCA3 is almost completely specific for prostate cancer because of 
its high overexpression in prostate cancer cells. Studies attempting to delineate the
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range of transcription factors that interact with the PCA3 promoter, and to determine the 
function of PCA3, are ongoing.
Conclusions
The CE-marked version of the TMA-based PCA3 test was launched at the end of 
2006, and is now commercially available in Europe and the US under the trade name 
Progensa™ PCA3 (Gen-Probe Inc., San Diego, CA). In contrast to serum PSA 
measurement, the TMA-based PCA3 test directly detects prostate cancer cells in urine. 
Several studies have shown that PCA3 is superior to serum PSA testing for predicting 
biopsy outcome [8, 14, 17-19]. Furthermore, the combination of PCA3 with TMPRSS2- 
ERG gene fusions improved the sensitivity for prostate cancer diagnosis without 
compromising the specificity [23]. The diagnostic accuracy can also be increased when 
PCA3 is combined with other diagnostic factors (for example, serum PSA level, DRE, 
first-degree family history of prostate cancer, biopsy history, age and black ethnicity) [18,
20]. Preliminary data demonstrate a correlation between PCA3 and Gleason score, 
tumor size, clinical significance of tumors, and extracapsular extension [18, 19, 26, 27].
The TMA-based PCA3 test is the first fully translated RNA-based molecular 
diagnostic assay for prostate cancer in body fluids that is available to urologists. It can 
aid in the diagnosis of prostate cancer, and its role as prognostic indicator seems 
promising. Other genetic markers, such as TMPRSS2-ERG gene fusions, are currently 
under evaluation in urine. Noninvasive biomarker-based assays for the diagnosis of 
prostate cancer have now become reality.
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Perspectives
Early diagnosis of prostate cancer
The ultimate challenge in the diagnosis of prostate cancer is the early identification of 
clinically significant prostate cancer. Since the introduction of serum PSA testing more 
than 20 years ago, serum PSA is regarded as the standard diagnostic marker. Following 
an elevated serum PSA level greater than 3 ng/ml, transrectal ultrasound (TRUS)-guided 
biopsies are the recommended diagnostic approach and the gold-standard for prostate 
cancer detection. Although the routine use of serum PSA testing has undoubtedly 
increased prostate cancer detection, one of the main drawbacks has been its lack of 
specificity that results in a high negative biopsy rate. This is especially true in patients 
with serum PSA values between 3-10 ng/ml, in whom the negative biopsy rate is 
approximately 60-75% [1]. Uncertainty about the future and waiting for biopsy results is 
the most stressful event in 65% of men [2]. Therefore, accurate prediction on whether 
prostate cancer is found on prostate biopsies would spare unnecessary negative 
biopsies in men without prostate cancer and identify men who need a re-biopsy.
It has become clear that new markers are urgently needed to improve the specificity 
of serum PSA. The number of serum markers is rapidly growing due to the extensive 
human kallikrein family. By themselves they will not be able to improve the specificity for 
the early detection of prostate cancer. It is apparent that a biomarker panel will provide 
significantly more diagnostic information than any one biomarker. Therefore, the 
combinations of hK2 with several forms of PSA, %fPSA with % KLK11, and fPSA with 
pro-PSA offer promising approaches for improving the specificity.
The detection of cancer cells directly by using prostate cancer-specific genes is not 
only expected to be more specific for cancer, but it is also a completely independent 
analysis for cancer compared to the surrogate markers in serum. The specificity of 
prostate cancer diagnosis can be improved by using prostate cancer-specific genes like 
PCA3 in adjunct to serum PSA testing as was shown by the studies described in this 
thesis. It was shown that in men undergoing a repeat biopsy, PCA3 was superior to 
serum PSA or %fPSA testing in predicting whether cancer is found on prostate biopsies 
[3-5]. As a result, the use of this marker as adjunct to serum PSA testing can lead to a 
reduction of the number of unnecessary negative biopsies in this population.
Currently, the CE-marked Progensa™ PCA3 test is the first fully translated RNA- 
based molecular diagnostic assay available to the urologist for the detection of prostate 
cancer in urine. The success of this test is due to the simplified specimen processing 
procedure that utilizes whole urine instead of urinary sediments, and its high informative 
rate of 98% (number of samples with sufficient RNA for analysis) even with varied clinical 
staff performing the DRE [6, 7]. If the latter would be lower, many patients must return to
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the clinic to provide another urine sample, which is inconvenient for the health care 
system and the patient. Recent results from a community-based screening setting 
showed that this test is acceptable to patients, can be performed in a busy screening 
setting, and minimally disrupts the clinic flow [7].
Because prostate cancer is a heterogeneous disease, the use of a panel of 
biomarkers can further improve diagnostic accuracy. The combination of PCA3 with 
TMPRSS2-ERG fusion transcripts especially holds promise for the future. In urinary 
sediments collected after digital rectal examination (DRE) of men with elevated serum 
PSA levels >3 ng/ml the PCA3-based test had a sensitivity of 62%, but combined with 
TMPRSS2-ERG fusion transcripts the sensitivity increased to 73%. In a cohort with 
persistently elevated serum PSA levels and a history of negative biopsies, the high 
positive predictive value of 94% of TMPRSS2-ERG fusion transcripts gives a better 
indication which patients require repeat prostate biopsies [8]. When the diagnostic value 
of this combination of biomarkers has been validated in larger trials, the decision of 
performing repeat prostate biopsies can be based on PCA3 and TMPRSS2-ERG.
There are many other biomarker candidates available as has been described in 
chapter 2 of this thesis. It is important that the diagnostic and/or prognostic potential of 
these biomarkers is validated in prospective multicenter studies in order to obtain the 
most optimal biomarker panel for the diagnosis of clinically significant prostate cancers. 
In future, it seems reasonable that both serum-based assays as well as prostate cancer- 
specific biomarker assays will be used effectively to provide much more accurate 
diagnostic and therapeutic decisions.
Until now, imaging has played a minor role in prostate cancer screening. This is due 
to the fact that correct staging of prostate cancer at initial diagnosis, as well as accurate 
staging and tumor localization with biochemical recurrence, is generally inaccurate with 
current imaging techniques. However, new innovations on imaging technologies may 
provide more accurate information on tumor location and volume. Magnetic resonance 
imaging (MRI) is emerging as the most important tool both for local staging and for 
noninvasive determination of the aggressiveness of prostate cancer. Improvements in 
this field have resulted in dynamic contrast-enhanced MRI and diffusion-weighed MRI 
that have higher accuracy for prostate cancer detection [9]. The first results using 
dynamic contrast enhanced 3 Tesla (T) MRI resulted in an improvement of tumor staging 
as well as recognizing extraprostatic extension [9, 10]. Combining PCA3 with the 
information obtained from 3T MRI may aid in treatment decisions in the future. The 
combination of a positive PCA3 score and positive TMPRSS2-ERG gene fusion test with 
targeted biopsies to a magnetic resonance image that is suspicious for cancer may also 
lead to an improved prostate cancer detection [9].
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It is important to note that the current studies on PCA3 and biopsy outcome were 
performed in an elevated serum PSA-based cohort. In an unscreened population, 80% of 
men aged 55-74 years present with a serum PSA value below 3 ng/ml [11]. As was 
shown by the Prostate Cancer Prevention trial (PCPT), only 14% of men with serum PSA 
levels below 3 ng/ml have prostate cancer [12]. Therefore, biopsy in men with serum 
PSA values less than 3 ng/ml should only be performed if there is a risk for prostate 
cancer based on for example family history, ethnicity, age and/or abnormal DRE [13]. 
However, 14% of prostate cancer patients in this population have potentially life- 
threatening disease [12]. Since PCA3 has a higher specificity, it could aid in the 
identification of these men. Therefore, it would be interesting to assess the value of 
PCA3 as predictor for initial biopsy outcome in an unscreened population.
Within the European Randomized Study for Screening of Prostate Cancer (ERSPC) 
Rotterdam section such a study is conducted to find out whether PCA3 as a screening 
test would yield better results than serum PSA in initial biopsy decisions [14]. The 
combination of PCA3 with other diagnostic indicators (serum PSA, DRE, family history of 
prostate cancer, biopsy history, age and ethnicity) might help to more accurately predict 
whether cancer is found on prostate biopsies. Recently, incorporation of PCA3 in the 
PCPT risk calculator significantly improved the diagnostic accuracy of the original model 
[15]. In future clinical practice, the improved risk-scoring based on the implementation of 
PCA3 into risk calculators could lead to the reduction of unnecessary negative biopsies.
Detection of (locally advanced) prostate cancer
The main goal of screening is to find men with aggressive prostate cancer, who 
would have died from their disease if not detected by screening. Recent results from the 
ERSPC, that was initiated in the early 1990s, showed that PSA-based screening reduces 
the rate of death from prostate cancer by 20% but is associated with a high risk of 
diagnosing clinically insignificant prostate cancers [16]. In the absence of screening, 
these cancers would not have been detected during a patient's lifetime. Many men will 
undergo radical treatments for their clinically insignificant prostate cancers and will suffer 
from the side effects of radical prostatectomy or radiotherapy such as urinary, 
gastrointestinal, and sexual complications without gaining a survival benefit.
Active surveillance is an option for men in the low risk group (low PSA, low Gleason 
Score and organ-confined prostate cancer). The major problem is to accurately identify 
the candidates for active surveillance. Prostate biopsies and current imaging techniques 
are not very accurate in assessing the true volume and location of cancer in the prostate 
gland which is necessary for an accurate decision on therapy. Therefore, the challenge
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is to identify markers that can distinguish between the potentially life-threatening prostate 
cancers that need to be detected at an early stage and the clinically insignificant prostate 
cancers that do not need treatment.
Imaging is a key component of diagnostic and therapeutic management. 
Implementation of prostate cancer-specific biomarkers may improve imaging for the 
detection of extra-prostatic disease. An accumulation of an antibody that targets a 
prostate-specific biomarker outside the organ would indicate metastases. Initial studies 
have provided proof of principle for prostate-specific membrane antigen (PSMA)-based 
imaging and therapies [17, 18]. PSMA, an integral, non-shed, type 2 membrane protein 
with abundant and nearly universal expression in prostate carcinoma, was shown to 
have limited extra-prostatic expression and is expressed in the neovasculature of other 
solid tumors [19, 20]. Second-generation antibody and vaccine products may hold the 
key to exploit PSMA not only for molecularly targeted imaging detection, but also for 
staging and monitoring of prostate cancer and molecularly targeted therapy for prostate 
cancer.
Association of a marker with tumor aggressiveness is obviously desirable. Although 
preliminary, there are studies that indicate a correlation between PCA3 and cancer 
aggressiveness [3, 21, 22]. These data show that the PCA3 score could be effective in 
helping to determine which men are candidates for active surveillance and which 
patients would benefit from early radical intervention. However, there are also studies in 
which no correlation was found between PCA3 score and adverse prostate cancer 
features [23, 24]. Differences in experimental design and patient population may be 
responsible for the discrepancies. Therefore, it is important that the true predictive value 
of PCA3 is determined through validation in future prospective trials of active 
surveillance and a screening cohort.
Efforts to further validate and expand the clinical utility of PCA3 continue. Potential 
applications include the use of PCA3 prior to first prostate biopsy, detecting local 
recurrence following radical prostatectomy or radiation therapy, or monitoring patients 
receiving drug therapies that affect serum PSA levels (for example, 5a-reductase 
inhibitors). Currently, a PCA3 score cut-off of 35 is used in all the studies that have been 
published on this biomarker. However, in the study by Haese et al. it was shown that if a 
PCA3 score cut-off of 35 is used, 67% of unnecessary biopsies could be avoided, while 
21% of clinically significant prostate cancers would be undetected. In their cohort, a 
PCA3 score cut-off of 20 would avoid 44% of unnecessary biopsies while leaving 9% of 
clinically significant cancers undetected [3]. This observation indicates that the PCA3 
score might be more useful in both diagnostic and prognostic applications as a 
continuous variable in combination with both clinical or pathological data [25].
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Since prostate cancer is a heterogeneous disease, multiple tumors may develop 
within a single prostate, each with their own morphology and clinical behavior. Research 
will continue to identify molecular pathways that lead to the development of aggressive 
prostate cancers and to the discovery of new potential biomarkers. The identification of 
TMPRSS2-ETS fusion transcripts in a subset of prostate cancers suggest that several 
molecular pathways define the risk of disease progression. The association of the 
TMPRSS2-ERG gene fusion with early high grade prostatic intraepithelial neoplasia 
(HGPIN) lesions, and the fact that the matching prostate cancers harbor the same fusion 
pattern suggest that TMPRSS2-ERG fusion-positive HGPIN is a precursor or TMPRSS2- 
ERG fusion-positive prostate cancer.
A  significant correlation was found between the presence of the most common 
TMPRSS2-ERG gene fusion (T1/E4; fusion of exon 1 of TMPRSS2 with exon 4 of ERG) 
with biochemical recurrence after radical prostatectomy [26]. Other studies did not show 
a significant correlation between the presence of a TMPRSS2-ERG gene fusion product 
and prostate cancer prognosis [27-32]. Recently, it was reported that expression of this 
androgen-regulated fusion gene did not correspond with duration of response to 
endocrine therapy [33]. This suggests that expression of the TMPRSS2-ERG gene 
fusion is not a candidate marker to select metastatic prostate cancer patients who will 
benefit more from endocrine treatment. It should be noted that more than 20 TMPRSS2- 
ERG gene fusion variants have been described and that the T1/E4 gene fusion is the 
most common variant and the best studied gene fusion [34-37]. Since other variants may 
be differently associated with prostate cancer prognosis, it is worthwhile to study the 
clinical relevance of these various gene fusion products.
Using fluorescence in situ hybridization (FISH) studies, it was shown that the overall 
survival was worse in patients in which the 5' portion of ERG is deleted compared with 
patients in which ERG was not disrupted. In case a patient with a 5' ERG deletion 
harbored two or more copies of the 3' ERG region (2+Edel), the 8 year survival rate was 
only 25% compared with 90% for patients without an ERG rearrangement [30]. Another 
study confirmed that a subgroup of cancers harboring 2+Edel was associated with higher 
clinical stage and aggressive disease [38]. As was already shown, the combination of 
PCA3 with TMPRSS2-ERG gene fusions leads to an improved specificity in the detection 
of prostate cancer in urine [8]. Furthermore, these data suggest that particularly the 
detection of 2+Edel may help to identify the prostate cancers at high risk for progression.
Untangling the genetics of prostate cancer is a major research area. Epidemiology 
studies have indicated that infection and inflammation may play a role in the 
development of prostate cancer [39]. The recent discovery that a xenotropic murine 
leukemia virus-related virus (XMRV) was almost exclusively expressed in malignant
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prostate epithelial cells suggests that some prostate cancers could indeed be caused by 
an infectious disease [40]. XMRV virus was present in 27% of the studied prostate 
cancers. XMRV belongs to the gammaretroviruses that are known to cause leukemia 
and sarcomas in rodents and primate species but have never been shown to cause 
cancer in humans. The association of infection with XMRV and a polymorphism in the 
RNaseL gene (hereditary prostate cancer 1 (HPC1) locus) is unclear [40, 41]. The active 
RNaseL enzyme degrades cellular and viral DNA to halt viral replication and is part of 
the cell's defense against viruses. An RNaseL polymorphism was shown to be 
associated with a higher susceptibility to XMRV infection, although a recent study 
showed that XMRV infection could be independent of that polymorphism [42]. The latter 
would implicate an increase in the population at risk for an XMRV infection. XMRV 
seems to be associated with aggressive prostate cancers and therefore an XMRV- 
specific marker may provide a new biomarker for the prediction of aggressive disease. 
However, the discovery of XMRV and prostate cancer raises many questions. Therefore, 
more studies are needed to assess the role of XMRV in the onset of prostate cancer and 
its correlation with outcome of disease. If a link of XMRV to prostate cancer can be 
found, then the focus would be on the detection of this virus for early diagnosis and 
prognosis of prostate cancer, antiviral therapy and vaccine development.
Conclusion
In the oncoming years, the number of potential biomarkers will grow substantially, as 
will our understanding of the aetiology of this disease. Until now, only few markers like 
PCA3 and TMPRSS2-ERG have been studied for their potential as diagnostic or 
prognostic biomarker in prospective multicenter studies. It has become clear that for 
different clinical applications the PCA3 score might be more useful as a continuous 
variable in combination with both clinical or pathological data [25]. Since a panel of 
biomarkers will provide much more clinical information than a single one, future research 
should focus on both finding new markers for aggressive disease and, just as important, 
determining the clinical relevance of already existing ones.
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Prostate cancer can develop w ith in and even outside the prostate in the absence of 
clinical symptoms. Radical prostatectom y and radiotherapy are curative therapeutic 
options fo r prostate cancer but are lim ited to organ-confined disease. If the disease has 
spread locally or d istantly, no curative trea tm ent is available and these patients will suffer 
from  a poor prognosis. Early detection of prostate cancer, when the disease is confined 
to the prostate, is therefore pivotal.
More than 20 years ago, prostate specific antigen (PSA), a protein tha t is produced 
by prostate epithelia l cells, was discovered. In a healthy male, m ost o f the PSA is 
excreted in the prostate ductal system  and little PSA leaks into the blood vessels. Due to 
a disruption o f the anatom ical prostate structure tha t is caused by for exam ple a growing 
tum or, PSA can leak into the blood stream. Using the PSA test, the am ount of the PSA 
protein in serum  can be determ ined. Nowadays, prostate cancer is detected at a pre- 
clinical and often curable stage and the num ber o f men with m etastasis at initial 
presentation has decreased. However, due to the increased life expectancy o f the 
western male population and the im plem entation o f serum  PSA testing, prostate cancer 
has becom e the m ost com m only diagnosed m alignancy in the Netherlands.
There are also three lim itations associated with the w idespread use o f serum  PSA 
testing. First, PSA is prostate-specific but not prostate cancer-specific. The substantial 
overlap in serum  PSA values between men with non-m alignant prostatic diseases and 
prostate cancer is the lim itation o f PSA as a prostate tum or marker. The low specific ity 
results in a high negative biopsy rate and anxiety among men undergoing further testing 
to find or rule out a potential prostate tumor. Second, PSA cannot d istinguish the 
c lin ica lly insign ificant prostate cancers from  the aggressive prostate cancers. Due to 
w idespread im plem entation o f the serum PSA test, many o f the detected prostate 
cancers are c lin ica lly insignificant. These clin ica lly insignificant tum ors are currently over­
treated w ith radical surgery or radiation therapy. Third, PSA cannot predict at an early 
stage which prostate cancers are locally advanced and for which radical treatm ent is less 
likely to be effective.
The focus o f the studies described in this thesis is on im proving the specific ity fo r the 
diagnosis o f prostate cancer. Using m olecular technolog ies such as genomics, 
transcriptom ics and proteom ics fo r the system atic evaluation o f genes tha t are 
specifica lly expressed in prostate cancers, more insight is gained in the specific 
m olecu lar characteristics of th is disease. These prostate cancer-specific genes can be 
used as biom arkers fo r the detection o f prostate cancer cells in body flu ids like blood or 
urine. This results in an improved specific ity fo r prostate cancer diagnosis and a better 
identification of men who require prostate biopsies.
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Because o f the heterogeneous nature o f cancer, it is more likely tha t a biom arker 
panel will provide significantly more diagnostic inform ation than any one biomarker. In 
Chapter 2 several prom ising prostate cancer biom arkers are discussed. Tests based on 
the com bination o f different proteins o f the kallikrein fam ily can im prove the specific ity for 
the d iagnosis of prostate cancer. Som e exam ples are tests based on com binations of 
hK2 w ith several form s o f PSA, % fPSA w ith %KLK11, and fPS A  with pro-PSA. The 
specific ity for prostate cancer diagnosis can be further improved with biom arkers tha t are 
specific for prostate cancer. A  prototype o f such a test is based on prostate cancer gene
3 (PCA3).
PCA3 is a prostate-specific non-coding m RNA which is highly over-expressed in 
more than 95% o f prim ary prostate cancers and prostate cancer metastases. A fter 
several years o f research it was concluded tha t PCA3 does not encode for a protein but 
functions as a non-coding RNA. The strong association o f PCA3 m RNA over-expression 
with m alignant transform ation o f prostate ep ithe lium  has identified its potential use as 
b iom arker fo r the d iagnosis o f prostate cancer.
In the absence o f a protein product, a quantitative m olecular assay based on PCA3 
m RNA has been developed. However, RNA is prone to degradation which can lead to a 
decreased sensitiv ity and reproducib ility o f RNA-based tests. Thus, a good clinical RNA- 
based test will rely on the robustness o f sam ple collection and having a high degree of 
sensitiv ity for its target. In 2003, an RNA-based am plification method has been 
developed for the quantification o f the num ber o f PCA3 m RNA transcripts in a sample. 
This method is based on a com bination o f reverse-transcriptase polym erase chain 
reaction (RT-PCR), dual tim e-resolved fluorescence, an exogenous internal control and 
an external calibration curve. W ith th is test, proof o f principle was provided to use PCA3 
m RNA as a b iom arker fo r the detection o f prostate cancer in urine samples. The 
m ethodology o f this research use-only (RUO) PCA3 test was robust, but also com plex 
and tim e-consum ing. Therefore, G en-probe Inc., translated th is test to an in vitro 
diagnostics (IVD) product using its transcription-m ediated am plification (TMA) platform. 
The procedure fo r sam ple collection has also been standardized and validated. In the 
study described c h a p te r 3, the IVD PCA3 test has been com pared to the RUO PCA3 
test to determ ine its analytical sensitivity. Both tests were shown to have the same 
analytical specifications for the detection o f prostate cancer cells in urinary sediments. 
The user-friendly IVD PCA3 test is simple, fast and sensitive enough to be used in 
specia lized clinical laboratories.
In chapter 4 the d iagnostic value o f the RUO PCA3 tes t is evaluated. It was shown 
that the expression o f PCA3 m RNA is restricted to the prostate and tha t it is present in 
normal prostate and benign prostatic hyperplasia (BPH) tissue at low, quantifiable levels.
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The m edian upregulation o f PCA3 m RNA in prostate cancer was 66-fo ld com pared with 
normal prostate tissue. In prostate tissue specim ens tha t contained < 10% prostate 
cancer cells, the m edian upregulation o f PCA3 m RNA was 11-fold. The com bined data 
indicate the utility o f the RUO PCA3 test as a m inim ally invasive tool to detect prostate 
cancer cells in body fluids. Therefore, the utility o f the RUO PCA3 test was evaluated to 
detect prostate cancer cells in urinary sedim ents after digital rectal exam ination (DRE). 
The reasoning behind th is was tha t m anipulation o f the prostate would transport the 
cancer cells via the prostatic ductal system  into the urethra. PSA m RNA was used to 
norm alize for the num ber o f prostate cells as its expression was shown to be relatively 
constant in both normal prostate cells and prostate cancer cells. The PCA3 score was 
defined as the ratio o f PCA3 m RNA/PSA m RNA multiplied by 1,000. The PCA3 score 
was determ ined in urine sedim ents o f 108 men who were adm itted for prostate biopsies 
based on serum PSA levels greater than 3 ng/ml. In this study, the RUO PCA3 test had 
67%  sensitiv ity and 83%  specific ity fo r detecting prostate cancer. The specific ity of 
serum  PSA in this cohort was only 22%. Furthermore, the high negative predictive value 
o f 90%  indicates tha t PCA3-based testing w ill have great utility in reducing the num ber of 
unnecessary, negative biopsies. This single institution study was the proof o f principle to 
dem onstrate the potential o f a quantitative PCA3-based urine test to aid in the prediction 
o f biopsy outcome.
In c h a p te r 5, the diagnostic perform ance o f the RUO PCA3 urine test was validated 
in a prospective Dutch m ulticenter study. First voided urine sam ples were collected from 
583 men who were to undergo prostate biopsies based on serum  PSA levels between 3 
ng/ml and 15 ng/ml. Post-DRE specim ens provided an inform ative rate (num ber of 
specim ens with suffic ient RNA fo r analysis) o f 92%. The diagnostic utility o f a test to 
discrim inate between healthy men and men w ith cancer is visualized by the area under 
an receiver operating characteristic curve (AUC-ROC). In this study, the AUC -RO C is 
0.66 fo r the RUO PCA3 test and 0.57 fo r the serum  PSA test. The RUO PCA3 test had 
65%  sensitiv ity and 66%  specific ity for detecting prostate cancer. A t the sam e sensitivity, 
the specific ity o f serum  PSA in this cohort was 47%. The negative predictive value was 
80%. The results from  th is study confirm ed that PCA3-based testing can improve the 
specific ity in prostate cancer diagnosis and, therefore, could lead to a reduction of 
unnecessary negative biopsies.
In c h a p te r 6 a study is described on the predictive value o f the IVD PCA3 test for 
adverse prostate cancer features. The PCA3 score was determ ined in urinary sedim ents 
o f 351 men who were adm itted fo r prostate biopsies based on serum  PSA levels greater 
than 3 ng/ml, and abnorm al DRE and/or a fam ily history o f prostate cancer using the IVD 
PCA3 test. The PCA3 scores were corre lated to biopsy G leason score. In 70 men who
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underwent a radical prostatectom y, the PCA3 score was also correlated to 
prostatectom y G leason score, tum or volum e and pathological stage. Unlike other 
studies, no corre lation was found between PCA3 score and clin ico-pathological features 
known to be associated with prostate cancer aggressiveness. There are some 
differences between the studies (like study design and study population) tha t could 
explain the inconsistency o f the results. First, there are system atic d ifferences in 
G leason grading, which is best illustrated by the paradoxical high fraction o f Gleason 
score 7 cancers in US cohorts. Second, it should be stressed that due to the original 
study design, urine sedim ents were analyzed. This may have yie lded different results 
than whole urine utilized in other studies. Third, the num ber o f radical prostatectom y 
specim en in th is study was relatively small, Perhaps a larger study could better 
differentiate the data. Fourth, our patient cohort had relatively few  men w ith a favourable 
prognostic outcome. Therefore, the predictive value o f the PCA3 test for adverse 
prostate cancer features should be studied in a larger, screening-based patient cohort.
A  b iom arker panel w ill provide significantly more diagnostic inform ation than any one 
biomarker. Recent studies have provided evidence fo r gene fusions in prostate cancer. 
An exam ple is the fusion o f the androgen-regulated transm em brane-serine protease 
gene (TMPRSS2) gene with the ETS transcription factors v-ets erythroblastosis virus 
E26 oncogene (ERG). ERG is an oncogene and belongs to the fam ily o f ETS 
transcription factors. The ETS transcription factors are switching devices tha t can 
regulate the on- and off- sw itching o f other genes. Fusions between TM PRSS2 and ets 
varian t gene 1 (ETV1), ETV4 and ETV5 have also been reported in prostate cancer. The 
fact tha t TMPRSS2-ERG gene fusions have been detected in ~50%  o f the prostate 
cancers and the fact tha t ERG is the m ost frequently overexpressed proto-oncogene 
described in m alignant prostate epithelia l cells, suggest its role in prostate 
tum origenesis. Because of this im portant role, the detection o f TM PRSS2-ER G  gene 
fusions in urine sedim ents m ay significantly contribute to the decision making on 
diagnosis and treatm ent o f prostate cancer.
In c h a p te r 7, an RT-PCR-based research assay is described for the detection of 
TMPRSS2-ERG gene fusion transcripts in urinary sedim ents. This TMPRSS2-ERG-gene 
fusion-based tes t has a sensitiv ity o f 37%  and a specific ity o f 93%  for the detection of 
prostate cancer in urine sedim ents o f 108 men adm itted for prostate biopsies based on 
an elevated serum  PSA level and/or abnorm al DRE. To evaluate the com bined use of 
PCA3-based testing w ith this tes t fo r TMPRSS2-ERG gene fusions, the positive PCA3 
scores determ ined in the urine sedim ents were com bined w ith the positive TMPRSS2- 
ERG gene fusion-based test results and were corre lated to biopsy results. The 
com bination o f these urine tests im proved the sensitiv ity from  62%  (PCA3 alone) to 73%
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(com bined) fo r the detection o f prostate cancer. Due to the high specific ity o f the 
TMPRSS2-ERG  gene fusion-based test, the specific ity o f this b iom arker panel was not 
com prom ised. The high positive predictive value o f 94%  o f TMPRSS2-ERG  gene fusion- 
based test is o f special interest, since in the cohort o f men with persistently elevated 
serum  PSA levels and a history o f negative biopsies the TMPRSS2-ERG gene fusion- 
based test could give a better indication which patients require repeat biopsies.
In chapter 8 an overview  is given o f the knowledge on PCA3 anno 2009. From  its 
identification and its system atic and critical evaluation to a fu lly  translated m olecular 
urine tes t tha t is valuable tool in predicting biopsy outcome.
The study described in chapter 4 o f th is thesis was the firs t to dem onstrate the 
diagnostic potential of a PCA3-based test. The RUO PCA3 test turned out to be a 
sensitive and very specific prostate cancer test. The RUO PCA3 test has been translated 
to an IVD validated technology platform  (G en-Probe Inc.) and the urine sam ple collection 
has been standardised. A t the end o f 2006, the CE-m arked version o f this IVD PCA3 test 
was launched under the trade name Progensa™  PCA3 test. This is the first, fully 
translated RNA-based m olecular diagnostic urine test fo r prostate cancer tha t is now 
available to urologists. This test can contribute to the decision making in the diagnosis of 
prostate cancer. The value o f the PCA3 test to predict the biological behaviour of 
prostate tum ors is not fu lly matured, although som e studies show prom ising results. 
S ince the serum  PSA test is still the subject o f many debates after 20 years o f usage in a 
clinical setting, it m ay take some tim e before the clinical positioning of th is new test is 
crystallized. In future, the PCA3 test w ill be used in com bination with a tes t based on 
TMPRSS2-ERG  gene fusions fo r the diagnosis o f prostate cancer. Non-invasive 
b iom arker-based assays for the diagnosis o f prostate cancer have now becom e reality.
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Samenvatting
Prostaatkanker is een ziekte die voorheen vaak in een laat stadium  ontdekt werd. De 
m eeste m annen met prostaatkanker vertonen nam elijk ten tijde van de diagnose geen 
klin ische symptomen. Radicale prostatectom ie en radiotherapie zijn curatieve 
therapeutische opties voo r prostaatkanker, m aar zijn alleen curatief indien de 
aandoening beperkt is to t de prostaat. Aangezien er m om enteel geen adequate 
behandelingsm ethoden zijn voor patiënten die gediagnosticeerd zijn met 
gem etastaseerd prostaatcarcinoom , is het be langrijk de z iekte in een vroeg stadium  te 
ontdekken.
M eer dan 20 ja a r geleden werd het prostaatspecifiek antigeen (PSA) ontdekt, een 
eiw it dat door epitheelcellen in de prostaatklier w ordt aangem aakt. O nder normale 
om standigheden kom t PSA in kleine hoeveelheden in de bloedcirculatie terecht. B ij een 
goedaard ige vergroting van de prostaat, een ontsteking van de prostaat of 
prostaatkanker stijg t de hoeveelheid PSA in het bloed. Met de PSA test w ordt in het 
bloed de hoeveelheid van dat eiw it bepaald. Door het serum van mannen op PSA te 
testen, w ordt prostaatkanker nu in een vroeger stadium  ontdekt. Echter, de incidentie 
van prostaatkanker is in de laatste twee decennia enorm  toegenom en door vergrijzing 
van de bevolking en het zeer frequente gebru ik van de PSA test. Op dit m om ent is 
prostaatkanker dan ook de m eest voorkom ende kanker bij m annen in Nederland.
Hoewel het gebru ik van de PSA test de kans op vroege opsporing vergroot, brengt 
deze benaderingswijze ook drie nadelen met zich mee. Ten eerste is PSA w elisw aar 
prostaatspecifiek, m aar niet prostaatkankerspecifiek. De aanzienlijke overlap van serum 
PSA waarden in m annen met goedaard ige prostaataandoeningen en prostaatkanker is 
de voornaam ste beperking van PSA als een m arker voor prostaatkanker. Bij gerezen 
verdenking op prostaatkanker, door een verhoogd serum  PSA, worden er echogeleide 
prostaatpuncties uitgevoerd. Hierbij worden er stukjes weefsel uit de prostaat verw ijderd. 
Het verkregen weefsel w ordt door een patholoog onder een m icroscoop onderzocht. 
H ierdoor kan de aanwezigheid van prostaatkanker worden bevestigd. Aangezien de 
specific ite it (de mate waarin de test in staat is om m annen zonder prostaatkanker terecht 
te identificeren) van de PSA test laag is, ondergaan veel m annen op grond van een 
foutpositieve uitslag onnodig biopsieën. Het wachten op de biopsie uitslag w ordt door het 
m erendeel van de mannen als stressvol ervaren. Ten tweede kan PSA niet worden 
gebru ikt om onderscheid te maken tussen de tum oren die niet levensbedreigend zijn 
(klinisch insignificant) en de tum oren met een agressie f karakter (klinisch significant). Als 
gevolg van de toegenom en vroegdetectie van de ziekte, v ind t er dan ook veel 
overbehandeling plaats van de tum oren die klinisch insign ificant zijn. Ten derde kan PSA 
niet gebru ikt worden om onderscheid te maken tussen een zich to t de prostaat
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beperkend carcinoom  o f een lokaal uitgebreid prostaatcarcinoom  (hierbij groeit de tum or 
door het kapsel van de prostaat).
In dit proefschrift worden studies beschreven die to t doel hebben de specific ite it in de 
diagnose van prostaatkanker te verbeteren. Door system atisch de genen in een 
prostaattum or te onderzoeken met behulp van m oleculaire technologieën als genom ics 
(op DNA niveau), transcriptom ics (op RNA niveau) en proteom ics (op eiw it niveau) wordt 
du idelijk  welke specifieke kenm erken deze heeft. Door gebru ik te maken van deze 
specifieke m oleculaire prostaatkankerkenm erken (b iom arkers) kunnen cellen van een 
aanwezige prostaattum or worden aangetoond in lichaam svloeistoffen zoals bloed en 
urine. H ierdoor kan de specific ite it worden verbeterd. Dit resulteert in m inder 
zogenaam de foutpositieve uitslagen en een verm indering van het aantal m annen dat 
onnodig een biopsie moet ondergaan.
Kanker vorm t in het algem een een heterogeen ziektebeeld, w aardoor het 
w aarsch ijn lijk  is dat m eerdere biom arkers nodig zijn om de tum or te identificeren en te 
classificeren. Veelbelovende prostaatkanker biom arkers worden in hoofdstuk 2 
geëvalueerd. Zo kan een test gebaseerd op een com binatie van eiwitten van de 
kallikreïne familie, w aartoe PSA behoort, de specific ite it voo r de opsporing van 
prostaatkanker verhogen. Voorbeelden hiervan zijn com binaties van hK2 met 
verschillende PSA gerelateerde iso-vormen, % fPSA met %KLK11 en fPSA met pro-PSA. 
De specific ite it zal verder kunnen verbeteren door gebru ik te maken van m arkers die wel 
specifiek zijn voor deze ziekte. De prostaatkanker gen 3 (PCA3) test is hiervan een 
prototype.
PCA3 m essenger-RN A (m RNA) kom t op zee r lage niveaus to t expressie in normale 
cellen van de prostaat en kom t sterk verhoogd to t expressie in m eer dan 95%  van de 
prim aire prostaattum oren en metastasen. Na een lange reeks experim enten waarbij 
geen PCA3 eiw it geïdentificeerd kon worden, volgde de conclusie dat PCA3 een niet- 
coderend RNA is. De hoge expressie van PCA3 m RNA in kwaadaardige gezwellen van 
de prostaat biedt de m ogelijkheid to t het ontw ikkelen van een diagnostische test voor 
deze ziekte. Aangezien PCA3 niet codeert voor een eiwit is er een kwantitatieve 
m oleculaire test ontw ikkeld die gebaseerd is op PCA3 m RNA expressie. Echter, RNA is 
gevoelig voo r afbraak, wat kan leiden to t een afnam e in de gevoeligheid en 
reproduceerbaarheid van RNA gebaseerde testen. De betrouwbaarheid van een 
klinische RNA gebaseerde test w ordt dan ook mede bepaald door de w ijze waarop 
klinische monsters worden verzam eld en verw erkt en door de gevoeligheid van de test 
voor de detectie van de RNA transcripten. In 2003 is er een RNA gebaseerde 
am plificatiem ethode ontw ikkeld om kwantitatief, d.m.v. een com binatie van 'reverse 
transcrip tase '-po lym erase ketting reactie (RT-PCR) m et een tweevoudige 'tim e-
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reso lved'-fluorescentie, de hoeveelheid PCA3 m RNA transcripten te bepalen. Deze RT- 
PCR gebaseerde m ethode heeft een hoge gevoeligheid voo r de detectie van PCA3 
m RNA transcripten en m aakt het m ogelijk het aantal PCA3 m RNA transcripten in een 
klinisch m onster te bepalen. Met deze test werd het 'p roo f o f princip le ’ geleverd voor de 
bruikbaarheid van de PCA3 score in urine als diagnostische m arker voo r prostaatkanker. 
Deze 'research use on ly ’ (RU O )-test is robuust, m aar ook arbe idsin tensie f en tijdrovend. 
De Am erikaanse firm a G en-Probe heeft deze test vertaa ld naar een in vitro diagnostiek 
(IVD) product op haar 'transcrip tion-m ediated ' am plificatie (TMA) platform. De procedure 
voo r het verzam elen van klinische m onsters werd gestandaardiseerd en gevalideerd. 
Om de analytische gevoeligheid van de IVD PCA3 test te kunnen bepalen, w ordt deze 
tes t in hoofdstuk 3 m et de RUO PCA3 test vergeleken. Beide testen blijken dezelfde 
analytische specificaties te hebben met betrekking to t het aantonen van 
prostaatkankercellen in urinesedim enten. De gebru iksvriendelijke IVD PCA3 test is 
eenvoudig, snel en gevoelig genoeg om in principe in elk gespecialiseerd laboratorium  
uitgevoerd te kunnen worden.
In hoofdstuk 4 w ordt de bruikbaarheid van PCA3 m RNA als d iagnostische m arker 
voo r prostaatkanker onderzocht d.m.v. de RUO PCA3 test. In prostaatweefsel met meer 
dan 10% tum orcellen is de m ediane expressie van PCA3 m RNA 66x hoger dan die in 
het normale prostaatweefsel. In prostaatweefsel m et m inder dan 10% kankercellen is de 
m ediane expressie van PCA3 m RNA 11 maal hoger dan die in de normale 
contro legroep. Deze data indiceren dat deze RUO PCA3 tes t een veelbelovend 
diagnostisch instrum ent kan zijn voor het aantonen van kwaadaardige prostaatcellen in 
bloed, urine o f ejaculaat. Om deze hypothese te testen zijn PCA3 m RNA transcripten 
gekwantificeerd in urinesedim enten die zijn verkregen na een rectaal toucher. Bij een 
rectaal toucher w ordt via de endeldarm  de prostaat met de v inge r gepalpeerd om 
afw ijkingen aan de prostaat vast te kunnen stellen. Door m anipulatie van de prostaat 
kunnen eventueel aanwezige kankercellen gem obiliseerd worden in de klierbuizen van 
de prostaat, om vervo lgens in de urethra prostatica terecht te komen. De eerste urine 
bevat de hoogste concentratie cellen van zowel blaas als prostaat en dus ook normale 
prostaatcellen. PSA m RNA w ordt gebru ikt om de test te norm aliseren voor het aantal 
prostaatcellen dat in het sedim ent aanwezig is. Het is bekend dat de PSA mRNA 
expressie re latie f constant is in normale prostaatcellen en prostaatkankercellen. De 
PCA3 score is gedefinieerd als de PCA3 m RNA/PSA m RNA ratio verm enigvuld igd met 
een factor 1.000. De PCA3 score werd bepaald in urinesedim enten van 108 m annen die 
op basis van een verhoogd serum  PSA prostaat biopsieën ondergingen. In dit onderzoek 
heeft de RUO PCA3 test een gevoeligheid van 67%  en een specific ite it van 83%  voor 
het aantonen van prostaatkanker. De specific ite it van serum  PSA is slechts 22%.
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Aangezien de negatief voorspellende waarde van deze test 90% is, kan het bijdragen 
aan het reduceren van het aantal onnodige biopten. In deze studie w ordt voor het eerst 
aangetoond dat de RUO PCA3 test een gevoelige en bovenal zeer specifieke 
prostaatkanker test is ( 'p roo f of p rinc ip le ').
In hoofdstuk 5 w ordt de bruikbaarheid van de RUO PCA3 test gevalideerd in een 
prospectieve studie waaraan v ijf Nederlandse onderzoekscentra meededen. Na een 
rectaal toucher is de eerste urine opgevangen van 583 m annen die op basis van een 
serum  PSA waarde tussen 3 en 15 ng/ml in aanm erking kwamen voo r het afnem en van 
prostaat biopten. De urinesedim enten van 92% van de m annen zijn vervo lgens 
succesvol geanalyseerd. Met het oppervlak ('area under the curve' (AUC)) onder een 
'rece iver operating characteristic ' (ROC) curve, kan het verm ogen van een test om een 
onderscheid te maken tussen gezonde en zieke personen worden weergegeven. In deze 
studie bedraagt de 'AUC-ROC ' 0,66 voor de RUO PCA3 test en 0,57 voo r de serum PSA 
test. De RUO PCA3 test heeft een gevoeligheid van 65%  en een specific ite it van 66% 
voor de detectie van prostaatkanker. De negatief voorspe llende waarde van de RUO 
PCA3 urinetest is 80%. De serum  PSA test heeft een specific ite it van 47%. Uit deze 
studie blijkt dat PCA3 gebaseerde testen de specific ite it in de d iagnostiek van 
prostaatkanker kunnen verhogen. H iermee kan het onnodig uitvoeren van prostaat 
biopten worden gereduceerd.
In hoofdstuk 6 wordt de waarde van de PCA3 score onderzocht in relatie tot 
h isto logische en pathologische karakteristieken van de prostaattum or. De PCA3 score is 
d.m.v. de IVD PCA3 test in de urinesedim enten van 351 mannen bepaald. Deze mannen 
ondergingen prostaat biopten op basis van een serum  PSA > 3 ng/ml, een afwijkend 
rectaal toucher en /o f genetische predispositie voo r prostaatkanker. Zeventig mannen 
met prostaatkanker hebben een radicale prostatectom ie ondergaan. De PCA3 score is 
vergeleken met de G leason score. De G leason score wordt bepaald in de biopten en 
het prostatectom iepreparaat en is een belangrijke factor die goed corre leert met de 
prognose van de ziekte. Tevens is de PCA3 score vergeleken met het klinische 
tum orstadium , het tum or volum e en het pathologische tum orstadium . In tegenstelling tot 
andere studies is er in deze studie geen corre latie gevonden tussen de PCA3 score en 
deze klinische en pathologische kenmerken die op dit m om ent gebru ikt worden als 
surrogaat m arkers voor de mate van agressiv ite it van prostaattum oren. De resultaten 
van deze studie konden de prognostische waarde van de IVD PCA3 test, die in andere 
studies werd aangetoond, niet bevestigen. Een aantal versch illen tussen de studies 
(bijvoorbeeld verschillen in onderzoeksm ethode en stud iepopulatie) zou deze resultaten 
kunnen verklaren. Ten eerste zijn er system atische versch illen in G leason gradering, 
w aardoor er zeer veel G leason score 7 tumoren in de A m erikaanse patiëntpopulatie
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worden gevonden. Ten tweede w ordt in deze studie, vanwege verschillen in studie- 
opzet, de PCA3 score bepaald in urinesedim enten en niet, zoa ls in de andere studies, in 
urine. Ten derde is het aantal patiënten met een radicale prostatectom ie aan de lage 
kant. M isschien dat de niet-significante data het gevolg zijn van de kle ine 
studiepopulatie. Ten vie rde bestaat onze studiepopulatie uit weinig m annen met een 
gunstige prognose. H e t is dan ook belangrijk de prognostische waarde van de PCA3 
score in een screenings cohort te onderzoeken.
Zoals we in hoofdstuk 2 al concludeerden, zal de com binatie van verschillende 
biom arkers veel m eer inform atie opleveren dan w anneer slechts een enkele b iom arker 
w ordt gebruikt. Uit recente studies is gebleken dat er fusies tussen genen kunnen 
voorkom en in prostaatkanker. In deze fusies kan onder m eer TMPRSS2, een 
prostaatspecifiek en androgeen-gereguleerd gen, gefuseerd worden met ERG. ERG is 
een oncogen dat behoort to t de fam ilie  van ETS transcriptie factoren. Dit zijn genetische 
schakelaars die de aan- en uitschakeling van andere genen kunnen regelen. O ok zijn er 
fusies aangetoond tussen TMPRSS2 met andere ETS transcriptie factoren zoals ETV1, 
ETV4 en ETV5. Het fe it dat de TMPRSS2-ERG genfusie in ongeveer 50%  van de 
prostaattum oren voorkom t en het feit dat het oncogen ERG to t expressie kom t in 
kwaadaardige cellen van de prostaat, suggereert een rol voor ERG in het ontstaan van 
prostaatkanker. Gezien deze belangrijke rol, zal het aantonen van de TMPRSS2-ERG 
genfusie in urinesedim enten een bijdrage kunnen leveren aan de besluitvorm ing voor de 
vervo lgd iagnostiek en behandeling van prostaatkanker.
In hoofdstuk 7 w ordt een RT-PCR m ethode beschreven om TMPRSS2-ERG 
genfusie transcripten aan te kunnen tonen in urinesedim enten. Deze TMPRSS2-ERG 
genfusie gebaseerde test heeft een gevoeligheid van 37% en een specific ite it van 93% 
voo r het aantonen van prostaatkanker in urinesedim enten van 108 m annen die in 
aanm erking kwamen voor prostaat biopsieën op basis van een verhoogd serum PSA 
en /o f afw ijkend rectaal toucher. Om de com binatie van de PCA3 test met de TMPRSS2- 
ERG genfusie test te evalueren, werden de positieve PCA3 scores en positieve 
TM PRSS2-ER G  test resultaten gecorre leerd aan de biopsie uitslag. Door com binatie van 
deze twee testen steeg de gevoeligheid voo r het aantonen van prostaatkanker van 62% 
(alleen PCA3) to t 73%  (PCA3 en TMPRSS2-ERG genfusies). Vanwege de hoge 
specific ite it van de TM PRSS2-ER G  genfusie test, is de specific ite it van dit m arker panel 
niet veel lager. Door de hoge positie f voorspe llende waarde van 94%  van de TM PRSS2- 
ERG genfusie test kan deze test bijdragen aan de beslu itvorm ing van vervo lgdiagnostiek 
van prostaatkanker.
Hoofdstuk 8 is een overzicht waarin de kennis over PCA3 anno 2009 wordt 
sam engevat ('state o f the art'). V ana f de ontdekking van PCA3 en de system atische en
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kritische evaluatie van het diagnostisch potentieel to t en m et de ontw ikkeling van een 
urinetest, die uitgaat van m oleculaire technologie, voo r het opsporen én uitsluiten van 
prostaatkanker.
Het diagnostisch potentieel van de PCA3 test werd voo r het eerst aangetoond in de 
studie die in hoofdstuk 4 van dit proefschrift is beschreven. De PCA3 test blijkt een 
gevoelige en zee r specifieke prostaatkankertest. Inm iddels is de m onsterafnam e 
gestandaardiseerd en is de PCA3 test ontw ikkeld op een IVD gevalideerd technologie 
platform  (G en-Probe Inc.). De Conform ité Européenne (CE)-gem arkeerde versie van de 
IVD PCA3 test kwam eind 2006 op de m arkt onder de naam  Progensa™  PCA3 test. Dit 
is de eerste klinisch beschikbare test die uitgaat van m oleculaire RNA technologie en die 
b ijdraagt aan de besluitvorm ing voo r de vervo lgd iagnostiek van prostaatkanker. De 
waarde van de PCA3 test voor het voorspellen van het biologische gedrag van 
prostaattum oren is nog niet uitgerijpt, hoewel enkele studies veelbelovende resultaten 
laten zien. Gezien het feit dat de PSA test, die al ruim 20 ja a r w ordt toegepast, nog 
steeds onderwerp van vele d iscussies is, kan het ook enige tijd duren voo rda t de exacte 
klinische positionering van deze nieuwe test is uitgekristalliseerd. In de toekom st za l de 
PCA3 test in com binatie m et andere testen gebaseerd op TMPRSS2-ERG  genfusies 
worden gebru ikt om de specific ite it in de d iagnostiek van prostaatkanker nog m eer te 
vergroten. De toepassing van een urinetest, die gebaseerd is op moleculaire 
technologie, voor de diagnose van prostaatkanker is w erkelijkheid geworden.
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begin gestaan van mijn wetenschappelijke carrière. Je hebt mij vana f het begin altijd 
aangem oedigd en gesteund en mij ongekende m ogelijkheden geboden me verder te 
ontw ikkelen. Bedankt voor de gegeven kans en je  vertrouwen in mij!
Mijn paranimf, ing. Frank Smit. Beste Frank, jo uw  vriendschap en niet aflatende steun en 
vertrouwen in mij is van onschatbare waarde en is van grote invloed geweest op het tot 
stand komen van dit boekje. Dank voo r het er zijn!
Mijn paranimf, dr. Adrie van Bokhoven. Beste Adrie, ik ben dankbaar voor je  vriendschap 
die ondanks de afstand is blijven bestaan. Je hebt me altijd aangem oedigd en je  bent 
een beetje een voorbeeld voor mij. Frank en Adrie, ik vind het geweldig dat ju llie  tijdens 
mijn verdediging naast me staan!
Mijn promotor, prof. dr. Fred W itjes. Beste Fred, door de BIOMED studie ben ik met jou 
in 1996 in contact gekomen. Je hebt me geïntroduceerd in de klin ische wereld van de 
urologie en ik m ocht zelfs aanwezig zijn bij een radicale prostatectom ie. Mijn eerste 
review over de bruikbaarheid van biom arkers in de diagnose van prostaatkanker schreef 
ik in opdracht van jou. Bedankt voor de leerzame en leuke sam enwerking en ik hoop dat 
we deze in de toekom st kunnen continueren!
Mijn promotor, prof. dr. Peter Mulders. Beste Peter, bij de vertaling van het fundam entele 
onderzoek naar de klin iek ben je  als behandelend clinicus en hoofd van de afdeling 
nauw betrokken. De sam enwerking tussen lab en klin iek is essentieel om de puzzel 
kanker te kunnen com pleteren. Bedankt voor de sam enwerking en de m ogelijkheid om 
op jo uw  afdeling mijn prom otieonderzoek te kunnen uitvoeren.
Dr. Gerald Verhaegh. Beste Gerald, bij de to tstandkom ing van dit proefschrift ben je 
nauw betrokken geweest. Jouw  naam  staat dan ook verm eld bij m erendeel van de 
artikelen in dit proefschrift. Voor mij ben je  mijn coprom otor! Bedankt voo r je  steun en
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hulp tijdens mijn onderzoek en ik hoop dat we de leuke sam enwerking kunnen 
continueren.
Dr. Marion Bussemakers. Beste Marion, jij mag zeker niet ontbreken aangezien jij PCA3 
hebt ontdekt! Dit proefschrift met PCA3 als onderwerp zal ook voor jou heel bijzonder 
zijn. Dank voor je  interesse en je  steun.
Ing. Onno van Hooij, ing. Sander Jannink en ing. Pim Peelen. Beste Onno en Sander, 
zoals de pipet op de voorkant van dit proefschrift illustreert is dit boekje to t stand 
gekom en door de vele testen die we samen hebben uitgevoerd en de publicaties die 
daaru it volgden. Beste Pim, de vele buizen urine die jij voor dit onderzoek hebt 
opgehaald en opgewerkt zijn ontelbaar. O ok op logistiek v lak  ben je  een grote steun 
geweest. Jullie zijn vana f het begin nauw bij mijn prom otie onderzoek betrokken geweest 
en we vorm en sam en een goed team! Ik wil ju llie  dan ook bedanken voo r ju llie  steun, de 
leuke tijd en de fijne sam enwerking.
Dr. Martijn van Gils. Beste Martijn, na jo u w  prom otie in septem ber 2009 volgt nu de 
tweede m et PCA3 als onderwerp. Jouw  klinische achtergrond en mijn technische 
achtergrond bleken inderdaad een goede match. Ondanks het fe it dat velen moesten 
lachen als we w eer eens dagen sam en achter de com puter doorbrachten, heeft het wel 
geresulteerd in vele gezam enlijke publicaties die in onze proefschriften zijn opgenomen. 
Ik wil jou  dan ook bedanken voor de gezellige tijd en de leuke, goede sam enwerking!
A lle coauteurs in binnen- en buitenland wil ik hierbij harte lijk danken. In het b ijzonder wil 
ik de urologen dr. Herbert Karthaus en dr. Eric Cornel danken voor hun aandeel in 
d iverse studies.
A lle m edewerkers van lab experim entele urologie. Bedankt voor ju llie  belangstelling, de 
gezellige tijd en de leuke sam enwerking. Beste Tilly, jou w il ik in het bijzonder danken 
voo r je  interesse en je  steun. Jouw  enthousiasm e voor elke vordering die ik maakte 
w erkte erg stimulerend!
Bastiaan de Leeuw, CEO NovioGendix. Beste Bastiaan, bedankt voo r de tijd en ruimte 
die je  me hebt gegeven om binnen NovioG endix het proefschrift a f te kunnen ronden. 
A lle m edewerkers van NovioGendix, bedankt voor ju llie  belangstelling!
De m edewerkers van de polik lin iek urologie, stafsecre tariaa t urologie en het arch ie f van 
de urologie. Dank voor ju llie  hulp en goede sam enwerking!
A lle patiënten die ingestem d hebben om deel te nemen aan de diverse studies wil ik 
hierbij bedanken. Zonder uw bijdrage zou dit proefschrift niet to t stand zijn gekomen.
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Dr. André Karthaus. Beste heer Karthaus, na onze ontmoeting op de Nürburgring zijn er 
heel w a t jaren verstreken voor we elkaar w eer zouden ontmoeten. Echter, uw 
belangstelling voor mijn persoon is er vana f die tijd altijd geweest. Ik vind het dan ook 
geweldig dat u voor mij deze prachtige omslag heeft ontworpen. Harte lijk dank!
Hierbij w il ik de m ensen in mijn directe om geving bedanken. Mijn vrienden en fam ilie die 
altijd hun interesse hebben getoond en me hebben gesteund op ieder hun eigen wijze. In 
het b ijzonder mijn zus Marja en broer Michael. Bedankt voor ju llie  steun, interesse in 
mijn wetenschappelijk  w erk en de voortgang van mijn prom otieonderzoek. Lieve 
Michael, dank voor je  hulp bij de lay-out van het boekje!
Mijn ouders. Lieve papa en mama, heel erg bedankt voor de steun, liefde en kansen die 
ju llie  mij hebben gegeven. Lieve papa, toen mijn boekje klaar was om naar de drukker te 
gaan vond u dit geweldig! Helaas bent u hier niet bij, maar ik w eet dat u en mama dit 
fantastisch vinden. Zonder ju llie  zou dit alleen nooit m ogelijk zijn geweest. Bedankt voor 
alles!
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